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General summary 
Inflammation is a protective response of the body which is activated upon the detection of foreign 
molecules, pathogens or damaged cells, and is important to eliminate the danger and initiate tissue 
repair. Inflammation is a tightly controlled process and uncontrolled activation can lead to the 
development of several autoinflammatory and autoimmune diseases and eventually to the 
development of cancer. The NF-κB family of transcription factors are crucial regulators of 
inflammatory pathways and immune responses, but are also involved in cell survival, development, 
cell proliferation, differentiation and metabolism. Several (auto)regulatory mechanisms control NF-
κB signaling in order to maintain tissue homeostasis and prevent sustained inflammation. In this PhD 
thesis, I will focus on the protein A20 (also known as Tumor Necrosis Factor alpha induced protein 3, 
TNFAIP3), a critical regulator of NF-κB signaling. Genome wide association studies have linked the 
A20/TNFAIP3 locus to a variety of human inflammatory and autoimmune diseases, including 
rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and inflammatory bowel disease (IBD). 
Moreover, whole exome sequencing has identified heterozygous loss-of-function mutations in the 
A20/TNFAIP3 gene (A20 haploinsufficiency, HA20) in patients with a rare, early-onset 
autoinflammatory syndrome, and bi-allelic somatic mutations are frequently observed in several B-
cell lymphomas. Experimental studies in mice have confirmed the importance of A20 for the 
prevention of inflammatory pathology. However, how A20 controls inflammatory signaling still 
remains elusive. The main aim of this PhD thesis was to understand the molecular mechanisms by 
which A20 regulates inflammatory signaling in vivo.  
In the first part of this thesis we investigated in vivo the importance of different A20 functionalities, 
by generating and characterizing new A20 mutant mouse lines which were engineered through 
CRISPR-Cas9 genome-editing technology to carry disruptive mutations in their ZnF7 domain (A20ZnF7) 
or in both the ZnF4 and ZnF7 domains (A20ZnF4ZnF7). Initially, A20 was described as a ubiquitin-editing 
enzyme that regulates NF-κB signaling by interfering with the ubiquitination status of target proteins, 
via its OTU and ZnF4 domains which have deubiquitinating and E3-ligase activities, respectively. 
However, mice with disruptive mutations in these domains do not develop spontaneous disease, 
questioning the in vivo role of these domains. A20ZnF7 mice, which are defective in their ability to bind 
linear ubiquitin, do develop a spontaneous disease, characterized by a reduced bodyweight, the 
presence of splenomegaly and lymphadenopathy, increased levels of inflammatory cytokines in 
serum, and the detection of tissue inflammation. Furthermore, these mice are hypersensitive to a 
sublethal dose of TNF leading to severe hypothermia and death. Mechanistically, we demonstrated 
that the ZnF7 mutation abolishes the recruitment of A20 to the TNFR1 complex, reducing the amount 
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of linear ubiquitin chains detected at the complex, leading to the destabilization of complex I and the 
induction of cell death. By the additional mutation of A20’s ZnF4 domain, known to have K63-
ubiquitin binding activity, we have generated mice that die perinatally due to severe multi-organ 
inflammation, phenocopying A20 deficient mice. In conclusion, with these studies we have 
demonstrated that A20 primarily functions as a ubiquitin-binding protein to prevent cell death and 
inflammation.  
In the second part of this thesis we further unraveled the role of A20 in preventing polyarthritis 
development in mice. Previous research from the group demonstrated that mice lacking A20 in their 
myeloid cells (A20myel-KO) spontaneously develop polyarthritis with many features of human 
rheumatoid arthritis. This was shown to be caused by enhanced Nlrp3 inflammasome-mediated 
caspase-1 activation, pyroptosis and IL-1β secretion in macrophages of these mice. However, how 
A20 regulates Nlrp3 inflammasome activation was still not clear. In collaboration with the group of 
Manolis Pasparakis (University of Cologne), we could show that A20 prevents NLRP3 inflammasome-
mediated arthritis development by preventing macrophage necroptosis, since A20myel-KO mice crossed 
into a RIPK3 or MLKL knockout background, or in a background of mice that express a kinase-dead 
RIPK1 mutant, no longer develop arthritis. We could further show that A20 prevents macrophage 
necroptosis, at least partly, by its ZnF7 function mediating linear ubiquitin binding, since mice 
mutated in their ZnF7 domain (A20ZnF7) spontaneously develop polyarthritis, comparable to A20myel-KO 
mice. LPS stimulation of BMDMs isolated from A20ZnF7 mice induced the release of bioactive IL-1β as 
well as IL-1α. IL-1α and IL-1β likely together with IL-18 and other DAMPs released by necroptotic 
macrophages activate MyD88-dependent proinflammatory signalling in synovial fibroblasts causing 
the development of arthritis.  
Finally, in the last part of this thesis, we have identified a role for A20 in the process of 
osteoclastogenesis by regulating signaling downstream the receptor activator of nuclear factor 
kappa-B (RANK). Previous research from the group showed that A20myel-KO mice have increased 
numbers of CD115+CD117+ osteoclast precursors in vivo,  and also produce more osteoclasts in vitro 
when blood leukocytes are stimulated with RANK ligand and macrophage colony-stimulating factor 
(M-CSF) compared to control A20 expressing cells. These observations suggest that A20 may play a 
direct role in the regulation of RANK-induced osteoclastogenesis. However, the enhanced 
osteoclastogenesis may also be the result of the more general inflammatory phenotype of A20 
deficient mice, since inflammatory cytokines such as TNF, IL-1 and IL-6 are known to promote 
osteoclastogenesis. To further address this, we here generated mice which specifically lack A20 in 
maturating osteoclasts, by crossing A20 floxed mice with mice expressing Cre under control of the 
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CathepsinK promotor (osteoclast-specific A20 knockout, A20OC-KO). We could show that these mice 
spontaneously develop osteoporosis with a significant increase in the number of TRAP-positive 
osteoclasts present at the growth plate, but without the systemic inflammation as seen in A20myel-KO 
mice. We further showed that A20 deficiency leads to increased and prolonged activation of RANK-
induced NF-κB signaling in osteoclasts. How A20 regulates RANK-induced signaling is, however, still 
not clear and requires  further research. 
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Algemene samenvatting 
Inflammatie, beter gekend als ontsteking, is een beschermende reactie van het lichaam als antwoord 
op de aanwezigheid van lichaamsvreemde stoffen, pathogenen of beschadigde cellen en weefsels. 
De ontstekingsreactie speelt een cruciale rol in het verwijderen van deze potentieel gevaarlijke 
stoffen en het induceren van een herstelreactie. Aanhoudende ‘chronische’ inflammatie kan echter 
leiden tot het ontwikkelen van auto-inflammatoire en auto-immuunziekten, en kan zelfs aanleiding 
geven tot het ontstaan van kanker. NF-ĸB eiwitten, een familie van transcriptiefactoren, zijn van 
cruciaal belang in de regulatie van onstekingsprocessen en immuunreacties, en verschillende 
cellulaire mechanismen zorgen ervoor dat  NF-ĸB activatie gecontroleerd gebeurt om zo chronische 
inflammatie te voorkomen. In deze doctoraatsthesis lag de focus op het eiwit A20 (ook gekend als 
Tumor necrosis factor alpha-induced protein 3, TNFAIP3), één van de belangrijkste regulatorische 
eiwitten betrokken in NF-ĸB activatie en inflammatie. Genoomwijde associatie-studies hebben 
polymorfismen (zogenaamde ‘single nucleotide polymorfismen’, SNPs) geïdentificeerd in de 
A20/TNFAIP3 locus, en deze gelinkt aan verschillende auto-inflammatoire en auto-immuunziekten 
waaronder reumatoïde artritis (RA), systemische lupus erythematosis (SLE) en inflammatoire 
darmziekten (IBD). Meer recent werden bij patiënten die lijden aan een zeldzaam auto-inflammatoir 
syndroom heterozygote mutaties gevonden in het A20/TNFAIP3 gen, aanleiding gevend tot A20 
haplo-insufficiëntie. Ook in verschillende B-cel lymfomen  worden frequent bi-allelische somatische 
mutaties in A20 gevonden. Genetische studies in muizen hebben de belangrijke rol van A20 in de 
regulatie van inflammatie bevestigd, maar het onderliggende mechanisme dat verklaart waarom A20 
dit doet is nog onvolledig gekend. Het doel van deze doctoraatsthesis was dan ook het verder 
onderzoeken van de moleculaire mechanismen waarmee A20 inflammatie reguleert. 
Het A20 eiwit bestaat uit een N-terminaal OTU domein en een C-terminaal deel met zeven ‘zinc 
finger’ (ZnF) domeinen. In het eerste deel van deze thesis hebben we de in vivo rol onderzocht van 
twee ZnF domeinen, namelijk het ZnF4 en ZnF7 domein die verantwoordelijk zijn voor binding van 
A20 aan respectievelijk K63- en M1-ubiquitine. Hiervoor werden nieuwe transgene muislijnen 
gemaakt met mutaties in het ZnF7 domein (A20ZnF7) enerzijds, of in zowel het ZnF4 als het ZnF7 
domein (A20ZnF4ZnF7). In vroegere studies werd gesuggereerd dat A20 werkzaam is als een zogenaamd 
‘ubiquitin-editing’ enzym, waarbij het NF-κB signalisatie reguleert via zijn deubiquitinerende en E3-
ligase activiteiten gemedieerd via zijn respectievelijk OTU en ZnF4 domein. Muizen met mutaties in 
het OTU of ZnF4 domein ontwikkelen echter geen spontaan inflammatoir fenotype, in tegenstelling 
tot A20 knock-out muizen, wat suggereert dat de anti-inflammatoire activiteit van A20 in vivo niet 
bepaald wordt door deze enzymatische activiteiten.  A20ZnF7 muizen, waarvan het A20 eiwit niet 
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langer kan binden aan lineaire (M1) ubiquitine ketens, ontwikkelen echter wel spontaan een 
inflammatoire pathologie. Deze muizen hebben een verminderd lichaamsgewicht, ontwikkelen 
splenomegalie en lymfadenopathie, en vertonen verhoogde niveaus van inflammatoire cytokines in 
hun serum. Ook kan de aanwezigheid van weefselinflammatie zoals in lever worden aangetoond in 
A20ZnF7 muizen. Injectie van een normaal subletale dosis TNF in A20ZnF7  muizen veroorzaakt 
hypothermie en dood van de muizen, in tegenstelling tot controle muizen die resistent zijn aan 
dergelijke inflammatoire blootstelling. Mechanistisch hebben we aangetoond dat in afwezigheid van 
een functioneel ZnF7 domein, A20 niet langer gerekruteerd wordt naar het TNFR1 complex, 
waardoor het niveau aan lineaire ubiquitinatie in dit complex zeer drastisch wordt gereduceerd, wat 
op zijn beurt leidt tot instabiliteit van het complex en inductie van celdood. Het additioneel muteren 
van het ZnF4 domein in deze muizen (A20ZnF4ZnF7 muizen), leidt tot het ontstaan van ernstige multi-
orgaan inflammatie en perinatale dood van de muizen. Dit fenotype is identiek aan het fenotype van 
A20 deficiënte muizen, wat het cruciale belang aantoont van de beide ubiquitine-bindende 
domeinen van A20 voor zijn anti-inflammatoire activiteit in vivo.   
In het tweede deel van deze thesis werd de rol van A20 in de ontwikkeling van artritis verder 
onderzocht. Vroeger onderzoek binnen onze onderzoeksgroep heeft aangetoond dat muizen die 
specifiek A20 ontberen in de myeloide cellen (A20myel-KO), spontaan artritis ontwikkelen, en deze 
pathologie sterke gelijkenissen vertoont met reumatoïde artritis in de mens. Verder onderzoek heeft 
aangetoond dat verhoogde Nlrp3 inflammasoom activatie en IL-1β secretie aan de basis liggen van 
deze artritis. Echter, het precieze moleculaire mechanisme dat verklaart waarom A20 deficiëntie leidt 
tot een verhoogde activatie van het Nlrp3 inflammasoom is echter nog steeds niet duidelijk. In 
samenwerking met de onderzoeksgroep van Manolis Pasparakis (Universiteit van Keulen) hebben we 
kunnen aantonen dat de artritis in A20myel-KO muizen wordt voorkomen wanneer deze muizen werden 
ingekruist met RIPK3 deficiënte, MLKL deficiënte of RIPK1 kinase-dood (KD) transgene muizen. 
Verder in vitro onderzoek kon aantonen dat A20 de activatie van het Nlrp3 inflammasoom 
controleert door het voorkomen van macrofaag necroptose. Hierbij konden we verder aantonen dat 
het ZnF7 domein van A20 hierin een cruciale rol speelt, aangezien A20ZnF7 muizen spontaan artritis 
ontwikkelen, vergelijkbaar met A20myel-KO muizen. LPS-gestimuleerde beenmerg-afgeleide 
macrofagen (BMDMs) afkomstig van A20ZnF7 muizen stellen IL-1α en IL-1β vrij in het cel medium, 
waarbij IL-1α en IL-1β, in samenwerking met IL-18 en andere DAMPs die vrijgesteld worden door 
necrotische macrofagen, op hun beurt MyD88-afhankelijke pro-inflammatoire signalisatie mediëren 
in de synoviale fibroblasten, wat uiteindelijk resulteert in het ontstaan van artritis. 
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In het laatste deel van deze doctoraatsthesis hebben we de rol onderzocht van A20 in de regulatie 
van osteoclastogenese en RANK signalisatie. Vroeger onderzoek binnen onze onderzoeksgroep heeft 
immers aangetoond dat A20myel-KO muizen meer CD115+CD117+ osteoclast precursoren hebben en 
dat, in vitro, meer osteoclasten worden gevormd wanneer bloed leukocyten van  A20myel-KO muizen 
worden gestimuleerd met RANK ligand en macrophage colony-stimulating factor (M-CSF)  in 
vergelijking met culturen van controle muizen. Dit suggereert dat A20 betrokken zou kunnen zijn in 
de regulatie van osteoclastogenese en RANK signalisatie, doch de verhoogde osteoclastogenese in 
deze muizen zou ook het gevolg kunnen zijn van  het inflammatoire fenotype van deze muizen, 
vermits is geweten dat inflammatoire cytokines zoals TNF, IL-1β en IL-6 osteoclastogenese kunnen 
stimuleren. Om dit verder te onderzoeken hebben we dan ook muizen gegenereerd die specifiek A20 
ontberen in mature osteoclasten (A20OC-KO), door het kruisen van A20 gefloxte muizen met muizen 
die Cre expresseren onder controle van de Cathepsine K (CtsK) promotor. We konden aantonen dat 
deze muizen spontaan osteoporose ontwikkelen met aanwezigheid van een groter aantal TRAP-
positieve osteoclasten in hun botweefsel. Ook konden we aantonen dat in vitro stimulatie van 
BMDMs met RANK ligand aanleiding geeft tot meer en langere activatie van RANK signalisatie. Deze 
bevindingen wijzen dus inderdaad op een belangrijke functie van A20 in de regulatie van RANK 
signalisatie en osteoclastogenese. Hoe A20 precies RANK signalisatie reguleert is nog onduidelijk, en 
vergt bijkomend onderzoek. 
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List of abbreviations 
A 
 
ABIN   A20-binding inhibitor of NF-κB 
ALR   AIM2-like receptor 
AIM2   Absent in melanoma 2 (AIM2) 
AP-1   Activator protein-1 
aPKC   Atypical protein kinase C 
ASC   Apoptosis-associated speck-like protein containing a CARD domain 
Ash1l   Absent small or homeotic-like 
ATP   Adenosine triphosphate 
 
B 
 
BAFFR   B cell activating factor receptor 
BM   Bone marrow 
BMDM   Bone marrow-derived macrophage 
BRC   Bone remodeling compartment 
 
C 
 
CalcR   Calcitonin receptor 
cIAP   Cellular inhibitor of apoptosis protein 
COPD   Chronic obstructive pulmonary disease 
CtsK   Cathepsin K 
CYLD   Cylindromatosis 
 
D 
 
DAMPs   Damage-associated molecular patterns 
DC-stamp  Dendrocyte expressed seven transmembrane protein 
DISC   Death-inducing signaling complex 
DRE   Downstream regulatory element 
DREAM   Downstream regulatory element antagonist modulator 
DSS   Dextran sodium sulfate 
DUB   Deubiquitinating enzyme 
 
E 
 
EAE   Experimental autoimmune encephalomyelitis 
EMT   Epithelial–mesenchymal transition 
ERK   Extracellular signal–regulated kinase 
ERRα   Estrogen-related receptor α 
 
F 
 
FADD   Fas-associated death domain 
 
G 
 
2 
 
GWAS   Genome wide association studies 
 
H 
 
H&E   Hematoxylin and eosin 
HOLI-1   Haem-oxidized IRP2 Ub ligase-1 
HOIP   HOIL-1 interacting protein 
 
I 
 
IBD   Inflammatory bowel disease 
IEC   Intestinal epithelial cell 
IFN   Interferon 
IKK   Inhibitor of ĸB kinase 
IL   Interleukin 
IL-1R   Interleukin-1 receptor 
IRAK   Interleukin-1 receptor-associated kinase 
IĸB   Inhibitor of ĸB 
 
 
J 
 
JNK   c-Jun N-terminal kinase 
 
K 
 
KD   Kinase dead 
KO   Knockout 
 
L 
 
LOF   Loss-of function 
LPS   Lipopolysaccharide 
LRR   Leucin-rich region 
LTβ   Lymphotoxin-β 
LTβR   Lymphotoxin-β receptor 
LUBAC   Linear Ub chain assembly complex 
LysM   Lysozyme M 
 
M 
 
M1   Linear ubiquitin 
MALT1   Mucosa-associated lymphoid tissue lymphoma translocation protein 1 
MAPK   Mitogen activated protein kinase 
M-CSF   Macrophage colony-stimulating factor 
miR   MicroRNA 
MITF   Microphthalmia transcription factor 
MK2   MAPK-activated protein kinase-2 
MLKL   Mixed lineage kinase domain-likepseudokinase 
MMP   Matrix metalloproteinase 
MSC   Mesenchymal stem cell 
MyD88   Myeloid differentiation primary response 88 
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N 
 
NEMO   NF-κB essential modifier 
NFATc1   Nuclear factor-activated T cells c1 
NF-ĸB   Nuclear factor-ĸB 
NIK   NF-ĸB-inducing kinase 
NLS   Nuclear localization signal 
NLR   Nucleotide oligomerization domain-like receptor  
NO   Nitric oxide 
NOD   Nucleotide oligomerization domain  
 
O 
 
OC-stamp  Osteoclast stimulatory transmembrane protein 
OPC   Osteoclast precursor cells 
OPG   Osteoprotegerin 
OTU   Ovarian tumor 
OTULIN   Ovarian tumor family linear chain deubiquitinase  
 
P    
 
PAMPs   Pathogen-associated molecular patterns 
PI(3)K   Phosphatidylinositol 3-OH kinase 
PRR   Pattern recognition receptor 
 
R 
 
RA   Rheumatoid arthritis 
RANK   Receptor activator of NF-κB 
RANKL   Receptor activator of NF-κB ligand 
RHD   Rel homology domain 
RIG   Retinoic acid-inducible gene 
RIPK   Receptor-interacting protein  
RLR   Retinoic acid-inducible gene-I-like receptor 
RNF11   RING finger protein 11 
 
S 
 
SCFβTRCP   Skp, Cullin, F-box containing complex, beta-transducin repeat containing 
protein 
SHARPIN   Shank-associated RH domain-interacting protein 
SLE   Systemic lupus erythematosus 
SNP   Single-nucleotide polymorphism 
 
T 
 
TAB2   TGFβ-activated kinase 1 binding protein 2 
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TAD   Transcription transactivation domain 
TAK1   TGFβ-activated kinase 1 
TANK   TRAF family member-associated NF-κB activator 
TAX1BP1  Tax1-binding protein 1 
TBK1   TANK-binding kinase 1 
TCR   T-cell receptor 
TGF-β    Transforming growth factor beta 
TIR   Toll/IL-1 receptor 
TIRAP   Toll/interleukin-1 (IL-1) receptor adaptor protein 
TLR   Toll-like receptor 
TNF   Tumor necrosis factor 
TNFAIP3  Tumor necrosis factor -α-induced protein 3 
TNFR   Tumor necrosis factor receptor 
TRADD   Tumor necrosis factor receptor –associated death domain protein 
TRAF   Tumor necrosis factor receptor–associated factor 
TRAM   TRIF-related adaptor molecule 
TRAP   Tartrate-resistant acid phosphatase  
TRIF   TIR-domain-containing adaptor protein inducing interferon-β  
 
U 
 
Ub   Ubiquitin 
UBC13/H5c  Ubiquitin carrier protein 13/H5c 
UBD   Ubiquitin-binding domain 
USF-1   Upstream stimulatory factor 1 
 
Z 
 
ZnF   Zinc finger 
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NF-ĸB signaling in inflammation and cell death 
 
NF-ĸB signaling downstream of immune receptors 
Inflammation is a protective response that is induced by the detection of pathogens or damaged cells 
through specific receptors, called pattern recognition receptors (PRRs). The PRRs comprise toll-like 
receptors (TLRs), Retinoic acid-inducible gene (RIG)-I-like receptors (RLRs), nucleotide oligomerization 
domain (NOD)-like receptors (NLRs) and C-type lectin receptors (CLRs). PRRs sense the presence of 
pathogen-associated molecular patterns (PAMPs), or damage-associated molecular patterns 
(DAMPs) released from damaged cells, initiating an inflammatory response through a multitude of 
intracellular signaling pathways1,2. Nuclear factor kappa B (NF-κB) signaling is a central pathway 
downstream of PRRs and plays a critical role in inflammatory signaling and immunity. Furthermore, 
NF-ĸB is also involved in cell survival, development, cell proliferation, differentiation and 
metabolism3.  
The NF-κB family of transcription factors consists of five members: RelA (p65), c-Rel, RelB and the 
precursor proteins p105 (NF-ĸB1) and p100 (NF-ĸB2) which are processed into p50 and p52, 
respectively. These proteins all share a N-terminal Rel homology domain (RHD), important for DNA 
binding and dimerization, and a nuclear localization signal (NLS). All NF-ĸB proteins, except p50 and 
p52, also contain a transcription transactivation domain (TAD) which enables them to initiate 
transcription. Upon activation, NF-ĸB family members form homo- or heterodimers to assemble 
functional transcription factors that bind to ĸB sites in the promotor of their target genes3. In resting 
conditions, however, NF-ĸB dimers are sequestered in the cytoplasm by binding to the inhibitor of κB 
(IĸB) family of proteins which masks their NLS sequence preventing nuclear translocation and gene 
transcription4.  
Ubiquitination in NF-κB signaling 
NF-κB signaling is tightly regulated by posttranslational modifications including ubiquitination, a 
process in which ubiquitin (Ub), a 76-amino-acid protein, is covalently attached to a target protein by 
the sequential action of 3 classes of enzymes: Ub-activating enzymes (E1), Ub-conjugating enzymes 
(E2) and Ub protein ligases (E3)5. Ubiquitin itself contains 7 lysine residues (K6, K11, K27, K29, K33, 
K48, and K63) which can be bound by another ubiquitin molecule, generating polyubiquitin chains of 
different linkage types. Also the amino-terminal methionine of ubiquitin can be bound by another 
ubiquitin molecule, forming linear ubiquitin chains (M1)5. The linear ubiquitin chain assembly 
complex (LUBAC), an E3 ubiquitin-ligase complex consisting of HOIP, HOIL-1 and SHARPIN, is the only 
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E3 ligase complex described that can form linear ubiquitin chains6. The role of LUBAC and linear 
ubiquitin in TNFR-signaling is described in more detail in chapter II of the introduction7. Different 
types of polyubiquitin chains mediate different effects, with K48, K63 and M1 chains being the most 
important in inflammatory signaling. K48 ubiquitination targets proteins for proteasomal 
degradation, while K63 and M1 chains mediate downstream signaling by facilitating low affinity 
binding of proteins containing a ubiquitin binding domain (UBD). More recently, also branched 
ubiquitin linkages have been described, consisting of mixed K63/M1 or K48/K63 chains, which 
facilitate downstream NF-ĸB signaling9,10.  
Two main signaling pathways are involved in the activation of NF-ĸB: the canonical (or classical) 
pathway and the non-canonical (or alternative) pathway. The canonical pathway is induced by 
several stimuli, including cytokine receptors, PRRs and B- and T- cell receptors11. A central process is 
the recruitment of 2 protein complexes, the TGFβ-activated kinase 1 (TAK1)-TAB2/3 complex which is 
recruited via the K63-binding affinity of TAB2/3 and the IκB kinase (IKK) complex, consisting of 2 
kinase subunits, IKK1 and IKK2 (also known as IKKα and IKKβ), and a regulatory subunit, called NF-κB 
essential modulator (NEMO) which selectively binds M1 chains via its UBAN domain12. The activated 
IKK complex will phosphorylate IĸB, thereby targeting it for ubiquitination by the Skp, Cullin, F-box 
containing, beta-transducin repeat containing protein (SCFβTRCP) complex and subsequent 
proteasomal degradation. This releases the NF-ĸB dimers from their inhibitor, allowing their 
translocation to the nucleus to induce gene transcription12. Alternatively, NF-ĸB can be activated via 
non-canonical signaling, which is induced by a number of tumor necrosis factor receptor (TNFR) 
superfamily members including the  lymphotoxin-β receptor (LTβR), the B cell activating factor 
receptor (BAFFR), CD40, the receptor activator for NF-κB (RANK) and TNFR213. In steady-state 
conditions, NF-κB-inducing kinase (NIK) is in complex with TNFR-associated factor (TRAF) 3, TRAF2 
and cellular inhibitor of apoptosis (cIAP) 1 and 2 proteins, where cIAP1/2 target NIK for proteasomal 
degradation via K48 ubiquitination, keeping levels of NIK very low. Upon receptor ligation, NIK is 
released from TRAF3, allowing it to phosphorylate and activate IKK1, which in turn mediates 
phosphorylation of p100, an IĸB-like protein that predominantly binds the NF-ĸB family member 
RelB. Phosphorylation of p100 induces K48-mediated degradation of the C-terminal part of p100, 
generating p52, which together with RelB translocates to the nucleus to induce gene expression13. 
Finally, ubiquitination is a reversible process, and several deubiquitinating enzymes (DUBs), including 
A20, CYLD and OTULIN, have been described to negatively regulate NF-ĸB activation by cleaving 
conjugated ubiquitin chains from signaling proteins14-17. Although the importance of the DUB 
function of A20 for the regulation of inflammation has always been a matter of debate18-21 (A20 is 
discussed in detail in chapter II), CYLD was shown to act as a DUB by removing both K63 and M1 
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chains, while OTULIN acts as a DUB specific for linear (M1) ubiquitin chains22. In conclusion, NF-ĸB 
signaling is regulated by the tight interplay between ubiquitin ligases, ubiquitin-binding proteins and 
deubiquitinases. Dysregulation of this interplay will lead to aberrant signaling and may induce the 
development of autoimmune and autoinflammatory disease23. As an example, patients which carry 
loss-of-function mutations in HOIL1, a component of the LUBAC complex responsible for linear 
ubiquitination, will suffer from both auto-inflammation and immunodeficiency24. Furthermore, loss-
of-function mutations in the A20 gene cause severe auto-inflammation25, and single-nucleotide 
polymorphisms (SNPs) in or near A20 have been linked to a variety of autoimmune and inflammatory 
diseases 7.  
Inflammasomes 
Next to the induction of inflammatory gene expression, a subset of cytosolic NLRs and ALRs (absent 
in melanoma 2 (AIM2)-like receptors) trigger the assembly of cytosolic multiprotein complexes called 
inflammasomes, important for the innate immune response26. In general, assembly of 
inflammasomes results in the proteolytical activation of Caspase-1, which in its turn processes pro-IL-
1β and pro-IL-18 into mature cytokines. In addition, inflammasome assembly can induce pyroptosis, 
a lytic form of cell death, via which IL-1β , IL-18  and DAMPs such as IL-1α and HMGB1 are released27. 
Cleavage of Gasdermin D (GSDMD) by caspase-1 or -11 (or -1, -4 and -5 in human) releases an amino-
terminal pore-forming GSDMD domain that oligomerizes and inserts in the plasma membrane, 
inducing membrane rupture and leakage of the cytosolic contents28 (Figure 1).  
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Fig. 1 NLRP3 inflammasome signaling. NLRP3 inflammasome activation requires a two-step 
mechanism. A priming signal (e.g. LPS-TLR4 signaling) induces the expression of NLRP3 and pro-IL-1β. 
The activating signal induces the formation of the inflammasome complex and the processing and 
activation of caspase-1, which processes pro-IL-1β and pro-IL-18 into mature cytokines. In addition, 
activated caspase-1 cleaves Gasdermin D and the N-terminal part translocates to the plasma 
membrane where it forms pores and induces pyroptotic cell death, allowing the release of IL-1β and 
IL-18. Alternatively, in the non-canonical NLRP3 inflammasome pathway, caspase-11 (or its human 
orthologs caspase-4 and -5) are activated by cytosolic LPS, inducing Gasdermin D cleavage and 
pyroptosis. 
Several cytosolic receptor proteins have been shown to assemble into inflammasome complexes, 
including NLRP1, NLRP3 and NLRC4, which belong to the NLR family of receptors, as well as the 
proteins AIM2 and pyrin26,27. The best characterized inflammasome is the NLRP3 inflammasome, 
which is activated by a wide variety of bacterial, fungal and viral PAMPs, and DAMPS such as 
adenosine triphosphate (ATP), crystals and protein aggregates26. Activation of the NLRP3 
inflammasome additionally requires an NF-ĸB mediated extracellular priming signal to 
transcriptionally upregulate the expression of NLRP3 and pro-IL-1β, e.g. via TLR signaling (Fig. 1). 
Upon sensing danger molecules, the NLRP3 proteins will oligomerize and recruit the adaptor protein 
apoptosis-associated speck like protein containing a caspase recruitment domain (ASC) via its pyrin 
domain (PYD), and pro-caspase 1 through its caspase 1 recruitment domain (CARD), thereby forming 
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the multiprotein inflammasome complex responsible for the activation of caspase-1 by proximity-
induced autoprocessing29. Alternatively, cytosolic lipopolysaccharide (LPS) can induce the activation 
of caspase-11 (or caspase-4/5 in humans) which then initiates pyroptosis by cleaving 
GSDMD.Caspase-11 is however not capable of processing pro-IL-1β and pro-IL-1827 (Fig. 1). 
 
LPS-TLR4 and IL-1/IL-1R signaling 
The TLR family of receptors are the best studied family of PRRs. These receptors are characterized by 
the presence of an extracellular leucin-rich region (LRR) and a cytoplasmatic Toll/IL-1 receptor (TIR) 
domain responsible for signal transduction30. Toll-Like Receptor 4 (TLR4) recognizes and binds LPS, a 
component of the bacterial membrane, activating downstream signaling.  The interleukin-1 receptor 
(IL-1R) also contains a cytoplasmatic TIR domain and shares TIR-domain containing adaptor proteins 
with the TLR family for downstream signaling31. Binding of LPS or IL-1α/β to their cognate receptor, 
respectively TLR4 and IL-1R, induces receptor dimerization leading to the recruitment of myeloid 
differentiation primary response 88 (MyD88) via the adaptor molecule Toll/interleukin-1 (IL-1) 
receptor adaptor protein (TIRAP), also known as Mal. This will now recruit interleukin-1 receptor-
associated kinase (IRAK) 4 which, upon activation by autophosphorylation, binds and phosphorylates 
IRAK1, which on its turn will recruit tumor necrosis factor receptor–associated factor 6 (TRAF6) into 
the complex. Autoubiquitination of TRAF6 with K63 chains forms a platform for the recruitment of 
the TAK1-TAB2/3 complex. Activated TAK1 subsequently phosphorylates and activates the IKK 
complex, inducing IKK2-mediated phosphorylation of IĸBα, promoting its degradation, leading to the 
release and activation of NF-ĸB transcription factors. Furthermore, TAK1 can activate mitogen-
activated protein kinase (MAPK) signaling pathways also inducing the expression of pro-inflammatory 
cytokines. In the MyD88-dependent pathway, MyD88 also recruits TRAF3, and proteasomal 
degradation of TRAF3, via cIAP1/2 mediated K48-ubiquitination, was shown to be crucial for 
activation of downstream MAPKs32. It is suggested that TRAF6 attaches K63 chains to cIAP1/2, 
thereby inducing cIAP1/2 K48 ligase activity33. Upon receptor endocytosis, TLR4 can also signal in a 
MyD88-independent way by recruiting TIR-domain-containing adaptor protein inducing interferon-
β (TRIF; also known as TICAM1) via adaptor molecule TRIF-related adaptor molecule (TRAM; also 
known as TICAM2). TRIF will now recruit TRAF6 and Receptor-interacting protein kinase 1 (RIPK1) to 
the receptor complex, followed by K63-ubiquitination of TRAF6 and RIPK1 by pellino-134, facilitating 
TAK1 recruitment and the activation of NF-ĸB and MAPK signaling pathways. Alternatively, TRIF can 
recruit TRAF3, activating the non-canonical IKKs TRAM-binding kinase-1 (TBK1) and IKKε, resulting in 
the phosphorylation and activation of the transcription factor Interferon regulatory factor-3 (IRF3) to 
induce the expression of type I interferons (Fig. 2)30,31,34-37. In contrast to its role in MyD88-dependent 
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signaling, auto-ubiquitinated TRAF3 was shown to be required for the activation of IRF332. The role of 
LUBAC and linear ubiquitin in TLR4/IL-1R signaling is still not clear. Sharpin deficiency results in 
impaired NF-ĸB activation and cytokine production, and K63-M1-hybrid chains can be detected upon 
activation of IL-1R or TLR1/2. How LUBAC is recruited as well as the identity of LUBAC targets are, 
however, still elusive10,38,39.  
Fig. 2 TLR4/IL-1R signaling. Binding of IL-1 or LPS to its receptor IL-1R or TLR4 induces receptor 
dimerization and recruitment of several adaptors. MyD88-dependent and TRIF-dependent signaling 
induces TAK1 activation and subsequent activation of  NF-κB and MAPK signaling, inducing the 
expression of proinflammatory cytokines. TLR4 induced TRIF-dependent signaling can also induce the 
expression of type I IFNs via IRF3 activation. 
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TNF-TNFR1 signaling 
Detailed information on the TNF-TNFR1 pathway : see chapter II, review Martens and van Loo, “A20 
at the crossroads of cell death, inflammation and autoimmunity”. 
 
Cell death and its role in inflammation 
Cell death has long been considered a consequence of sustained inflammation in many diseases, 
however recent studies identified cell death as a driver of inflammation. Apoptosis, which relies on 
the activation of the initiator caspases-8/10 or 9 and the downstream effector caspases-3 and -7, is 
considered a non-inflammatory form of cell death whereby the integrity of the plasma membrane is 
preserved and dying cells are removed by phagocytosis. Although, aberrant apoptosis in e.g. the 
intestinal epithelium results in intestinal barrier disruption, inducing systemic inflammation and 
lethality in mice40. In contrast, lytic forms of cell death, such as necroptosis and pyroptosis, are 
known to induce inflammation by the release of DAMPS41,42. Necroptosis is a lytic form of regulated 
cell death and depends on the activation of receptor interacting protein kinase-3 (RIPK3) and its 
substrate mixed lineage kinase like (MLKL). Upon phosphorylation by RIPK3, MLKL oligomerizes into a 
pore-forming complex that inserts in the plasma membrane and induces plasma membrane 
disruption, allowing the release of DAMPS (e.g. IL-1α) which can induce an inflammatory response. In 
normal conditions, caspase-8 prevents necroptosis and subsequent inflammation. Indeed, caspase-8 
deficiency in mice results in embryonic lethality due to aberrant necroptosis, as was shown by the 
rescue of the phenotype of caspase-8 knockout mice in a RIPK3 or MLKL deficient background43-45. 
Pyroptosis is induced by GDSMD cleavage by caspase-1 or caspase-11 (human caspase-4/5), and the 
N-terminal part of GSDMD will oligomerize and form pores in the cell membrane allowing the release 
of IL-1β, IL-18 and DAMPS28. In conclusion, more and more evidence has shown that cell death is not 
only a consequence of inflammation, but can also be the driving force of inflammation in many 
inflammatory diseases. 
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A20 is a potent anti-inflammatory protein, acting by inhibiting nuclear factor κB (NF-κB)
signaling and inflammatory gene expression and/or by preventing cell death.Mutations in the
A20/TNFAIP3 gene have been associated with a plethora of inflammatory and autoimmune
pathologies in humans and in mice. Although the anti-inflammatory role of A20 is well
accepted, fundamental mechanistic questions regarding its mode of action remain unclear.
Here, we review new findings that further clarify the molecular and cellular mechanisms by
which A20 controls inflammatory signaling and cell death, and discuss new evidence for its
involvement in inflammatory and autoimmune disease development.
Inﬂammation is a protective response to in-duce repair in conditions of cellular damage
and stress. It involves activation of the nuclear
factor κB (NF-κB) family of transcription fac-
tors leading to the expression of inﬂammatory
cytokines and chemokines to establish an
appropriate immune response. Activation of
NF-κB also induces the expression of cell-sur-
vival genes to protect the cell from dying (Zhang
et al. 2017). NF-κB signaling is tightly regulated
at multiple levels and strongly depends on re-
versible modiﬁcation of signaling proteins, with
important roles for phosphorylation and ubiq-
uitination. Ubiquitination is a posttranslational
protein modiﬁcation in which ubiquitin (Ub), a
small 76-amino-acid protein, is covalently at-
tached to lysine residues of target proteins by
the stepwise activity of an E1 Ub-activating en-
zyme, E2 Ub-conjugating enzymes, and E3 Ub
protein ligases. Each of the seven lysine residues
(K6, K11, K27, K29, K33, K48, and K63) in Ub
can themselves be bound to another Ub, lead-
ing to the formation of polyubiquitin chains on
the target protein. Linear Ub chains (M1), in
which Ub is bound via the amino-terminal
methionine (M1) residue to another Ub, also
happens, and has been shown to be crucially
important for NF-κB signaling (Iwai and Toku-
naga 2009). Depending on the type of chain,
ubiquitination can target the modiﬁed protein
for proteasomal degradation, or function as a
scaffold for proteins that contain a Ub-binding
domain (UBD) andmediate downstream signal-
ing. Ubiquitination is reversed by deubiquitinat-
ing enzymes (DUBs) that cleave Ub chains from
their substrate (Hrdinka and Gyrd-Hansen
2017). Hence, the ubiquitination of proteins,
deﬁned by the tight interplay between Ub
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ligases, Ub-binding proteins, and DUBs, con-
trols NF-κB signaling.
The importance of ubiquitination for the
regulation of inﬂammatory signaling has been
studied extensively for the prototype inﬂamma-
tory pathway induced by the cytokine tumor
necrosis factor (TNF) (Verhelst et al. 2011).
Binding of TNF to its cognate receptor TNF
receptor 1 (TNFR1) mediates NF-κB-depen-
dent gene activation through assembly of a
primary membrane-bound signaling complex
known as complex I (Ting and Bertrand 2016).
This complex is assembled through the recruit-
ment of TNF receptor–associated death domain
protein (TRADD), receptor-interacting protein
1 (RIPK1), TNF receptor–associated factor 2
(TRAF2) and/or TRAF5, and cellular inhibitor
of apoptosis protein-1 (cIAP1) and cIAP2.
cIAP1 and cIAP2 are E3 Ub ligases that on
recruitment conjugate RIPK1 and cIAPs them-
selves with K63-linked polyubiquitin chains,
which now serve as a platform for the recruit-
ment of the linear Ub chain assembly complex
(LUBAC), consisting of HOIP, HOIL1, and
SHARPIN. As a consequence, LUBAC will con-
jugate several components of the TNFR1 com-
plex with M1-linked chains, followed by the re-
cruitment and activation of the TAB–TAK1
complex and the NEMO–IKK complex via their
UBD domains (Haas et al. 2009). This allows
TAK1 to phosphorylate and activate the IKK
complex, the latter phosphorylating the inhibi-
tor of κB α (IκBα), targeting it for proteasomal
degradation. Degradation of IκBα releases NF-
κB, which now translocates to the nucleus where
it induces the expression of proinﬂammatory
and cell-survival genes (Fig. 1; Zhang et al.
2017). Besides activating NF-κB and inducing
inﬂammatory gene activation and cell survival,
TNF can also induce the assembly of a cytosolic
death-inducing signaling complex (DISC) com-
posed of TRADD, Fas-associated death domain
(FADD), and caspase-8 (complex IIa), or
composed of RIPK1, FADD, and caspase-8
(complex IIb, also called the Ripoptosome). In
conditions of caspase-8 inhibition, TNF can in-
duce necroptosis by further recruitment of
RIPK3 and mixed lineage kinase domain-like
pseudokinase (MLKL) assembling the ne-
crosome (Fig. 1; Pasparakis and Vandenabeele
2015; Ting and Bertrand 2016).
Deregulation of inﬂammatory NF-κB and
cell-death signaling has been associated with
several (auto)inﬂammatory diseases and cancer
(Kondylis et al. 2017; Lork et al. 2017). There-
fore, tight regulation of these pathways is
required to avoid chronic inﬂammation and
maintain tissue homeostasis. In this context, nu-
merous (auto)regulatorymechanisms have been
described (Renner and Schmitz 2009), and A20,
CYLD, andOTULIN have been identiﬁed as key
players in the negative regulation of NF-κB and
cell death in response to TNF (Lork et al. 2017).
In this review, we will discuss the molecular
mechanisms by which A20 regulates NF-κB sig-
naling and cell death, its own regulation, and our
current knowledge on its involvement in inﬂam-
matory and autoimmune pathology.
A20 STRUCTURE AND MECHANISM
OF NF-κB REGULATION
A20, also known as TNF-α-induced protein 3
(TNFAIP3), was ﬁrst discovered as a primary
response gene that is expressed on stimulation
of human endothelial cells with TNF, protecting
the cells from TNF-induced cell death (Dixit
et al. 1990). Although A20 was initially charac-
terized as an inhibitor of TNF-induced apopto-
sis, further studies identiﬁed A20 as a negative
regulator of TNF-inducedNF-κB activation, but
also of NF-κB signaling downstream from the
interleukin 1 receptor (IL-1R), pathogen recog-
nition receptors (PRRs), NOD-like receptors
(NLRs), T- and B-cell receptors, and CD40
(Opipari et al. 1990; Catrysse et al. 2014). The
basal expression of A20 is low in most cell types,
but is rapidly and transiently induced in inﬂam-
matory conditions through NF-κB-dependent
transcription owing to the presence of two κB
elements in the A20 promotor region (Krikos
et al. 1992). A20 thus behaves as a prototype
negative feedback regulator of NF-κB signaling.
A20 has been characterized as a so-called
“Ub-editing” enzyme that inhibits NF-κB sig-
naling by interfering with the ubiquitination
status of multiple NF-κB signaling proteins
(Wertz et al. 2004). The A20 protein consists
A. Martens and G. van Loo
2 Advanced Online Article. Cite this article as Cold Spring Harb Perspect Biol doi: 10.1101/cshperspect.a036418
 on August 20, 2019 - Published by Cold Spring Harbor Laboratory Press http://cshperspectives.cshlp.org/Downloaded from 
22
of an amino-terminal ovarian tumor (OTU) do-
main, which has DUB activity, and carboxy-ter-
minal zinc ﬁnger (ZnF) domains, with the
fourth ZnF domain shown to have Ub E3 ligase
activity (Wertz et al. 2004). In addition, theZnF4
domain was shown to act as a UBD for K63-
linked polyubiquitin (Bosanac et al. 2010).
More recently, the seventh ZnF (ZnF7) domain
ofA20was shown to function as aUBD, butwith
high binding afﬁnity for M1-linked Ub (Fig. 2;
Tokunaga et al. 2012; Verhelst et al. 2012). The
Ub editing function of A20 was ﬁrst shown in
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Figure 1.Tumor necrosis factor (TNF)-induced nuclear factor κB (NF-κB) signaling, apoptosis, and necroptosis.
Binding of TNF to TNF receptor 1 (TNFR1) induces receptor trimerization that allows the recruitment of TNF
receptor-associated death domain protein (TRADD) and receptor-interacting protein 1 (RIPK1). TRADD
recruits TRAF2/5 and the E3 ubiquitin (Ub) ligases cIAP1 and cIAP2. cIAP1 and cIAP2 conjugate RIPK1 as
well as themselves with K63-linked polyubiquitin chains, which serve as a platform for the recruitment of the
LUBAC complex, consisting of HOIP, HOIL1, and SHARPIN. Linear Ub chain assembly complex (LUBAC)
conjugates several components of the TNFR1 complex, including NEMO and RIPK1, with linear Ub chains
(M1). The TAB2/3–TAK1 complex binds K63-linked chains on RIPK1, whereas the IKK complex is recruited via
NEMO binding to M1-linked polyubiquitin. This allows TAK1 to phosphorylate and activate the IKK complex.
On activation, IKK2 phosphorylates the inhibitor of κB α (IκBα), targeting IκBα for ubiquitination with K48-
linked chains and proteasomal degradation. This releases the p50/p65 NF-κB dimer, which translocates to the
nucleus where it induces the expression of NF-κB response genes. A20 is recruited to the TNFR1 signaling
complex via M1-linked Ub, which binds to ZnF7. In addition, A20 has been shown to act as a deubiquitinating
enzyme (DUB) that removes K63-linked polyubiquitin from different target proteins, including RIPK1 and
NEMO. Furthermore, A20 has been shown to target RIPK1 and TNFR1 for proteasomal degradation through
its ZnF4 E3 ligase activity. Binding of A20 to M1-linked polyubiquitin prevents downstream signaling by
competing with other Ub-binding proteins and by preventing the degradation of M1-linked chains by CYLD
(not shown). Loss of M1-linked chains destabilizes complex I and results in the formation of a cytosolic death-
inducing signaling complex (DISC), consisting of TRADD, Fas-associated death domain (FADD), and caspase 8
(complex IIa) or RIPK1, FADD, and caspase-8 (complex IIb). Homodimerization and activation of caspase-8
leads to the activation of downstream executioner caspases 3 and 7 (not shown) and apoptotic cell death. If
caspase-8 activity is compromised, RIPK1 associates with RIPK3 (the necrosome), which is activated by auto-
phosphorylation. The activated necrosome recruits and activates MLKL inducing necroptotic cell death.
A20 in Cell Death, Inﬂammation, and Autoimmunity
Advanced Online Article. Cite this article as Cold Spring Harb Perspect Biol doi: 10.1101/cshperspect.a036418 3
 on August 20, 2019 - Published by Cold Spring Harbor Laboratory Press http://cshperspectives.cshlp.org/Downloaded from 
23
TNFR1 signaling. Using its tandem DUB-E3 li-
gase activities, A20 was shown to negatively reg-
ulate NF-κB signaling by replacing K63-linked
chains on RIPK1 with K48-linked chains, which
targeted RIPK1 for proteasomal degradation
(Wertz et al. 2004). A20 was also shown to de-
ubiquitinateTNFR1 andNEMOafterTNFstim-
ulation (Mauro et al. 2006; Wertz et al. 2015).
This DUB activity of A20 was further shown to
be promoted by IKK2-mediated phosphoryla-
tion of A20 at Ser381 (Fig. 2; Mauro et al.
2006; Wertz et al. 2015).
Besides its role in regulating TNF-induced
NF-κB signaling, the DUB activity of A20 was
shown to regulate TLR4- and NOD2-induced
NF-κB activation by removing K63-linked
chains from TRAF6 and RIPK2, respectively
(Boone et al. 2004; Hitotsumatsu et al. 2008).
Furthermore, A20 was shown to negatively reg-
ulate T-cell receptor (TCR)-induced NF-κB ac-
tivation by deubiquitinating MALT1, thereby
preventing the interaction between MALT1
and the IKK complex (Mauro et al. 2006; Duwel
et al. 2009). Besides functioning as a DUB, A20
can also affect the ubiquitination of signaling
mediators indirectly by interfering with the in-
teraction between E2 and E3 enzymes, limiting
polyubiquitin formation. In this context, A20
was shown to disrupt the interaction of TRAF6
with the E2 conjugating enzymes Ubc13 and
UbcH5c in response to IL-1 and LPS stimula-
tion. Similarly, on TNF stimulation, A20 was
shown to prevent the association between
Ubc13 and both cIAP1 and TRAF2 (Shembade
et al. 2010).
Despite many reports claiming a crucial role
of A20 as aDUB regulatingNF-κB signaling, the
physiological relevance of the deubiquitinase ac-
tivity of A20 is still unclear. Recently, a number
of transgenic mouse lines bearing a point muta-
tion in the catalytic OTU domain (A20-C103A,
A20OTU mice) to abrogate A20 DUB activity
were generated (Lu et al. 2013; De et al. 2014;
Wertz et al. 2015). These mice are grossly nor-
mal and do not develop the severe phenotype of
A20-deﬁcient mice, which die perinatally be-
cause of multiorgan inﬂammation and cachexia
(Lee et al. 2000). However, A20OTU mice were
shown to be sensitized to TNF and LPS treat-
ment, and to dextran sodium sulfate (DSS)-in-
duced colitis and experimental autoimmune
encephalomyelitis (EAE) (Lu et al. 2013; Wertz
et al. 2015). De and colleagues, however, did not
observe sensitization of A200TU mice to LPS-in-
duced pathology, nor did they observe any
difference in TNF- or LPS-induced NF-κB sig-
naling or cell death in cells derived from these
mice. They concluded that the DUB function of
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Figure 2. Domain structure of the A20 protein. The amino terminus of A20 contains an ovarian tumor (OTU)
domain, which has deubiquitinating enzyme (DUB) activity relying on the catalytic residue Cys103. The car-
boxy-terminal part of A20 contains seven zinc ﬁnger (ZnF) domains. The fourth ZnF domain has K63-linked
polyubiquitin-binding afﬁnity and possesses E3 ubiquitin (Ub) ligase activity, whereas the seventh ZnF domain
has strong binding afﬁnity for linear (M1) Ub chains. IKK2-mediated phosphorylation of A20 at Ser381 en-
hances the DUB activity of A20 toward K63-linked polyubiquitin. MALT1 cleaves A20 at Ala439 in human, or
between the third and fourth ZnF domains inmouse. Mutations that were introduced to generate OTU (C103A),
ZnF4 (C609A, C612A), or ZnF7 (C764A, C767A) domain-speciﬁc mutant mice are depicted by red stars. Both
the OTU and ZnF4 domains have been shown to bind to E2 enzymes Ubc13 and UbcH5c.
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A20 is dispensable for inﬂammatory signaling in
vivo (De et al. 2014). A20 transgenic mice with a
mutation in the E3 ligase activity (A20-C609A/
C612A, A20ZnF4mice) have also been generated,
but these mice also develop normally without
any spontaneous phenotype (Lu et al. 2013;
Wertz et al. 2015). Mouse embryo ﬁbroblasts
isolated from A200TU or A20ZnF4 mice show in-
creasedK63-linked ubiquitination of RIPK1 and
TNFR1, resulting in slightly increased mitogen-
activated protein kinase (MAPK) and NF-κB
signaling on TNF stimulation (Lu et al. 2013;
Wertz et al. 2015). Together, these ﬁndings
indicate that neither theDUBnor E3 ligase func-
tions of A20 critically contribute to its anti-in-
ﬂammatory function in vivo. Simultaneous in-
activation of the OTU and ZnF4 domains may
be required to fully abolish its function and
phenocopyA20-deﬁcientmice. However, recent
in vitro and in vivo evidence indicates that ZnF7
of A20 plays a more prominent role. A20 was
shown to impair IKK activation through a non-
enzymatic mechanism based on its binding to
polyubiquitin via ZnF7 (Skaug et al. 2011). Ad-
ditional studies have shown that A20 recruit-
ment to TNFR1 andNOD2-associated signaling
complexes by binding of ZnF7 to LUBAC-gen-
erated M1-linked polyubiquitin is required to
inhibit downstream NF-κB signaling (Iwai and
Tokunaga 2009; Tokunaga et al. 2012; Verhelst
et al. 2012; Draber et al. 2015). Recently, we gen-
erated mice bearing a mutation in A20 ZnF7
domain (A20-C764A/C767A, A20ZnF7 mice)
that abolishes its capacity to bind to M1-linked
chains. These mice develop a spontaneous in-
ﬂammatory arthritis and have reduced body-
weight and splenomegaly, showing an indis-
pensable function for ZnF7 in A20-mediated
suppression of inﬂammation in vivo (Polykratis
et al. 2019). The ZnF7 mutation abolished the
recruitment of A20 into the TNFR1 signaling
complex, and reduced the amount of linear Ub
chains within the complex (Draber et al. 2015;
Polykratis et al. 2019). These observations indi-
cate that A20 through its ZnF7 stabilizes M1
linkages in the TNFR1 signaling complex,
shielding them from degradation by DUBs that
are capable of cleaving linear Ub chains in sig-
naling complexes. However, the spontaneous
inﬂammatory phenotype of A20ZnF7 mice is
mild compared with the severe multiorgan in-
ﬂammation and postnatal lethality seen in A20
knockout mice (Lee et al. 2000), suggesting that
other domains also critically contribute to A20’s
anti-inﬂammatory function in vivo. Knockin
mice with combined domain mutations may
be required to fully inactivate A20 and pheno-
copy the A20 knockout.
A20 IN THE REGULATION OF CELL DEATH
In addition to its role in the regulation of NF-κB
signaling, A20 also acts as a strong inhibitor of
cell death in many cell types. Originally, A20
was identiﬁed as an inhibitor of TNF-induced
apoptosis in endothelial cells (Dixit et al. 1990),
but it can also limit apoptosis in thymocytes and
ﬁbroblasts (Lee et al. 2000), pancreatic β cells
(Liuwantara et al. 2006; Catrysse et al. 2015;
Fukaya et al. 2016), hepatocytes (Catrysse et al.
2016), and intestinal epithelial cells (IECs) (Ve-
reecke et al. 2010, 2014; Kattah et al. 2018;
Slowicka et al. 2019).
Besides dying from caspase-dependent
apoptosis, cells can also undergo caspase-inde-
pendent but RIPK3- and MLKL-dependent
necroptosis (Fig. 1; Pasparakis and Vandena-
beele 2015; Ting and Bertrand 2016). A20 has
also been proposed as an inhibitor of necropto-
sis in some cell types. A20-deﬁcient T cells were
shown to be more susceptible to anti-CD3/
CD28-induced cell death, independent of cas-
pase activation but dependent on RIPK3 and the
kinase activity of RIPK1 (Onizawa et al. 2015).
In addition, RIPK3 deﬁciency or inhibition of
RIPK1 could considerably delay the early post-
natal lethality of A20 knockout mice (Onizawa
et al. 2015; Newton et al. 2016). In contrast,
MLKL deﬁciency could not rescue the early le-
thality of A20 knockout mice, questioning the
role of necroptosis in the pathology of these
mice (Newton et al. 2016). We recently showed
that A20-deﬁcient macrophages can die from
RIPK1/RIPK3/MLKL-dependent necroptosis,
causing inﬂammasome activation and arthritis
development in myeloid-speciﬁc A20-deﬁcient
mice (Polykratis et al. 2019). Therefore, inhibi-
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tion of necroptosis is a critical anti-inﬂamma-
tory function of A20 in vivo.
Finally, in some cell types, A20 may have
proapoptotic functions. A20-deﬁcient B cells
and dendritic cells were shown to be protected
from Fas-mediated cell death, most likely owing
to the up-regulation of NF-κB-dependent ex-
pression of antiapoptotic proteins such as
Bcl-2 and Bcl-x (Tavares et al. 2010; Kool et al.
2011). A20 was also shown to sensitize smooth
muscle cells to apoptosis through a mechanism
depending on nitric oxide (NO) production
(Patel et al. 2006).
Although it is clear that A20 is a key regula-
tor of cell death, the mechanisms by which it
does this are still incompletely understood. On
activation of death receptors, A20 was shown to
be recruited to the DISC, where it physically
interacted with caspase-8. This interaction was
suggested to prevent cullin3-mediated ubiquiti-
nation of caspase-8, inhibiting caspase-8 activa-
tion and apoptosis (Jin et al. 2009). Alterna-
tively, A20 was shown to inhibit TNF-induced
apoptosis by preventing the recruitment of
RIPK1 and TRADD to TNFR1, thereby inhibit-
ing the recruitment of FADD and caspase-8 (He
and Ting 2002). A20 was also shown to inhibit
TNF-induced c-jun amino-terminal kinase
(JNK) activation and apoptosis by targeting
upstream ASK1 for ubiquitination and protea-
somal degradation (Won et al. 2010). In the
context of its protective function against necrop-
tosis, A20 was shown to restrict RIPK3 ubiquiti-
nation, preventing the formation of RIPK1–
RIPK3 complexes and necroptosis induction
(Onizawa et al. 2015).
Although these latter studies suggest that
A20 acts as either a DUB or an E3 ligase, it is
becoming more established that the nonenzy-
matic, polyubiquitin-binding function of A20
plays a prominent role in the regulation of cell
death. A reduction of linear Ub chains within
TNFR1 complex I was shown to promote cell
death by inducing complex II assembly (Ikeda
et al. 2011; Peltzer et al. 2014). The ZnF7 domain
of A20 stabilizes linear Ub chains in complex I,
inhibiting TNFR1-mediated cell death (Draber
et al. 2015; Yamaguchi and Yamaguchi 2015).
Hence, a mutation in the ZnF7 domain of A20
abolishes the recruitment of A20 and reduces
the amount of linear Ub chains in TNFR1 com-
plex I (Tokunaga et al. 2012; Draber et al. 2015;
Polykratis et al. 2019). Interestingly, the binding
of M1-linked chains by ZnF7 in A20 was shown
to protect these chains from degradation by
CYLD, thereby stabilizing complex I and pre-
venting the formation of the DISC (Fig. 1;
Draber et al. 2015).
MECHANISMS THAT REGULATE A20
ACTIVITY
A20 expression and function is under the
control of several regulatory mechanisms, viz.
transcriptional, posttranscriptional, and post-
translational. In most cell types, A20 expression
levels are low at steady state, but are rapidly up-
regulated in inﬂammatory conditions as a result
of NF-κB activation (Krikos et al. 1992; Ver-
strepen et al. 2010). Different transcription fac-
tors work together to ﬁne-tune the expression of
A20 and the strength of NF-κB signaling.
DREAM (downstream regulatory element an-
tagonist modulator) has been shown to consti-
tutively repress expression of A20 by binding to
downstream regulatory elements (DREs) in the
A20 promoter, whereas upstream stimulatory
factor 1 (USF1) has been shown to bind to the
DRE-associated E-box domain in A20 to acti-
vate its expression in response to an inﬂamma-
tory stimulus (Amir-Zilberstein and Dikstein
2008; Tiruppathi et al. 2014). Also, the orphan
nuclear estrogen-related receptor α (ERRα), a
key metabolic regulator, has been shown to pro-
mote expression ofA20 inmice (Yuket al. 2015).
ERRα binds to an Esrra consensus motif in the
A20 promoter, inducing expression of A20 and
suppressing NF-κB signaling in LPS-stimulated
macrophages (Yuk et al. 2015). Finally, the his-
tone methyltransferase Ash1l (absent small or
homeotic-like) was shown to enhance expres-
sion of A20 through H3K4 methylation of the
A20 promoter, suppressing inﬂammatory sig-
naling (Xia et al. 2013).
T lymphocytes constitutively express high
levels of A20, which are down-regulated on
TCR activation and NF-κB induction (Tewari
et al. 1995). Proteasomal degradation of A20,
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as well as its cleavage by the paracaspase
MALT1, contribute to the down-regulation of
A20 following TCR stimulation (Coornaert
et al. 2008; Duwel et al. 2009). Methylation of
theA20 promotor, preventing expression of A20
and stimulating constitutive NF-κB activation,
has been observed in several types of lympho-
mas (Honma et al. 2009; Chanudet et al. 2010).
Expression ofA20 is also regulated by several
microRNAs (miRs). In diffuse large B-cell lym-
phomas, miR-125a and miR-125b were shown
to down-regulate expression of A20, leading to
constitutive activation of NF-κB, B-cell prolifer-
ation, and lymphomagenesis (Kim et al. 2012).
miR-125-mediated inhibition of A20 has also
been shown in lung infection and in chronic
obstructive pulmonary disease (COPD) (Hsu
et al. 2017). miR-19, miR-29, miR-221, and
miR-let-7 are other miRNAs that have been
shown to suppress A20, leading to enhanced
NF-κB signaling and/or cell death (Wang et al.
2011; Gantier et al. 2012; Balkhi et al. 2013;
Kumar et al. 2015; Langsch et al. 2016; Zhao
et al. 2016).
A20 interacts with different partners to per-
form its regulatory functions. Multiple Ub-
binding proteins have been described that bind
to A20 and recruit it to its substrates. A20-bind-
ing inhibitor of NF-κB (ABIN1) was shown to
recruit A20 to polyubiquitinated NEMO to re-
move Ub chains from NEMO (Heyninck et al.
1999; Mauro et al. 2006; Wagner et al. 2008).
Tax1-binding protein 1 (TAX1BP1) negatively
regulates NF-κB signaling by recruiting A20 to
TRAF6 and RIPK1 (Shembade et al. 2007; Iha
et al. 2008). Itch and RING ﬁnger protein 11
(RNF11) have been shown to function as sub-
units of an A20 Ub-editing complex to inhibit
NF-κB signaling (Shembade et al. 2008, 2009).
The activity of A20 is also regulated by post-
translational modiﬁcations. On receptor activa-
tion, A20 is phosphorylated at Ser381 by IKK2,
increasing its inhibitory capacity (Hutti et al.
2007). Although A20 hydrolyzes K63-linked
Ub chains in vivo via its OTU domain, recom-
binant A20 expressed in bacteria preferentially
cleaves K48-linked chains in vitro (Komander
and Barford 2008; Lin et al. 2008). The phos-
phorylation status of A20 appears to account for
this discrepancy because phosphorylated A20
was shown to efﬁciently cleave K63-linked
chains in vitro (Wertz et al. 2015). In T lympho-
cytes, A20 can be ubiquitinated by the E3 Ub
ligase RNF114, thereby stabilizing A20 and
restraining NF-κB responses (Rodriguez et al.
2014). In smooth muscle cells exposed to high
glucose levels, A20 can be O-glycosylated
and subsequently ubiquitinated and targeted
for proteasomal degradation (Shrikhande et al.
2010). Finally, A20 is also regulated by reversible
oxidation of the catalytic cysteine residue, mod-
ifying its activation state (Kulathu et al. 2013;
Lee et al. 2013).
A20 AS A DISEASE SUSCEPTIBILITY GENE
Several single-nucleotide polymorphisms
(SNPs) in or near the A20 gene have been
linked to a variety of autoimmune and inﬂam-
matory diseases, including systemic lupus ery-
thematosus (SLE), rheumatoid arthritis, psori-
asis, type 1 diabetes, Crohn’s disease, celiac
disease, coronary artery disease in type 2 dia-
betes, systemic sclerosis, and Sjogren’s syn-
drome (Ma and Malynn 2012; Catrysse et al.
2014). Associations have also been reported
for autoimmune hepatitis (de Boer et al. 2014)
and primary biliary cirrhosis (Cordell et al.
2015). Most of these disease-associated variants
are located in upstream or downstream non-
coding regions or in intronic regions of the
A20 gene, possibly affecting the expression of
A20 (Graham et al. 2008; Adrianto et al. 2011).
Downstream SNPs can inﬂuence expression of
A20 by affecting the function of cell- and acti-
vation-speciﬁc enhancers. For example, dele-
tion of a downstream region containing four
enhancers was shown to signiﬁcantly reduce
expression of A20, resulting in enhanced in-
ﬂammatory responses (Sokhi et al. 2018). One
of these enhancers harbors the TT >A variant
that was linked to SLE susceptibility (Adrianto
et al. 2011; Wang et al. 2013a). Deletion of this
TT >A enhancer in mice induced spontaneous
inﬂammatory arthritis, thereby establishing the
importance of this enhancer in preventing
inﬂammatory pathology and autoimmunity
(Sokhi et al. 2018). Besides the many noncod-
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ing variants, two SNPs have been identiﬁed in
exon 3 of A20 that induce nonsynonymous
mutations (rs5029941/A125V and rs2230926/
F127C) (Musone et al. 2008; Lodolce et al.
2010). These mutations are suggested to affect
the DUB activity of A20, although this has not
been evaluated in vivo.
Recently, whole-exome sequencing identi-
ﬁed heterozygous loss-of-function mutations
in the A20/TNFAIP3 gene (A20 haploinsufﬁ-
ciency, HA20) of patients with a rare, early-on-
set autoinﬂammatory syndrome (Zhou et al.
2016). These nonsense and frameshift muta-
tions are all localized in the DUB or the ZnF4
domains of A20, and the mutant proteins are
likely unstable because A20 was not detected
in cells from HA20 patients (Zhou et al. 2016).
Patients’ cells displayed increased NF-κB signal-
ing, NLRP3 inﬂammasome activity, and in-
creased expression of proinﬂammatory cyto-
kines (Zhou et al. 2016). Several other cases of
germline HA20 have since been identiﬁed in
patients with early-onset autoimmune disease
(Fig. 3; Table 1; Aeschlimann et al. 2018; Dun-
can et al. 2018). Overall, HA20 patients develop
recurrent oral, genital, and/or gastrointestinal ul-
cers, musculoskeletal and gastrointestinal prob-
lems, episodic fever, and recurrent infections.
However, disease severity is strongly patient-de-
pendent, ranging from very mild disease to se-
vere multiorgan inﬂammation, and treatment
regimens need to be adjusted to disease severity
(Aeschlimann et al. 2018).
Finally, A20 has been identiﬁed as a tumor
suppressor gene, because biallelic somatic mu-
tations in A20 are frequently observed in several
B-cell lymphomas, including MALT lympho-
ma, Hodgkin’s lymphoma, diffuse large B-cell
lymphoma, and follicular lymphoma. These
loss-of-function mutations are associated with
constitutive NF-κB signaling and uncontrolled
cell proliferation (Compagno et al. 2009;Honma
et al. 2009; Kato et al. 2009; Novak et al. 2009;
Schmitz et al. 2009; Okosun et al. 2014). Biallelic
mutations in A20 have also been identiﬁed in
Sézary syndrome, an aggressive variant of cuta-
neous T-cell lymphoma (Braun et al. 2011).
However, A20 has also been described as a
tumor promotor, likely connected to its anti-
apoptotic functions, and high levels of A20
have been detected in glioma (Guo et al. 2009),
glioblastoma (Hjelmeland et al. 2010), and acute
lymphoblastic leukemia (Chen et al. 2015). Fur-
thermore, A20 was shown to be up-regulated
in human basal-like breast cancers in which
it promotes epithelial–mesenchymal transition
(EMT) through monoubiquitination and nucle-
ar stabilization of SNAIL1, a transcription factor
that drives EMT (Lee et al. 2017).
TISSUE-SPECIFIC FUNCTIONS OF A20
A20 is an important anti-inﬂammatory protein
that acts as a direct inhibitor of NF-κB signaling,
or as an inhibitor of proinﬂammatory cell death.
However, inﬂammatory signaling pathways and
OTUN CZnF1 ZnF2 ZnF3 ZnF4 ZnF5 ZnF6 ZnF7
C103A
C609A
C612A
C764A
C767A
c.133C>T
TNFAIP3
c.671delT c.799del6
c.994G>T
c.918C>G
c.1345delA
c.1466_1467delTG
c.1760_1771del11
c.1809delG c.2209delC
c.1906C>T
c.1906+1G>A
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Figure 3. Schematic representation of the TNFAIP3 gene indicating mutations causing A20 haploinsufﬁciency
(HA20). Exons (1–9) are represented as rectangles. Exons encoding the ovarian tumor (OTU) domain are
depicted in green and exons encoding the ZnF domains are depicted in orange; noncoding exons are shown
in gray. HA20 mutations depicted in the ﬁgure are also listed in Table 1.
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cell death are differentially regulated in different
cell types; hence, A20 may have cell-speciﬁc
contributions to prevent inﬂammation and dis-
ease pathogenesis. Because A20 knockout mice
die prematurely because of severe multiorgan
inﬂammation (Lee et al. 2000), conditional, lin-
eage-speciﬁc knockout strategies are needed to
unravel the tissue-speciﬁc functions of A20. Sev-
eral tissue-speciﬁc A20-deﬁcientmice have been
generated in recent years that clearly show the
importance of A20 in maintaining tissue ho-
meostasis by regulating inﬂammatory responses
and cell death (Table 2). In this section, we refer
to a number of recentmouse studies that provide
new information on the role of A20 in the pre-
vention of cell death and its implications for
inﬂammatory pathology.
Mice lacking A20 in their myeloid cells
(A20Myel-KO) develop spontaneous polyarthritis
withmany characteristics of human rheumatoid
arthritis, including autoantibodies against type
II collagen and rheumatoid arthritis–associated
cytokines (Matmati et al. 2011). The arthritis
phenotype in A20Myel-KO mice was shown to
require IL-6 and TLR4-MyD88, but not TNF.
Primary macrophages from these mice show
sustained NF-κB activation in response to lipo-
polysaccharide (LPS), in agreement with a role
for A20 as an inhibitor of NF-κB signaling (Mat-
mati et al. 2011). A20-deﬁcient macrophages
also express higher levels of STAT1 and
STAT1-dependent genes upon stimulation
with interferon γ (IFN-γ) or IL-6. Inhibition of
JAK-STAT signaling in vivowith the JAK inhib-
itor tofacitinib was shown to suppress the de-
velopment of enthesitis in A20Myel-KO mice (De
Wilde et al. 2017). Interestingly, myeloid A20 de-
ﬁciency was also shown to promote osteoclasto-
genesis, suggesting a role for A20 in regulating
receptor activator of the NF-κB (RANK)-in-
duced NF-κB signaling. Further studies, prefer-
ably using osteoclast-speciﬁc A20 targeting, are
needed to conﬁrm a direct regulatory role of A20
in regulating osteoclastogenesis and bone for-
mation.
Arthritis development in A20Myel-KO mice
relies on activation of the Nlrp3 inﬂammasome
and IL-1R signaling (Vande Walle et al. 2014).
Thus, A20Myel-KO mice crossed into an Nlrp3-,
caspase-1/11-, or IL-1R-deﬁcient background
no longer develop arthritis. Primary A20-de-
ﬁcient macrophages show enhanced Nlrp3
inﬂammasome-mediated caspase-1 activation,
pyroptosis, and IL-1β secretion by soluble and
Table 1. Overview of identified HA20 mutations
cDNA alteration
Amino acid
alteration Domain References
c.680T <A p.Leu227 Ovarian tumor (OTU) Zhou et al. 2016; Aeschlimann et al. 2018
c.671delT p.Phe224Serfs4 OTU
c.811C >T p.Arg271 OTU
c.1809delG p.Thr604Argfs93 ZnF4
c.918C >G p.Tyr306 OTU
c.799delG p.Pro268Leufs19 OTU
c.252delC p.Trp85Glyfs11 OTU Shigemura et al. 2016; Ohnishi et al. 2017;
Takagi et al. 2017; Kadowaki et al. 2018c.133C >T p.Arg45 OTU
c.1760_1770del11 p.Ala588Valfs80 Between ZnF3-4
c.1345delA p.Asn449Thrfs28 Between ZnF1-2
c.1906 + 1G>A p.Phe637Glu2 Between ZnF4-5
c.2209delC p.Gln737Serfs79 ZnF6
c.2088 + 5G>C p.His636Glufs55 ZnF4
c.728G >A p.Cys243Tyr OTU
c.1245-1248del4 p.Lys417Serfs4 Between ZnF1-2
c.994G >T p.Glu332 OTU Berteau et al. 2019
c.1466_1467delTG p.Val489Alafs7 ZnF2 Duncan et al. 2018
c.1906C >T p.His636fs1 ZnF4 Lawless et al. 2018
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Table 2. Phenotypes of tissue-specific A20 knockout and A20 transgenic mice
Cell type OE/KO Phenotype References
Myeloid cells KO Spontaneous severe destructive polyarthritis Matmati et al. 2011;
Vande Walle et al.
2014; De Wilde et al.
2017; Polykratis et al.
2019
KO Protected from inﬂuenza A virus infection Maelfait et al. 2012
Dendritic cells KO Spontaneous colitis, IBD-associated arthritis Hammer et al. 2011
KO Systemic autoimmunity resembling SLE Kool et al. 2011
KO Multiorgan inﬂammation, hypersensitive to LPS Xuan et al. 2015
B cells KO Development of autoimmune syndrome in older mice
(autoreactive immunoglobulins, glomerular
immunoglobulin deposits, ↑ germinal center B cells, B-cell
resistance to Fas-mediated cell death)
Tavares et al. 2010; Chu
et al. 2011; Hovelmeyer
et al. 2011
T cells KO No spontaneous phenotype, ↓ iNKT cell numbers Drennan et al. 2016
KO No spontaneous phenotype, protected from EAE Onizawa et al. 2015
KO Lymphadenopathy but no detectable pathology, enhanced
antitumor activity
Giordano et al. 2014
KO ↑ Treg cell numbers Fischer et al. 2017
HSC KO Loss of HSC quiescence causing anemia, lymphopenia, and
postnatal lethality
Nakagawa et al. 2015
Mast cells KO Hypersensitive to allergic airway responses and collagen-
induced arthritis
Heger et al. 2014
IEC KO No spontaneous pathology, enhanced susceptibility to DSS-
induced colitis and to TNF toxicity
Vereecke et al. 2010;
Kattah et al. 2018
OE Protected from LPS-induced barrier disruption Kolodziej et al. 2011
OE Protected from DSS-induced IEC death and barrier
disruption
Rhee et al. 2012
OE Hypersensitive to TNF-induced IEC death and systemic
inﬂammation
Garcia-Carbonell et al.
2018
IEC+myeloid
cells
KO Spontaneous severe ileitis and colitis, colorectal cancer Vereecke et al. 2014
Hepatocytes KO Chronic liver inﬂammation, enhanced sensitivity to TNF and
LPS toxicity and to chemically and high fat diet–induced
hepatocarcinogenesis
Catrysse et al. 2016
Keratinocytes Keratinocyte hyperproliferation, ectodermal organ
abnormalities, sensitized to experimental psoriasis, and
atopic dermatitis
Lippens et al. 2011; Devos
et al. 2019
Neurons KO No phenotype McGuire et al. 2013
CNS
progenitor
cells
KO
Microglia KO ↑Microglia numbers andmicroglia activation, hypersensitive
LPS and EAE
Voet et al. 2018
Astrocytes KO Hypersensitive to EAE Wang et al. 2013b
Airway
epithelial
cells
KO Protected from inﬂuenza Avirus infection, highly sensitive to
allergic airway inﬂammation
Schuijs et al. 2015;
Maelfait et al. 2016
Pancreatic β
cells
KO No phenotype Liuwantara et al. 2006;
Catrysse et al. 2015;
Fukaya et al. 2016
OE, Overexpression; KO, knockout; IBD, inﬂammatory bowel disease; SLE, systemic lupus erythematosus; LPS, lipopoly-
saccharide; iNKT, invariant natural killer T cell; EAE, experimental autoimmune encephalomyelitis; HSC, hematopoietic stem
cell; IEC, intestinal epithelial cell; DSS, dextran sodium sulfate; TNF, tumor necrosis factor.
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crystalline Nlrp3 stimuli. Myeloid-speciﬁc ASC
deﬁciency substantially ameliorated arthritis in
A20Myel-KO mice, indicating that cell-intrinsic
inﬂammasome activation in A20-deﬁcient my-
eloid cells drives pathology (Polykratis et al.
2019). Although A20 was shown to regulate
Nlrp3 inﬂammasome activation in vitro by neg-
atively regulating NF-κB-dependent priming
needed for optimal expression of pro-IL-1β
and Nlrp3 (Vande Walle et al. 2014), inhibition
of IKK/NF-κB signaling in A20-deﬁcient mye-
loid cells was not sufﬁcient to prevent arthritis
development (Polykratis et al. 2019). Rather,
regulation of cell death, and particularly of
necroptosis, was identiﬁed as the key anti-in-
ﬂammatory function of A20 in preventing the
development of arthritis. Indeed, RIPK1/
RIPK3/MLKL-dependent macrophage necro-
ptosis was shown to induce inﬂammasome
activation, IL-1β production, and arthritis de-
velopment in A20Myel-KO mice (Polykratis et al.
2019). These data are supported by real-time
single-cell imaging experiments, which show
that IL-1β is secreted exclusively by dying
A20-deﬁcient macrophages. An earlier study
had suggested that inﬂammasome activation
and IL-1β release in A20-deﬁcient macrophages
occurs in the absence of cell death (Duong et al.
2015). A20 has also been shown to control mi-
croglia activation and neuroinﬂammation via
regulation of Nlrp3 inﬂammasome activation
(Voet et al. 2018). How A20 regulates Nlrp3
activation, and whether this is directly or indi-
rectly preventing microglia cell death, needs
further investigation.
An important prosurvival role for A20 has
also been shown in IECs. Although IEC-speciﬁc
A20 knockout mice (A20IEC-KO) do not develop
spontaneous disease, they are highly susceptible
to DSS-induced colitis and are hypersensitive to
a normally sublethal dose of TNF. IECs from
A20IEC-KO mice are hypersensitive to apoptosis,
leading to loss of intestinal barrier integrity and
bacterial inﬁltration in A20IEC-KO mice (Ve-
reecke et al. 2010). The antiapoptotic property
of A20. in IECs was conﬁrmed in transgenic
mice with IEC-speciﬁc overexpression of A20.
These mice are protected from DSS- and LPS-
induced IEC apoptosis and loss of barrier func-
tion (Kolodziej et al. 2011; Rhee et al. 2012), but
are highly susceptible to TNF-induced IEC apo-
ptosis, intestinal damage, and systemic inﬂam-
mation. The latter phenotype required RIPK1
and caspase-8, and was mediated by ZnF7 of
A20 (Garcia-Carbonell et al. 2018). Thus, A20
binding to linear Ub appears to stabilize the
Ripoptosome and potentiate its apoptosis-in-
ducing activity (Garcia-Carbonell et al. 2018).
Although A20IEC-KO mice do not develop a
spontaneous intestinal phenotype (Vereecke
et al. 2010; Kattah et al. 2018), mice lacking
A20 in both IECs and myeloid cells develop se-
vere ileitis and colitis, associated with epithelial
apoptosis and hyperproliferation, which eventu-
ally leads to the development of colon cancer
(Vereecke et al. 2014). Combined IEC-speciﬁc
deletion of A20 and the A20-interacting protein
ABIN1 also induces spontaneous intestinal in-
ﬂammation and severe pathology because of the
caspase-8 and RIPK1-dependent death of IECs
(Kattah et al. 2018). Similarly, combined dele-
tion of A20 and Atg16L1 in IECs induces spon-
taneous inﬂammatory bowel disease (IBD)-like
pathology caused by IEC apoptosis (Slowicka
et al. 2019). Interestingly, both ABIN-1 and
Atg16L1 have been associatedwith IBD (Hampe
et al. 2007; Rioux et al. 2007; Jostins et al. 2012)
and have been shown to bind to A20 and to Ub
(Wagner et al. 2008; Fujita et al. 2013; Slowicka
et al. 2019). Collectively, these data suggest that
inﬂammatory signaling and autophagy cooper-
atively control intestinal homeostasis by pre-
venting the death of enterocytes thatwould com-
promise intestinal barrier integrity.
Finally, A20 was shown to have hepatopro-
tective activities. Hepatocyte-speciﬁc A20-deﬁ-
cient mice (A20LPC-KO) spontaneously develop
mild liver inﬂammation and steatosis, but suc-
cumb to a normally sublethal dose of TNF ow-
ing to excessive hepatocyte apoptosis.Moreover,
chronic liver inﬂammation and enhanced hepa-
tocyte apoptosis in A20LPC-KO mice increased
their susceptibility to chemically and high fat
diet–induced hepatocellular carcinoma devel-
opment (Catrysse et al. 2016). A20 overexpres-
sion in liver has been shown to be protective
in models of hepatectomy and acute toxic
hepatitis, owing to antiapoptotic and anti-
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inﬂammatory mechanisms (Arvelo et al. 2002;
Ramsey et al. 2009; Damrauer et al. 2011; da
Silva et al. 2013).
CONCLUDING REMARKS
A20 was identiﬁed nearly 30 years ago (Dixit
et al. 1990; Opipari et al. 1990) and has emerged
as a critical regulator of inﬂammatory signaling
to preserve tissue immune homeostasis. Al-
though inhibition of NF-κB activation has
long been considered the key anti-inﬂammatory
function of A20, it is becoming more evident
that its role in preventing cell death is a major
mechanism for suppressing inﬂammation.
However, A20 may have different modes of ac-
tion in different cell types given the phenotypes
of different tissue-speciﬁc A20 knockout mice.
NF-κB inhibitory activities, antiapoptotic func-
tions, as well as antinecroptotic functions, and
even proapoptotic functions have been identi-
ﬁed in different cell types. Mechanistically, A20
has been proposed to function as a DUB, but the
physiological relevance of its function as a DUB
has been challenged by the ﬁnding that DUB-
inactive A20 knockinmice do not develop spon-
taneous inﬂammatory disease. Recent evidence
suggests that A20 mainly acts as a Ub-binding
protein via its ZnF7 domain, which primarily
recruits A20 into speciﬁc protein complexes to
prevent downstream signaling. However, ﬁne-
tuning of signaling may require additional
A20-speciﬁc activities, including A20 DUB ac-
tivity. Generation of knockin mice with com-
bined domain mutations will be essential to
dissect the importance of and redundancies be-
tween the different functional domains of A20.
Such studies will help to better understand the
role of A20 in inﬂammation and immunity,
which might help to develop new therapeutics
for the treatment of disease.
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INFLAMMATORY RESPONSE
A20 phosphorylation controls A20 function
A new study has identified various previously unknown mutations in the genes encoding human and mouse A20 
that affect its phosphorylation and its function as an inhibitor of the transcription factor NF-κB, with implications 
for immunity and inflammatory disease.
Arne Martens and Geert van Loo
Inflammation is a protective response for resistance to infections and the induction of repair in conditions of damage and 
stress. However, excessive inflammatory 
responses can lead to chronic inflammation, 
tissue damage and the development of 
disease, indicative of the need for tight 
control of inflammatory processes. 
One of the key molecules that regulate 
inflammatory signaling via the transcription 
factor NF-κB is A20, and mutations in the 
gene encoding A20 (TNFAIP3) have been 
identified in patients with inflammatory 
or autoimmune diseases1. In this issue 
of Nature Immunology, Zammit et al. 
demonstrate how different newly discovered 
TNFAIP3 alleles encoding A20 variants 
can modulate, to different degrees, the 
phosphorylation of A20, with graded effects 
on NF-κB responses, microbial tolerance 
and immunity2.
A20 has been characterized as a 
‘ubiquitin-editing’ enzyme that inhibits 
the activation of NF-κB by changing the 
ubiquitination status of NF-κB signaling 
proteins through the presence (in A20) 
of an amino-terminal ovarian tumor 
(OTU) domain with deubiquitinase 
(DUB) activity, and of a carboxy-terminal 
zinc-finger domain with E3 ligase activity 
and ubiquitin-binding properties1,3. 
A20’s own activity is under the control of 
several regulatory mechanisms, including 
phosphorylation. In inflammatory 
conditions, A20 is phosphorylated at Ser381 
by the NF-κB-activating kinase IKK2, which 
increases its inhibitory capacity4. Indeed, 
when phosphorylated, A20 has been shown 
to more efficiently cleave ubiquitin chains 
and suppress inflammatory signaling, 
which illustrates the importance of its 
phosphorylation for its DUB activity5.
In their study, Zammit et al. describe 
three new A20 variants, each with a different 
alteration in the OTU domain that affects 
the phosphorylation and activation of  
A20 to a different degree2 (Fig. 1). First,  
they identify the allele encoding the  
A20 variant consisting of the T108A and 
I207L substitutions (collectively called  
‘T108A/I207L’ here) through whole-genome 
sequencing of healthy subjects of Maori 
and Pacific Islander ancestry. This A20 
variant turns out to be frequent among 
people of Island Southeast Asia and Oceania 
who acquired part of their genome from 
Denisova hominins, archaic humans who 
migrated from Siberia (from the so-called 
‘Denisova Cave’ in the Altai Mountains) 
through Asia to settle in the islands of 
Southeast Asia and Oceania. The Denisovan 
T108A/I207L variant is associated with 
enhanced expression of NF-kB response 
genes after stimulation of carrier peripheral 
blood mononuclear cells with the cytokine 
TNF, indicative of a (partial) loss of function 
of A20 as an inhibitor of NF-κB. The second 
A20 OTU variant, I325N, is identified in 
an N-ethyl-N-nitrosourea–mutagenized 
mouse strain with an increased frequency 
of activated and/or memory and regulatory 
T cells. Immune cells from these mice show 
increased activation of NF-κB, and I325N 
macrophages produce more inflammatory 
cytokines after being stimulated with 
lipopolysaccharide in vitro. The third OTU 
domain mutant, C243Y, was identified, 
through whole-exome sequencing, in a 
Japanese family with a history of Behcet’s 
disease and was shown to affect proper 
regulation of NF-κB, which led to enhanced 
production of inflammatory cytokines6. 
Next, Zammit et al. introduce the human 
TNFAIP3 alleles encoding the A20 variants 
I207L and C243Y into mice via CRISPR-
Cas9 gene editing for functional studies2. 
In agreement with the human condition, 
mice homozygous for the allele encoding 
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Fig. 1 | Newly discovered A20 variants that affect phosphorylation of A20, NF-κB signaling, microbial 
tolerance and immunity. a, A20 and the mutant variants (top left) of its OTU domain (purple), including 
the C103A variant of the OTU catalytic residue, and the T108A, I207L, C243Y and I325N variants 
(encoded by missense mutations) identified by Zammit et al.2, as well as the Ser381 (S381) IKK2 
phosphorylation site (P), and seven zinc-finger domains (ZnF1–ZnF7; green). b, Increased immunity 
versus increased pathogenicity in wild-type mice (WT) and mice bearing the A20 variants (above plot) 
described by Zammit et al.2, as well as other effects of the variants (left margin). A20P, phosphorylated 
A20; LPS, lipopolysaccharide.
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the I207L Denisovan mutant (C57BL/6 
mice already have the mutation encoding 
T108A) develop normally without overt 
signs of disease, while mice homozygous 
for the allele encoding C243Y are runted, 
display severe signs of inflammatory 
pathology in different organs and often die 
prematurely. Mice homozygous for the allele 
encoding I325N seem to be healthy but have 
reduced body weight compared with that 
of wild-type mice and display low-grade 
inflammation in multiple organs, consistent 
with reduced control of NF-κB signaling.
None of the three mutants have 
altered expression or stability of A20, 
in contrast to the recently identified 
nonsense and frameshift HA20 mutations 
that probably generate unstable proteins, 
since A20 expression could not be 
detected in cells from patients with such 
mutations7. However, the three mutations 
identified affect, to different degrees, the 
phosphorylation status of A20 protein, 
which leads to varying loss of Ser381 
phosphorylation: mild (T108A/I207L), 
intermediate (I325N) or severe and almost 
complete (C243Y). The graded effect of the 
different variants on the phosphorylation 
status of A20 consequently causes a graded 
reduction in A20’s function and its control 
of NF-κB.
An interesting observation from Zammit 
et al. is the difference in microbial tolerance 
among mice bearing each of the three 
alleles2. In contrast to mice expressing 
the wild-type allele, which all die, I207L 
mice are substantially protected from 
infection with a normally lethal dose of 
coxsackievirus, and I325N and C243Y 
mice are fully protected from this. The 
graded reduction in A20 phosphorylation 
among the three A20-mutant mouse strains 
(I207L < I325N < C243Y) enhances their 
protective immunity to viral infection. In 
an experimental model of septic shock, 
however, the opposite is shown, with  
I325N and C243Y mice demonstrating 
greater mortality than Denisovan or 
wild-type mice after a challenge with 
lipopolysaccharide. Similarly, I325N mice 
are highly sensitive to infection with a 
mouse variant of smallpox. Beyond the 
difference in microbial tolerance, I325N 
mice are also more prone to develop 
autoimmunity in a model of autoimmune 
diabetes than are wild-type mice. This  
shows that the outcome of alterations  
in the microbial resistance–microbial 
tolerance balance can be beneficial or 
detrimental, depending on the context  
(Fig. 1). Collectively, these data demonstrate 
how differences in the amount of A20 
phosphorylation have a serious effect 
on immunity and microbial tolerance 
in different environmental conditions 
and suggest that specific alleles encoding 
A20 may have been critical in the genetic 
selection of indigenous populations.
Despite many reports claiming that 
A20 acts as a DUB, transgenic mouse lines 
expressing the OTU protease-dead C103A 
variant show minimal differences in NF-κB 
signaling and do not develop spontaneous 
inflammatory pathology5,8,9. This study 
demonstrates that the three newly identified 
OTU A20 variants, which diminish A20 
phosphorylation to different degrees, have 
a much greater effect on NF-κB inhibition, 
immunity and microbial tolerance than 
does the catalytic C103A variant. This 
supports the conclusion that A20’s function 
is critically regulated by phosphorylation 
and suggests that phosphorylation-mediated 
activation of A20 also has an effect on other 
activities of A20 beyond its DUB function. 
However, additional studies are needed 
to fully understand how phosphorylation 
regulates the activation of A20, as well 
as to identify the involvement of other 
phosphorylation sites or mechanisms 
whereby A20 is regulated. Finally, although 
inhibition of NF-κB’s activation has long 
been considered the key anti-inflammatory 
function of A20, it is becoming more and 
more evident that its role in preventing cell 
death is a major mechanism of suppressing 
inflammation. Published evidence has 
demonstrated that the non-enzymatic, 
ubiquitin-binding function of A20 has a 
predominant role in this10,11. Further studies 
should investigate how the A20 variants 
described in this study act in the context of 
cell death and should asses the importance 
of the phosphorylation of A20 at Ser381 or 
other sites for its cytoprotective functions. 
Such studies will generate new insights 
in the molecular mechanisms behind 
pathologies associated with impaired A20 
function and may lead to better therapies for 
such diseases. ❐
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PROTEIN EVOLUTION
Too much can be as bad as too little
Transcription-factor paralogs are not equivalent and serve distinct roles in immune cells. Analysis of the RUNX 
family of transcription factors reveals insights into the non-redundant roles of RUNX1 and RUNX3.
Wooseok Seo and Ichiro Taniuchi
Stronger binding to motif sequences  in DNA by distinct paralogs  within a transcription-factor family 
is not always better, as weak DNA-binding 
interactions can nevertheless have  
important biological functions. In this  
issue of Nature Immunology, Bruno et al. 
assess transcription factors of RUNX 
(‘RUNT-related’) family that are expressed  
in cells of the immune system and reveal 
that RUNX proteins differ in their  
regulatory strength (and, hence, their 
functional activity) and report how this 
evolution of varying ‘strength’ serves a 
biological role1.
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Osteoclasts in health and disease 
 
Bone homeostasis 
The human skeleton consists of bone, a connective tissue of which the main function is to provide 
structural support to the body and to protect vital internal organs, including the bone marrow. Next 
to this, bone functions as a metabolic organ assuring homeostasis by serving as a reservoir for 
calcium, phosphate and  growth factors1. Two distinct types of bone can be distinguished : the 
cortical bone consisting of mineralized hardened bone providing strength, and the spongy 
trabecular bone found in the axial skeleton and at the end of long bones2. Bone is a highly 
dynamic organ which is constantly broken down, a process called ‘bone resorption’, and reformed by 
a process called ‘bone remodeling’. This is a highly regulated process that requires  the “coupling” of 
bone resorption and bone formation to maintain bone homeostasis. Perturbations in this balance 
result in low bone density, a disease called osteoporosis, or in too dense bones, known as 
osteopetrosis3.  
Bone cells and their role in remodeling 
Four distinct types of bone cells that play an important role in bone remodeling have been described: 
osteocytes, osteoblasts, bone lining cells and osteoclasts4,5. Osteocytes are a highly abundant cell 
type distributed in the bone matrix that act as mechanosensors and are important regulators of the 
bone remodeling process 4-6. Bone lining cells are flat-shaped mature osteoblasts that are in a 
quiescent state and line the bone surface as a monolayer. The exact functions of these cells are still 
not completely understood5. Osteoblasts are mononucleated cells derived from mesenchymal stem 
cells (MSC) that are responsible for the formation of bone mineral matrix by  producing osteoid, an 
organic matrix consisting largely of type I collagen5. Finally, osteoclasts are the bone resorbing cells. 
These are multinucleated cells that differentiate from the monocyte/macrophage lineage under 
influence of two critical factors, namely macrophage colony-stimulating factor (M-CSF) and receptor 
activator of NF-κB (RANK) ligand (RANKL)5.  
Bone remodeling, replacing old bone with new bone, takes place in micro-scale in the so called bone 
remodeling compartment (BRC). The BRC is a highly vascularized closed compartment, delineated by 
a canopy of bone lining cells, which brings osteoclasts and osteoblasts in close proximity to support 
“coupling”4,7(Fig. 1). A cycle of bone remodeling consists of four major stages. It starts with the 
initiation or activation stage where osteocytes induce the detachment of bone lining cells from the 
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surface to form a canopy and recruit osteoclast precursors cells (OPC) from the circulation, which will 
then differentiate into mature bone resorbing osteoclasts. This is followed by a resorption phase 
where osteoclasts brake down bone matrix, releasing several factors form the matrix that couple 
bone degradation to bone reformation to prevent a change in bone mass after each cycle. This phase 
ends with a process of osteoclast apoptosis. During the bone formation stage, osteoblasts 
differentiate from MSCs, get activated and produce osteoid to fill the gaps formed by bone 
resorption. Finally, during the termination phase, new bone matrix is formed by the mineralization of 
the osteoid. Osteoblast are removed via apoptosis, differentiate into bone lining cells, or are 
captured in the newly formed matrix and differentiate into osteocytes 4,7. 
Fig. 1 The bone remodeling compartment. Different stages of the bone remodeling cycle. 1) The 
activation stage initiated by osteocyte signaling. Bone lining cells detach from the bone surface and 
form a canopy to which OCPs are recruited to form mature multinucleated osteoclasts. 2) The bone 
resorption stage, during which osteoclasts degrade bone matrix, releasing several factors from the 
matrix that couple bone degradation to bone reformation. Bone resorption is ended by osteoclast 
apoptosis. 3) The bone formation stage, where osteoblast are differentiated from MSC and are 
recruited to the bone surface where they produce osteoid. 4) The termination phase, where new 
bone matrix is formed by the mineralization of osteoid. Osteoblasts are removed via apoptosis, 
differentiate into bone lining cells or are captured in the newly formed matrix and differentiate into 
osteocytes. HSC, Hematopoietic stem cell; MSC, Mesenchymal stem cell; OCP, Osteoclast precursor; 
OBP, Osteoblast precursor. 
Osteoclasts 
Osteoclasts are multinucleated cells formed by the fusion of osteoclast precursors derived from the 
monocyte/macrophage lineage. These cells have an irregular shape in which distinct membrane 
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areas can be delineated (Fig. 2). Activated osteoclasts adhere to the bone surface and form tightly 
sealed resorption pits. These resorption pits are formed by a circular outer membrane domain in the 
osteoclasts, called the sealing zone, that is formed by podosomes mainly consisting of actin 
microfilaments, actin binding proteins, adhesion proteins and integrins. This structure is also known 
as the actin ring8,9.  Within the sealing zone, the membrane, called the ruffled border, consists of 
membrane expansions that are responsible for the trafficking of protons and proteases into the 
resorption pit to degrade the bone matrix8,9. Finally, the degraded matrix products are taken up by 
the osteoclast via endocytosis and are released into the vascular system through the functional 
secretory domain (FSD), the membrane located at the opposite site of the ruffled borded8,9 (Fig. 2).  
Fig. 2 Bone resorbing osteoclast. Schematic overview of a mature multinucleated osteoclast 
attached to the bone surface via the sealing zone, forming a tightly sealed resorption pit. Osteoclasts 
acidify the resorption pit by the release of protons (H+) to demineralize the inorganic matrix, and by 
the secretion of Cl- to neutralize the H+ release. Lytic enzymes, cathepsin-K (Ctsk) and tartrate-
resistant acid phosphatase (TRAP), are also secreted via the ruffled border to degrade the organic 
matrix. Bone degradation products are taken up by endocytosis and released via the functional 
secretory domain (FSD) into the vascular system. 
 
Bone consists of both inorganic (primarily hydroxyapatite) and organic (primarily type I collagen) 
material. Osteoclasts acidify the resorption pit through the release of protons (H+), to demineralize 
the bone matrix and expose the organic content. Next, also lytic enzymes, of which tartrate-resistant 
acid phosphatase (TRAP) and cathepsin K (CtsK) are the most important, are secreted into the 
resorption pit to degrade the organic matrix4,10.  
Osteoclastogenesis depends on M-CSF and RANKL, two critical factors that are sufficient to induce 
osteoclast differentiation in vitro11. Binding of M-CSF to its cognate receptor c-Fms stimulates 
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osteoclast precursor proliferation and survival, and is important in mature osteoclasts for 
cytoskeletal reorganization and osteoclast motility12. M-CSF is produced by different cell types, of 
which osteoblasts and stromal cells are the most important ones in the context of 
osteoclastogenesis4. Next to M-CSF, also RANKL is critically important for osteoclastogenesis, and 
RANK deficient mice do not have mature osteoclasts and develop osteopetrosis13. RANK expression 
on the surface of osteoclast precursors is induced by M-CSF. Several cell types express RANKL in the 
context of bone remodeling, including stromal cells, osteoblasts, osteocytes, B cells and T cells4. 
Binding of RANKL to its receptor RANK activates several downstream signaling pathways, eventually 
leading to the expression of osteoclast-specific genes important for osteoclast differentiation, 
activation and bone degradation10. Osteoclastogenesis is also regulated by osteoprotegerin (OPG), a 
soluble protein expressed by osteoblasts and stromal cells that blocks osteoclast differentiation and 
activation by acting as a decoy receptor for RANKL thereby competing with RANK14. Strictly regulated 
expression of RANKL and OPG is therefore important to keep proper bone homeostasis. 
RANK signaling in osteoclastogenesis 
Since RANK, a member of the tumor necrosis factor (TNF) receptor (TNFR) superfamily, does not 
contain intrinsic enzymatic activity, it requires the recruitment of adaptor molecules to facilitate 
downstream signaling and induce gene expression15. Upon binding of RANKL to RANK, various TNFR-
associated factors (TRAFs) are recruited to the cytoplasmic tail of RANK, including TRAF2, TRAF5 and 
TRAF6. However, only deletion of TRAF6 in mice results in the absence of mature osteoclasts and the 
development of osteopetrosis16, while deletion of TRAF2 or TRAF5 only results in minor effects on 
osteoclastogenesis in vitro17,18. Recruitment of TRAF6 to the ligated RANK receptor rapidly induces 
the activation of several downstream signaling pathways, eventually leading to the activation of the 
transcription factors nuclear factor-ĸB (NF-ĸB) and activator protein-1 (AP-1) (Fig. 3). Canonical NF-ĸB 
is activated through the recruitment and activation of the TAK1 (TGFβ-activated kinase 1)-TAB2 
(TAK1 binding protein 2) complex, which in its turn activates the inhibitor of ĸB (IĸB) kinase (IKK) 
complex by phosphorylation of IKKβ, leading to the degradation of IĸBa, releasing the p50/p65 NF-κB 
dimer19,20. Alternatively, the IKK complex can be activated through the p62-mediated recruitment of 
the atypical protein kinase C (aPKC), which has been shown to be important for induced but not basal 
osteoclastogenesis21. Binding of RANKL to RANK can also activate signaling through the non-canonical 
NF-ĸB pathway, involving NF-ĸB-inducing kinase (NIK) and IKKα, inducing the expression of 
osteoclast-specific genes. However, while OCPs from NIK-/- or IKKα-/- mice do not form osteoclasts in 
vitro upon RANKL stimulation, mice deficient for NIK, p100, RelB or IKKα do not develop an 
osteopetrosis phenotype nor show a reduction in the number of osteoclasts, indicating that non-
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canonical signaling is important for the induced osteoclastogenesis but not the basal 
osteoclastogenesis19 (Fig. 3).  
 
Fig. 3 RANK-induced signaling important for osteoclastogenesis. Binding of RANKL to its cognate 
receptor RANK induces the recruitment of several adaptor molecules of which TRAF6 is the central 
player, activating several downstream signaling pathways involving the activation of NF-ĸB, MAP 
kinases and the PI(3)K/AKT pathway This induces the expression of the master regulator of 
osteoclastogenesis, NFATc1, and initiates expression of osteoclast-specific genes important for 
osteoclastogenesis.  
 
Also members of the mitogen activated protein kinase (MAPK) family, c-Jun N-terminal kinase (JNK), 
p38 and extracellular signal–regulated kinase (ERK) 1/2 play an important role in osteoclastogenesis 
downstream of RANK3. Activation of these kinases relies on the recruitment of TRAF6 to the RANK 
receptor. JNK, activated through the RANK-TRAF6-TAK1-MKK4/7 axis, phosphorylates the Jun 
component of the AP-1 transcription factor, inducing the expression of osteoclast-specific genes22. 
p38, phosphorylated and activated through the RANK-TRAF6-TAK1-MKK3/6 axis, directly 
phosphorylates and activates the transcription factors nuclear factor-activated T cells c1 (NFATc1) 
and microphthalmia transcription factor (MITF, important for the differentiation of osteoclasts)22-24. 
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Furthermore, p38 was shown to directly promote NF-ĸB transcriptional activity by phosphorylating 
the p65 subunit of NF-ĸB25. Finally, p38 also directly phosphorylates STAT1, important for the 
adhesion and migration of osteoclasts, and MAPK-activated protein kinase-2 (MK2), critical for the 
expression of genes responsible for OPC fusion, including osteoclast stimulatory transmembrane 
protein (OC-stamp) and dendrocyte expressed seven transmembrane protein (DC-stamp)22. Although 
ERK1/2 is activated upon RANKL stimulation and has been shown to promote osteoclastogenesis, it is 
still not clear how ERK is involved in RANK signaling. However, ERK is important for M-CSF-induced 
signaling and directly phosphorylates MITF and Fos26,27 (Fig. 3).  
Finally, TRAF6 also recruits Src to the receptor, allowing downstream signaling through 
phosphatidylinositol 3-OH kinase (PI(3)K) and the serine/threonine protein kinase AKT. PI(3)K and 
AKT are important for cell survival, cytoskeletal rearrangements and osteoclast motility, and 
mutation of the c-src proto-oncogene results in the development of osteopetrosis in mice. PI(3)K 
signaling is negatively regulated by SHIP, a lipid phosphatase, and SHIP deficiency results in increased 
numbers of osteoclasts and in the development of severe osteoporosis in mice 3,10 (Fig. 3). 
Several osteoclast-specific genes, critical for osteoclast differentiation, are expressed via activation of 
the transcription factors NF-ĸB and AP-1. However, the main downstream target of RANK signaling is 
the so called “master regulator of osteoclast differentiation”, NFATc1, a transcription factor 
responsible for the expression of critical osteoclast genes such as TRAP, cathepsin K and the 
calcitonin receptor (CalcR)28, while RANK-induced transcription factors c-Fos, p65/p50 NF-ĸB and AP-
1 are mainly important for the expression of NFATc129. 
Inflammation and osteoclasts 
Several inflammatory cytokines, including TNF, interleukin (IL)-1 and IL-6 have a stimulatory effect on 
osteoclast differentiation in vitro and promote bone resorption in the presence of RANKL in vivo. 
RANKL, TNF, IL-1 and IL-6 share common downstream signaling pathways and might therefore act 
synergistically to induce osteoclastogenesis3. Elevated levels of inflammatory cytokines are found in 
rheumatoid arthritis (RA) patients, where bone loss can be detected at the sites of (peri)-articular 
inflammation30. IL-6 alone or in cooperation with TNF can indirectly induce osteoclastogenesis by 
upregulating the expression of RANKL by synovial fibroblasts31. This is important in the context of RA, 
since mice lacking RANKL specifically in the synovial fibroblasts are greatly protected from a model of 
inflammatory arthritis32. TNF directly stimulates osteoclastogenesis by stimulating OPC proliferation 
and by promoting osteoclast differentiation in presence of permissive levels of RANKL33,34. In absence 
of RANKL, TNF/IL-6 can induce mature functional osteoclasts in vitro35. Also IL-1 can induce 
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differentiation of multinucleated bone-resorbing osteoclasts from OCPs in vitro in the absence of 
osteoblasts/stromal cells36. 
NF-ĸB signaling is heavily regulated by reversible ubiquitination and several deubiquitinating 
enzymes (DUBs), including A20, cylindromatosis (CYLD) and OTULIN, have been shown to critically 
regulate NF-ĸB signaling downstream of several immune receptors, including TNF and IL-1. CYLD has 
also been shown to negatively regulate RANK-induced NF-ĸB signaling and osteoclastogenesis, and 
CYLD knockout mice were shown to develop severe osteoporosis. Upon RANK activation, CYLD is 
recruited to TRAF6 via interaction with the adaptor protein p6237. No other DUBs regulating RANK-
induced signaling have been characterized so far. However, mice that lack A20 in their myeloid cells 
(A20myel-KO) develop spontaneous erosive polyarthritis that resembles human RA, and blood 
leukocytes from these mice show significantly increased osteoclastogenesis in the presence of RANKL 
in vitro38. This suggests that the enhanced osteoclastogenesis observed in A20myel-KO is due to the 
presence of increased levels of inflammatory cytokines, or is a direct consequence of the lack of 
control on RANK signaling and osteoclastogenesis in the absence of A20. To study the specific role of 
A20 in the direct regulation of RANK-induced osteoclastogenesis, osteoclast-specific deletion of A20 
will be needed.  
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Aims and objectives 
NF-ĸB signaling is essential in immunity, inflammation and development, and dysregulation of NF-ĸB-
dependent gene expression contributes to a variety of (auto-)inflammatory and autoimmune 
diseases, and eventually cancer1,2. Therefore tight regulation of NF-ĸB signaling is needed to maintain 
tissue homeostasis and prevent the development of inflammatory pathology. Several 
(auto)regulatory mechanisms are known to control inflammatory pathways3. One critical regulator of 
NF-ĸB activation is A20, a protein that is rapidly induced in inflammatory conditions4.  
A20 is a potent anti-inflammatory protein, acting by inhibiting NF-κB signaling and inflammatory 
gene expression and/or by preventing cell death. Genome-wide association studies (GWAS) have 
identified single nucleotide polymorphisms (SNPs) in or around the A20/TNFAIP3 locus, identifying 
A20 as a disease susceptibility gene for a variety of human inflammatory and autoimmune diseases, 
including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and inflammatory bowel 
disease (IBD)5,6. More recently, in patients with an early-onset autoinflammatory syndrome, 
heterozygous loss-of-function mutations in the A20/TNFAIP3 gene have been identified7-9. 
Experimental studies in mice have confirmed the important anti-inflammatory role of A20. Mice 
deficient for A20 die perinatally due to severe multi-organ inflammation, and tissue-specific deletion 
of A20 demonstrated the importance of A20 in preventing cell death and inflammation in order to 
maintain tissue homeostasis. Together, these data illustrate the important function of A20 in the 
regulation of inflammatory signaling and cell death, however, the in vivo mechanisms by which A20 
performs these functions still remain elusive.  
While in vitro experiments have shown that A20 regulates NF-ĸB signaling by removing ubiquitin 
chains via the DUB activity of its OTU-domain and targets proteins for ubiquitination and subsequent 
degradation via the E3 ligase activity of its ZnF4 domain 10, transgenic mouse lines abrogating in vivo 
the DUB activity or the E3 ligase activity do not develop spontaneous disease, questioning the in vivo 
importance of these functions11-13. However in vitro studies have shown that the ZnF7 domain of 
A20, which binds to linear ubiquitin chains, is critical for the recruitment of A20 to TNFR1 and NOD2 
receptor complexes, and prevents NF-κB signaling and cell death in a non-enzymatic way 14-17.  
The main aim of this PhD thesis was to further understand the molecular mechanisms by which A20 
regulates inflammation and cell death in vivo. Therefore, we generated mice with disruptive point 
mutations in the ZnF7 domain of A20 abrogating its capacity to bind linear ubiquitin. In parallel, we 
generated mice with mutations in both the ZnF4 and ZnF7 domains of A20, also preventing the 
binding of A20 to K63-specific ubiquitin. These mice and cells thereof were used to challenge the 
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hypothesis that A20 prevents inflammation in a non-catalytic way by acting as a ubiquitin-binding 
protein. 
Next to its role in inflammatory signaling, A20 was previously demonstrated to control non-
inflammatory developmental signaling pathways. In this context, epidermis-specific A20 deficient 
mice were shown to develop ectodermal organ abnormalities due to dysregulated NF-κB signaling 
induced by the activation of Ectodysplasin A receptor (EDAR) signaling18. Myeloid-specific A20 
deficient mice develop spontaneous polyarthritis resembling human rheumatoid arthritis19. 
Interestingly, these mice have increased numbers of osteoclast precursors and form more TRAP-
positive multinucleated osteoclast from leukocytes stimulated with RANKL in vitro, suggesting a role 
for A20 in regulating RANK-induced NF-κB signaling19. This enhanced osteoclastogenesis may, 
however, also result from the more general inflammatory condition of myeloid-specific A20 deficient 
mice, since inflammatory cytokines are known to promote osteoclastogenesis20,21. To investigate the 
direct role of A20 in regulating osteoclastogenesis, we have generated osteoclast-specific A20 
deficient mice. In vivo and in vitro analyses of these mice and cells thereof were used to demonstrate 
a direct regulatory role of A20 in the regulation of RANK-induced osteoclastogenesis and bone 
homeostasis in vivo.  
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Two distinct ubiquitin-binding motifs in A20 mediate its anti-
inflammatory and cell- protective activities 
 
Abstract 
Protein ubiquitination regulates protein stability and modulates the composition of signaling 
complexes. A20 is a negative regulator of inflammatory signaling, but the molecular mechanisms 
involved are ill-understood. Here, we generated Tnfaip3 gene-targeted A20 mutant mice bearing 
inactivating mutations in the zinc finger 7 (ZnF7) and ZnF4 ubiquitin-binding domains, revealing that 
binding to polyubiquitin is essential for A20 to suppress inflammatory disease. We demonstrate that 
a functional ZnF7 domain was required for recruiting A20 to the tumor necrosis factor receptor 1 
(TNFR1) signaling complex and to suppress inflammatory signaling and cell death. The combined 
inactivation of ZnF4 and ZnF7 phenocopied the postnatal lethality and severe multi-organ 
inflammation of A20-deficient mice. Conditional tissue-specific expression of mutant A20 further 
revealed the key role of ubiquitin-binding in myeloid and intestinal epithelial cells. Collectively, these 
results demonstrate that the anti-inflammatory and cytoprotective functions of A20 are largely 
dependent on its ubiquitin-binding properties. 
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Main 
A20, also referred to as Tumor Necrosis Factor alpha-induced protein 3 (TNFAIP3), has been 
implicated in diverse inflammatory diseases, and has been shown to act by repressing inflammatory 
NF-κB signaling and by promoting cell survival 1,2. A20 is thought to act as a ‘ubiquitin-editing’ 
enzyme that inhibits NF-κB signaling by modulating the ubiquitination status of specific signaling 
proteins through  the combined action of its deubiquitinase (DUB) activity and its E3 ubiquitin ligase 
activity that promotes K48-linked polyubiquitination and proteasomal degradation of its targets 
following tumor necrosis factor receptor 1 (TNFR1) activation 3. However, transgenic mouse strains 
with inactivating mutations in A20's DUB or E3 ligase domains are grossly normal and do not develop 
spontaneous disease 4-6, in sharp contrast to the systemic inflammatory and perinatal lethality seen 
in A20-deficient mice 7. These studies challenged the notion that A20 primarily acts via a ‘ubiquitin 
editing’ mechanism to suppress inflammation in vivo. Other studies suggest that the 7th zinc finger 
domain of A20 competes with the IκB kinase (IKK) adaptor protein  NEMO for binding to linear (M1) 
ubiquitin chains generated by the linear ubiquitin chain assembly complex (LUBAC) to repress TNF-
induced NF-κB signaling in vitro 8-10. However, the physiological role of A20’s ZnF7 domain is not 
known. 
To determine the physiological role of the ZnF7 domain of A20 in vivo, we generated Tnfaip3 gene-
targeted A20 mutant mice carrying two cysteine to alanine point mutations in the ZnF7 motif - C764A 
and C767A (hereafter referred to as A20ZnF7) (Extended Data Fig. 1a), which was previously shown to 
abrogate A20’s ability to bind to linear polyubiquitin chains 8,10,11. Homozygous A20ZnF7/ZnF7 knock-in 
mice, derived from interbred A20ZnF7/+ mice, were born with expected Mendelian frequency and did 
not display perinatal lethality (Extended Data Fig. 1b). This phenotype contrasts markedly with 
Tnfaip3–/– mice that, in our mouse facility, develop perinatal cachexia and die before weaning age 
(data not shown). However, all A20ZnF7/ZnF7 knock-in mice had severely reduced body weight (Fig. 1a, 
Extended Data Fig. 1c) and only rarely produced offspring. Macroscopic and histological examination 
of young A20ZnF7/ZnF7 mice revealed splenomegaly and lymphadenopathy (Extended Data Fig. 1d), paw 
swelling with absence of nails (Extended Data Fig. 1e), bone erosion (Extended Data Fig. 1f) and joint 
inflammation (Extended Data Fig. 1g), as previously shown 11, but also inflammation and immune cell 
infiltration in other tissues such as in the liver (Fig. 1b). Staining for cleaved caspase-3 revealed the 
presence of numerous apoptotic cells in A20ZnF7/ZnF7 livers but not in control livers (Fig. 1c, d), 
suggesting that A20ZnF7 expression sensitized hepatocytes to apoptosis. This can be due to a direct 
role for the ZnF7 domain in preventing hepatocyte apoptosis, or indirectly due to the increased levels 
of cytotoxic cytokines. In agreement with the observed phenotype, A20ZnF7/ZnF7 knock-in mice had 
high serum concentrations of the inflammatory cytokines TNF and interleukin 6 (IL-6, Fig. 1e). Flow 
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cytometric analyses of spleen tissue from 20 week-old mice revealed that A20ZnF7/ZnF7 knock-in mice 
had increased numbers of myeloid cells but reduced numbers of B cells, T cells and natural killer (NK) 
cells, demonstrating that A20’s ZnF7 domain regulates immune homeostasis (Fig. 1f, Extended Data 
Fig. 2). Finally, in agreement with the increased TNF concentrations detected in their serum, 
A20ZnF7/ZnF7 myeloid cells displayed enhanced amounts of intracellular TNF (Fig. 1g). 
Cachexia and premature lethality in A20-deficient mice were shown to be promoted by MyD88-
mediated pro-inflammatory responses in the absence of A20 12. To address the role of MyD88-
dependent signaling in the inflammatory pathology of A20ZnF7/ZnF7 mice, these mice were crossed with 
Myd88–/– animals. As described recently 11, deletion of Myd88 in A20ZnF7/ZnF7 mice partly restored 
body weight (Extended Data Fig. 3a, b) and A20ZnF7/ZnF7 Myd88–/– mice were partly protected from 
developing spontaneous tissue inflammation, as shown by reduced inflammation in liver (Extended 
Data Fig. 3c) and absence of swollen toes and ankles (Extended Data Fig. 3d). Inflammatory cytokine 
concentrations in serum of A20ZnF7/ZnF7Myd88–/– mice were, however, elevated compared to control 
animals (Extended Data Fig. 3e). Together, these data demonstrate that MyD88-dependent 
mechanisms contribute to the local inflammatory pathology in the absence of ZnF7-dependent A20 
functions, while more systemic inflammation is unaffected. 
The role of A20 ZnF7 in regulating inflammation was further evaluated by examining the sensitivity of 
A20ZnF7/ZnF7 mice to TNF in vivo. Indeed, an important anti-inflammatory and cytoprotective role for 
A20 has been demonstrated in intestinal epithelial cells (IECs), and IEC-specific A20-deficient mice 
(A20IEC-KO) were previously shown to die from a challenge with a normally sublethal dose of TNF 13. In 
contrast to the control mice, which all survived and only showed a modest drop in body temperature 
in the first hours after TNF injection, A20ZnF7/ZnF7 mice displayed typical symptoms associated with 
TNF toxicity, including hypothermia and severe diarrhea, and all died within 3 h after TNF injection 
(Fig. 1h). A20ZnF7/ZnF7 mice displayed severe damage of the small intestine, showing extensive 
epithelial destruction and presence of numerous cleaved caspase-3 positive apoptotic IECs, in 
contrast to control littermates which maintained tissue integrity without showing epithelial cell 
apoptosis. Next to the damage of the intestinal tissue, massive apoptosis could be detected in liver 
tissue of A20ZnF7/ZnF7 mice upon exposure to TNF (Fig. 1i). Together, these data establish that A20’s 
ZnF7 motif is essential to restrict inflammatory responses in vivo. 
68 
69 
 
Figure 1. A20ZnF7/ZnF7 knock-in mice develop spontaneous inflammatory pathology and are 
sensitized to TNF induced toxicity. (a) Bodyweight of A20ZnF7/+ and A20ZnF7/ZnF7 mice in function of 
time. Each dot represents a biologically independent mouse (9 week-old mice: A20ZnF7/+, n=16; 
A20ZnF7/ZnF7, n=6; 12 week-old mice: A20ZnF7/+, n=15; A20ZnF7/ZnF7, n=7; 15week-old mice: A20ZnF7/+, 
n=11; A20ZnF7/ZnF7, n=7). Data are expressed as mean ± SEM. **** represents p<0.0001 (parametric 
two-way ANOVA between indicated genotypes). (b) Representative hematoxylin-eosin-stained 
sections of liver from 28-week-old control (A20+/+) and A20ZnF7/ZnF7 littermates. Scale bar, 200 µm and 
50 µm (insert). Picture representative for at least 5 biologically independent mice per group. (c-d) 
Immunohistochemistry for cleaved caspase 3 on liver sections from A20ZnF7/ZnF7 mice and control 
(A20+/+) littermates (c), and number of cleaved caspase 3-positive cells per mm2 (A20ZnF7/ZnF7, n=5 
biologically independent samples; A20+/+, n=4 biologically independent samples) (d). Pictures shown 
are representative for 5 biologically independent mice per group. Scale bar, 20 μm (insert, 10 µm) 
Data are expressed as mean ± SEM. * represents p=0.0159 (Two-sided non-parametric Mann 
Whitney test between indicated genotypes). (e) Levels of IL-6 and TNF in serum of control (A20+/+), 
A20ZnF7/+ and A20ZnF7/ZnF7 mice at the age between 15 and 30 weeks. Each dot represents a biologically 
independent mouse (IL-6: A20+/+, n=16; A20ZnF7/+, n=14; A20ZnF7/ZnF7, n=25; TNF: A20+/+, n=11; A20ZnF7/+, 
n=4; A20ZnF7/ZnF7, n=20).  Data are expressed as mean ± SEM. *, ** and **** represent p=0.0133, 
p=0.0014 and p<0.0001 respectively (parametric one-way ANOVA between indicated genotypes). (f) 
Absolute cell numbers of indicated immune cell populations in the spleens of A20+/+, A20ZnF7/+ and 
A20ZnF7/ZnF7 mice, as measured by flow cytometry. Each dot represents a biologically independent 
mouse (A20+/+, n=6; A20ZnF7/+, n=6; A20ZnF7/ZnF7, n=8). Data are expressed as mean ± SEM. *, **, *** 
represents p < 0.05, p < 0.01 and p < 0.001 (Two-sided non-parametric Mann-Whitney test between 
indicated genotypes). (g) Splenocytes isolated from A20+/+, A20ZnF7/+ and A20ZnF7/ZnF7 mice were 
incubated for 4 hours in the presence of protein transport inhibitors to assess intracellular TNF 
production by flow cytometry. Bar graphs represent percentage TNF that is produced within total 
macrophage (top) and Ly6Chi monocyte (bottom) populations. Each dot represents a biologically 
independent mouse (A20+/+, n=5; A20ZnF7/+, n=4; A20ZnF7/ZnF7, n=5). Data are expressed as mean ± SEM. 
* and ** represent p < 0.05 and p < 0.01 respectively (Two-sided non-parametric Mann-Whitney test 
between indicated genotypes). (h) Body temperature and survival of A20ZnF7/ZnF7 mice and control 
littermates injected with recombinant mTNF (i.p., 5 μg / 20 g of bodyweight), in function of time  
(A20+/+, n=7; A20ZnF7/+, n=5; A20ZnF7/ZnF7, n=5 mice). Data are expressed as mean ± SEM. p < ** and *** 
represent p<0.01, p<0.001, respectively (body temperature, REML analysis and survival, two-sided 
mantel-cox test). (i) Cleaved caspase 3 staining on sections from small intestine (SI) and liver from 
control (A20+/+) and A20ZnF7/ZnF7 mice. Scale bar, 200 µm (liver) and 100 µm (SI). Pictures shown are 
representative for 5 biologically independent mice per group.  
 
Consistent with the essential role of A20 as a negative feedback regulator of inducible NF-κB–
dependent gene expression, cultured mouse embryonic fibroblasts (MEFs) from A20ZnF7/ZnF7 knock-in 
mice demonstrated increased TNF-induced NF-κB signaling, as reflected by earlier phosphorylation 
and sustained degradation of the NF-κB inhibitory molecule IκBα, and enhanced IL-6 production 
upon TNF stimulation compared to wild-type MEFs (Fig. 2a, b). Also cultured bone marrow-derived 
macrophages (BMDMs) from A20ZnF7/ZnF7 knock-in mice showed sustained degradation of IκBα and 
expressed and produced increased amounts of cytokines than control BMDMs in response to 
lipopolysaccharide (LPS) and TNF (Fig. 2c,d, Extended Data Fig. 4). In agreement with the reported 
role of A20 ZnF7 in binding M1 ubiquitin chains8-10, A20 recruitment to the TNFR1 complex was 
severely impaired upon stimulation of A20ZnF7/ZnF7 BMDMs with Flag-tagged TNF, similar to what is 
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observed in A20-deficient BMDMs (Fig. 2e). Absence of A20 at the membrane-bound signaling 
complex (known as complex I) was also associated with reduced abundance of M1 chains in the 
TNFR1 signaling complex I (Fig. 2f), which is consistent with the reported role of A20 recruitment in 
protecting M1 chains from degradation9,14. Mutation of ZnF7 did not prevent the recruitment of 
RIPK1 and TRADD adaptor proteins to the TNFR1 complex (Fig. 2f). Destabilization of complex I by 
reduced M1 ubiquitination favored formation of the death-inducing complex II and activation of an 
apoptotic caspase cascade (Fig. 2g, h), as previously reported9,14.  
We previously demonstrated that mice with a myeloid-restricted deficiency in A20 spontaneously 
develop polyarthritis caused by myeloid cell necroptosis, NLRP3 inflammasome hyperactivation and 
IL-1 receptor (IL-1R) signaling 11,15,16. In agreement, A20ZnF7/ZnF7 BMDMs showed significantly 
enhanced NLRP3 inflammasome-mediated caspase-1 activation, pyroptosis and IL-1β and IL-18 
secretion upon stimulation with LPS and ATP (Fig. 2i-k). Together, these data illustrate the 
importance of the ZnF7 domain of A20 for preserving TNFR1 receptor complex integrity, and 
preventing cell death, inflammasome activation and inflammation. 
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Figure 2. ZnF7 is critical for A20-mediated suppression of inflammatory signaling and cell death. (a) 
Western blot analysis of whole cell lysates from A20+/+, A20ZnF7/ZnF7 and A20-/- MEF cells stimulated 
with TNF for the indicated time periods. Actin is shown as a loading control. Figure representative for 
3 independent experiments. (b) IL-6 secretion by control A20+/+, A20ZnF7/ZnF7 and A20-/- MEF cells, 
either or not stimulated with TNF for 4 h (A20+/+, n=3; A20ZnF7/ZnF7, n=3; A20-/-, n=3 independent cell 
cultures). **** represents p<0.0001 (parametric two-way ANOVA between indicated genotypes). 
Data are expressed as mean ± SEM. (c) Western blot analysis of whole cell lysates from A20+/+, 
A20ZnF7/ZnF7 and A20myel-KO BMDMs stimulated with LPS as indicated. β-tubulin is shown as a loading 
control. Figure representative for 3 independent experiments. (d) TNF and IL-6 secretion by BMDMs 
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isolated from control A20+/+ (n=5), A20ZnF7/ZnF7(n=5) and A20myel-KO (n=5) mice, either or not stimulated 
with LPS for 6 h. *** and **** represent p<0.001 and p<0.0001 respectively (parametric two-way 
ANOVA between indicated genotypes). Data are expressed as mean ± SEM. (e) TNFR1 pulldown assay 
in BMDMs isolated from A20+/+, A20myel-KO and A20ZnF7/ZnF7 mice after stimulation with Flag-TNF (1 
µg/ml) for the indicated time periods, and immunoprecipitation of the TNFR1 complex with anti-Flag 
beads in presence of USP2 (24 µg/ml) and immunoblot for A20. Actin is shown as a loading control. 
Figure representative for 3 independent experiments. (f) TNFR1 pulldown on BMDMs isolated from 
A20+/+, A20myel-KO and A20ZnF7/ZnF7 mice stimulated with Flag-TNF (1 µg/ml) for the indicated time 
periods, and immunoprecipitation of the TNFR1 complex using anti-Flag beads and immunoblotted 
for A20, RIPK1, TRADD and M1. Figure representative for 3 independent experiments. (g) Cell death 
induction in A20+/+, A20ZnF7/ZnF7 and A20-/- MEFs stimulated with mouse TNF, in function of time as 
measured by SytoxGreen (SG+) positivity. Data are expressed as mean ± SEM, and representative of 3 
independent experiments (A20+/+, n=3; A20ZnF7/ZnF7, n=3; A20myel-KO, n=3 independent cell cultures). ** 
represents p<0.01 (RELM analysis) (h) Western blot analysis for expression of A20, full-length (FL) 
and cleaved (Cl) caspase-3 in A20+/+, A20ZnF7/ZnF7 and A20-/- MEFs stimulated with mouse TNF for the 
indicated time points. Actin is shown as loading control. Figure representative for 3 independent 
experiments (i) Immunoblot for procaspase-1 and cleaved caspase-1 (p20) in BMDMs from A20+/+, 
A20ZnF7/ZnF7 and A20myel-KO either or not stimulated with LPS and/or ATP. Actin is shown as loading 
control. Data are representative of three independent experiments. (j) IL1β and IL18 secretion by 
BMDMs isolated from A20+/+ (n=5), A20ZnF7/ZnF7 (n=5) and A20myel-KO (n=5) mice either or not stimulated 
with LPS and ATP. Data represent the mean ± SEM.**, **** represent p<0.01 and p<0.0001, 
respectively (parametric two-way ANOVA between indicated genotypes). (k) Pyroptosis induction in 
BMDMs from A20+/+ (n=5), A20ZnF7/ZnF7 (n=5) and A20myel-KO (n=5) mice stimulated with LPS and ATP, as 
measured by Sytox Green (SG) uptake. Data are presented as mean ± SEM and are representative of 
three independent experiments. *** represents p<0.001 (RELM analysis). 
Although A20ZnF7/ZnF7 mice develop a spontaneous inflammatory phenotype, they do not fully 
recapitulate the phenotype of Tnfaip3–/– mice that develop severe multi-organ inflammation and 
cachexia and die in the first weeks after birth. This observation suggests that A20 exerts additional 
protective functions independent of its ZnF7 linear ubiquitin binding activity. In this respect, the ZnF4 
domain of A20 has been demonstrated to bind K63-linked polyubiquitin, and mutations in the A20 
ZnF4 ubiquitin-binding interface were shown to result in slightly impaired regulation of NF-κB 
signaling 4,17. Gene-targeted mice mutated in the A20 ZnF4 domain, however, did not develop 
spontaneous pathology4,6. To clarify the physiological role of A20’s ZnF4 domain in suppressing 
inflammation, we introduced two cysteine to alanine point mutations in the ZnF4 motif – C609A and 
C612A – of A20ZnF7 mice, generating mice with combined inactivation of the K63 polyubiquitin 
binding ZnF4 and M1 polyubiquitin binding ZnF7 domains (hereafter referred to as A20ZnF4ZnF7 mice) 
(Extended Data Fig. 5a). Heterozygous A20ZnF4ZnF7/+ mice had a normal appearance without evidence 
of clinical pathology. In contrast, although A20ZnF4ZnF7/ZnF4ZnF7 mice were born at normal frequencies, 
they were severely runted and none of these animals survived past weaning age (Table 1, Extended 
data Fig. 5b). Gross and histological examination of tissues of 2-week-old A20ZnF4ZnF7/ZnF4ZnF7 mice 
revealed severe inflammation in multiple organs, including intestine, liver, and skin (Fig. 3a, b), and 
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cleaved caspase 3-positive cells were detected in livers of A20ZnF4ZnF7/ZnF4ZnF7 mice, indicative of 
spontaneous liver cell apoptosis (Fig. 3c, d).  In addition, systemic inflammation in A20ZnF4ZnF7/ZnF4ZnF7 
mice was also evident from the detection of high serum concentrations of the inflammatory 
cytokines TNF and IL-6 (Fig. 3e).  
A20ZnF4ZnF7/ZnF4ZnF7 mice in a MyD88-deficient background did not die in the first postnatal weeks as is 
the case with A20ZnF4ZnF7/ZnF4ZnF7 mice (Extended Data Fig. 5c) and did not develop the severe tissue 
pathology as seen in MyD88-sufficient controls (Fig. 3f). However, these mice still failed to thrive, 
presented with severely reduced bodyweight and did not survive beyond 20 weeks of age (Fig 3g). 
Although 15 week-old A20ZnF4ZnF7/ZnF4ZnF7Myd88–/– did not display pronounced swelling of ankles and 
toes (Fig. 3h), histological examination still revealed inflammation in liver tissue of these mice (Fig. 
3i). These results demonstrate that MyD88 drives dysregulated homeostatic TLR signals in the 
absence of ZnF4 and ZnF7-dependent A20 functions in young mice, whereas MyD88-independent 
inflammatory signaling contributed to pathology at older age.  
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Figure 3. A20ZnF4ZnF7/ZnF4ZnF7 knock-in mice phenocopy A20 knockout mice. (a) Gross appearance of 
livers of 2-week old control A20+/+, A20ZnF4ZnF7/+ and A20ZnF4ZnF7/ZnF4ZnF7 mice. Note pale acellular regions 
in A20ZnF4ZnF7/ZnF4ZnF7 livers. Picture representative for 3 biologically independent mice. (b) 
Representative hematoxylin-eosin-stained sections from 2-week old control A20+/+, A20ZnF4ZnF7/+ and 
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A20ZnF4ZnF7/ZnF4ZnF7 intestine (small intestine and colon), liver and skin. Note severe inflammation in all 
A20ZnF4ZnF7/ZnF4ZnF7 tissue sections. Scale bar, 100 μm. Pictures representative for 3 biologically 
independent mice. (c) Immunostaining for cleaved caspase 3 on liver sections from 2-week old 
control A20+/+ and A20ZnF4ZnF7/ZnF4ZnF7 mice. Pictures representative for 3 biologically independent 
mice. Scale bars, 50 µm (insert, 20 µm). (d) Quantification of cleaved caspase 3-positive cells in 
sections from the liver of 2-week old control A20+/+and A20ZnF4ZnF7/ZnF4ZnF7 mice. Number of cleaved 
caspase 3-positive cells per mm2 is shown (A20ZnF4ZnF7/ZnF4ZnF7, n= 5; A20+/+, n=3 mice)  Data are 
expressed as mean ± SEM. Each dot represents an individual mouse. *, p=0.036 (two-sided non-
parametric Mann Whitney test between indicated genotypes). (e) Levels of IL-6 and TNF in serum of 
control A20+/+, A20ZnF4ZnF7/+ and A20ZnF4ZnF7/ZnF4ZnF7 mice at the age of 2 weeks. Each dot represents a 
biologically independent mouse (A20+/+, n=19; A20ZnF4ZnF7/+, n=21; A20 ZnF4ZnF7/ ZnF4ZnF7, n=11).  Data are 
expressed as mean ± SEM. ****, p<0.0001 (parametric one-way ANOVA between indicated 
genotypes). (f) Representative hematoxylin-eosin-stained sections from liver and skin tissue of 2 
week-old A20ZnF4ZnF7/ZnF4ZnF7MyD88-/- mice and A20ZnF4ZnF7/ZnF4ZnF7MyD88+/- littermates. Scale bar, 100 
μm. Pictures representative for 3 biologically independent mice. (g) Bodyweight of 15-week old 
A20ZnF4ZnF7/ZnF4ZnF7MyD88-/- mice compared to control mice. Data are expressed as mean ± SEM. Each 
dot represents a biologically independent mouse (A20ZnF4ZnF7/+MyD88+/+, n=5; A20+/+MyD88-/-, n=11; 
A20ZnF4ZnF7/ZnF4ZnF7MyD88-/-, n=5). **** represents p<0.0001 (parametric one-way ANOVA between 
indicated genotypes). (h) Representative pictures of hindpaws of 15 week-old 
A20ZnF4ZnF7/ZnF4ZnF7MyD88-/- mice and control wild-type mice. (i) Representative hematoxylin-eosin-
stained liver sections from 15 week-old A20ZnF4ZnF7/ZnF4ZnF7MyD88-/- mice and control wild-type mice 
(scale bars, 50μm). Pictures representative for 3 biologically independent mice. Mark that 
A20ZnF4ZnF7/ZnF4ZnF7 could not be used as control mice in Fig. 3g-i since these mice do not survive beyond 
the age of 3 weeks. 
 
Because A20ZnF4ZnF7/ZnF4ZnF7 mice are not viable, we next developed mice with a conditional ‘floxed’ 
allele of Tnfaip3, allowing tissue-specific expression of the ZnF4 and ZnF7 mutations through 
expression of a Cre recombinase (Extended data Fig. 6a). Mice homozygous for the loxP-flanked 
Tnfaip3ZnF4ZnF7 allele expressed normal amounts of A20 and developed normally (data not shown). 
General deletion of the loxP-flanked Tnfaip3ZnF4ZnF7 alleles through expression of a ubiquitous Cre 
recombinase triggered severe pathology and postnatal lethality, reminiscent of our observations in 
A20ZnF4ZnF7/ZnF4ZnF7 mice (Fig. 4a and Extended Data Fig. 6b). To test if myeloid-specific 
Tnfaip3ZnF4ZnF7/ZnF4ZnF7 mice (Tnfaip3ZnF4ZnF7/ZnF4ZnF7LysM-Cre) also developed spontaneous arthritis as 
seen in myeloid-specific A20-deficient mice 11,15,16, we crossed loxP-flanked Tnfaip3ZnF4ZnF7 mice with 
LysM-Cre mice. Indeed, Tnfaip3ZnF4ZnF7/ZnF4ZnF7LysM-Cre mice developed a progressive polyarthritis, 
characterized by immune cell infiltration, cartilage destruction indicated by decreased proteoglycan 
staining with toluidine blue, and bone erosion with increased osteoclast activity detected by tartrate-
resistant acid phosphatase (TRAP) staining (Fig. 4b-e and Extended Data Fig. 6c). Myeloid-specific 
Tnfaip3ZnF4ZnF7/ZnF4ZnF7 mice also had significantly higher serum concentrations of the inflammatory 
cytokines TNF and IL-6 compared to control littermate mice (Fig. 4f). In line with these in vivo 
observations, cultured BMDMs from Tnfaip3ZnF4ZnF7/ZnF4ZnF7LysM-Cre mice produced significantly more 
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cytokines upon stimulation with LPS compared to control BMDMs (Fig. 4g), consistent with the role 
of A20 as a negative feedback regulator of inducible NF-κB–dependent gene expression.  
To investigate the consequence of mutant A20ZnF4ZnF7 expression in intestinal epithelial cells (IECs), we 
generated IEC-specific Tnfaip3ZnF4ZnF7/ZnF4ZnF7 mice by crossing loxP-flanked Tnfaip3ZnF4ZnF7 mice with 
villin-Cre mice (Tnfaip3ZnF4ZnF7/ZnF4ZnF7Vil1-Cre), and challenged these animals with a normally sublethal 
dose of TNF. As expected, control littermates all survived and only showed a modest drop in body 
temperature. In contrast, and as previously demonstrated in IEC-specific A20-deficient mice 13, IEC-
specific Tnfaip3ZnF4ZnF7/ZnF4ZnF7 mice displayed typical symptoms associated with TNF toxicity, including 
hypothermia and severe diarrhea, and all died between 5 and 10 h after injection due to the TNF-
induced apoptosis of A20 mutant IECs (Fig. 4h-j). Finally, IEC-specific Tnfaip3ZnF4ZnF7/ZnF4ZnF7 mice and 
control littermates were evaluated in the model of dextran sodium sulfate (DSS)-induced colitis. Mice 
were subjected to 1.5 % DSS in drinking water for 5 days and monitored daily for clinical pathology. 
Compared with control mice, IEC-Tnfaip3ZnF4ZnF7/ZnF4ZnF7 mice showed increased susceptibility to DSS-
induced colitis, similar to what had been shown with IEC-specific A20-deficient mice 13 (Extended 
Data Fig. 6d). In agreement, IEC-Tnfaip3ZnF4ZnF7/ZnF4ZnF7 mice showed more pronounced loss of 
intestinal barrier integrity after 5 days of DSS compared to the control group (Extended Data Fig. 6e). 
Unchallenged mice, however, did no show spontaneous barrier permeability (Extended Data Fig. 6e). 
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Figure 4. Tissue-specific A20ZnF4ZnF7 expression phenocopies tissue-specific A20 deficiency. (a) Gross 
appearance of livers of 2-week old control (Tnfaip3ZnF4ZnF7/ZnF4ZnF7CreDel+/+) and 
Tnfaip3ZnF4ZnF7/ZnF4ZnF7CreDelTg/+ littermate mice. Note pale acellular regions in 
Tnfaip3ZnF4ZnF7/ZnF4ZnF7CreDelTg/+ livers. (b) Representative picture of the hind paws of 32 week-old 
control (Tnfaip3ZnF4ZnF7/ZnF4ZnF7LysMCre+/+) and Tnfaip3ZnF4ZnF7/ZnF4ZnF7LysMCreTg/+ littermate mice. (c) 
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Biweekly clinical arthritis scores of the ankles of  control (Tnfaip3ZnF4ZnF7/ZnF4ZnF7LysMCre+/+) and 
Tnfaip3ZnF4ZnF7/ZnF4ZnF7LysMCreTg/+ littermate mice (Tnfaip3ZnF4ZnF7/ZnF4ZnF7LysMCre+/+, n=6-15 mice per 
age, Tnfaip3ZnF4ZnF7/ZnF4ZnF7LysMCreTg/+, n=12-25 mice per age). Data are expressed as mean ± SEM. ** 
represents p=0.002 (REML analysis) (d) Histological images of H&E-stained ankle joints of mice with 
the indicated genotypes. Pictures representative for 5 biologicaly independent mice. (e) Graphs 
depicting histological scores for inflammation, bone erosion and cartilage destruction in mice with 
the indicated genotypes (28-33 weeks). Dots in the graphs indicate individual mice 
(Tnfaip3ZnF4ZnF7/ZnF4ZnF7LysMCre+/+, n=10; Tnfaip3ZnF4ZnF7/ZnF4ZnF7LysMCreTg/+, n=21). Data are expressed as 
mean ± SEM. *, *** and **** represent p=0.0141, p=0.0003 and p<0.0001 respectively (Two-sided 
non-parametric Mann-Whitney test between indicated genotypes). (f) Levels of IL-6 and TNF in 
serum of control (Tnfaip3ZnF4ZnF7/ZnF4ZnF7LysMCre+/+) and Tnfaip3ZnF4ZnF7/ZnF4ZnF7LysMCreTg/+ mice at the 
age of 30-40 weeks. Each dot represents a biologically independent mouse 
(Tnfaip3ZnF4ZnF7/ZnF4ZnF7LysMCre+/+, n=11, Tnfaip3ZnF4ZnF7/ZnF4ZnF7LysMCreTg/+, n=27). Data are expressed as 
mean ± SEM. ** and **** represent p=0.0017 and p<0.0001 respectively (Two-sided non-parametric 
Mann-Whitney test between indicated genotypes). (g) TNF and IL-6 secretion by BMDMs isolated 
from control (Tnfaip3ZnF4ZnF7/ZnF4ZnF7LysMCre+/+, n=6), Tnfaip3ZnF4ZnF7/ZnF4ZnF7LysMCreTg/+ (n=6) and 
A20myel-KO (n=6) littermate mice stimulated with LPS for the indicated time points. Data are expressed 
as mean ± SEM. **, *** and **** represent p<0.01, p<0.001 and p<0.0001 respectively (parametric 
two-way ANOVA between indicated genotypes at each time point). (h-j) 
Tnfaip3ZnF4ZnF7/ZnF4ZnF7villinCreTg/+ (n=5) and control (Tnfaip3ZnF4ZnF7/ZnF4ZnF7villinCre+/+, n=6) littermate 
mice were injected i.p. with 5 μg recombinant mouse TNF per 20 g of bodyweight. Body temperature 
(h, mean ± SEM, *** represents p<0.001, REML analysis) and survival (i, ** represents p=0.0018, 
Two-sided mantel-cox test) in function of time. (j) Representative cleaved caspase 3-specific staining 
on sections of small intestine of mice with the indicated genotypes 5 h past TNF injection. Scale bar, 
100μm.  
In conclusion, we have demonstrated that A20 acts primarily as an ubiquitin-binding protein via both 
its ZnF4 and ZnF7 domains to suppress pro-inflammatory signaling. Upon TNFR1 and TLR4 activation, 
A20 is recruited to the receptor complexes through binding to linear ubiquitin chains via its ZnF7 in 
order to stabilize the respective signaling complexes and dampen downstream inflammatory 
signaling. We further show that A20’s anti-inflammatory activity also relies on its K63 ubiquitin-
binding ZnF4 domain, and mice lacking both functional ZnF4 and ZnF7 domains phenocopy A20-
deficient mice in that they die perinatally due to severe multi organ inflammation. Together, our 
observations suggest a mainly non-enzymatic role for A20 in suppressing inflammation by allowing its 
recruitment and the stabilization of ubiquitin chains in the receptor complex. However, A20’s DUB 
function may still be important in the downstream regulation of signaling. More studies, however, 
are needed to further investigate this.  
Multiple genetic studies over the past ten years have associated TNFAIP3 polymorphisms to diverse 
human inflammatory and autoimmune diseases2. These disease-associated variants are mostly 
located in upstream or downstream non-coding regions or in intronic regions of the TNFAIP3 gene, 
which may affect the expression of A20 possibly by interfering with the function of cell- and 
activation-specific enhancers 18-21. Also loss-of-function mutations and deletions in TNFAIP3 have 
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been identified, especially in patients with B cell lymphomas 22-24. The majority of these TNFAIP3 
mutations concern frameshift and premature stop codon mutations preventing the synthesis or 
compromising the ubiquitin-binding ability of the C-terminal ZnF7 domain 8,22-24. Furthermore, A20 
haploinsufficiency has recently been shown to cause a severe early-onset autoinflammatory disease, 
and peripheral blood monocytes isolated from these patients show severely reduced A20 expression 
25. Our findings presented here suggest that these mutations may cause a polyubiquitin-binding 
defect, that in these patients may be sufficient to affect homeostatic regulation of NF-κB signaling 
and cell death.  
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Materials and Methods 
Mice. For the generation of gene-targeted A20-ZnF7 mice, Cas9 mRNA (Sigma) and protein (VIB 
Protein Service Facility, Ghent) together with a 151 bp single-stranded repair template (IDT) 
containing the homologous sequence around the mutations and two short guide RNAs (sgRNAs, 
Synthego) targeting the ZnF7 domain of the murine Tnfaip3 gene were microinjected into the 
pronucleus of zygotes obtained from C57BL/6J mice. Embryos were overnight incubated in KSOM 
medium and transferred the next day to foster mothers via oviduct transfer. sgRNA1: 5’-
AGCCATACATCTGCTTGAACTGG-3’; sgRNA2: 5’-ATTGCAGTAACCATTACACTTGG-3’; ssDNA 
oligonucleotides used as repair template containing two Cys-to-Ala point-mutations [TGC>GCC 
(C764A); TGC>GCT (C767A)] and two silent mutations [GCC>GCT (A758); TAC>TAT (Y768)] to avoid re-
editing after recombination: 5’-
GCCTGAAGAGCCCCCTAAACAGCGCTGCCGGGCCCCTGCTTGTGATCACTTTGGCAATGCTAAGTGTAATGGT
TACGCCAATGAGGCTTATCAGTTCAAGCAGATGTATGGCTAAGTGCGAACACATTGACAGGTCCAGCAAGAAG
GAGCC-3’. For the generation of A20-ZnF4/ZnF7 knockin mice, Cas9 protein together with a donor 
vector containing ~1 kb 5' and 3' homologous arms around the Cys-to-Ala mutations [TGC>GCC 
(C609A); TGT>GCT (C612A); TGC>GCC (C764A); TGC>GCC (C767A)] and two synonymous mutations 
[TCC>TCA (S577); TAC>TAT (Y768)], and two sgRNAs (sgRNA1: 5’- CTCCTGGAGTCCGTGCAGCCTGG-3’; 
sgRNA2: 5’-AGCCATACATCTGCTTGAACTGG-3’) targeting the ZnF4 and ZnF7 domain of the murine 
A20 gene were microinjected into the pronucleus of zygotes obtained from C57BL/6 mice. 
Conditional LoxP-flanked A20-ZnF4/ZnF7 knockin alleles were generated through homologous 
recombination in C57BL/6 ES cells. A neomycin resistance cassette flanked with RoxP sites was 
introduced after the last exon (exon 9) of the Tnfaip3 gene. Exons 6-9 and the neo cassette are 
flanked with LoxP sites. At the 3’ of the loxP flanked region we introduced a mutated exon 6-9 
containing the ZnF4 (C609A/C612A) and ZnF7 (C764A/C767A) mutations. In Tnfaip3ZnF4ZnF7 floxed 
mice the neomycine cassette has been removed by Dre-mediated recombination. Cre-mediated 
recombination excises the LoxP-flanked fragment containing the wild-type exons 6-9, resulting in the 
expression of the mutated exons 6-9. Mice with conditional LoxP-flanked Tnfaip3ZnF4ZnF7 alleles were 
crossed with the LysM-Cre26 or Vil1-Cre transgenic lines27. Myd88–/– mice were previously 
described28. Mice were housed in individually ventilated cages at the VIB Center for Inflammation 
Research, in a specific pathogen-free animal facility. All experiments on mice were conducted 
according to institutional, national and European animal regulations. Animal protocols were 
approved by the ethics committee of Ghent University. 
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Histological analysis of tissue sections. Liver, spleen, small intestine, colon, skin and joint sections 
were fixed in 4% paraformaldehyde for hematoxylin and eosin or immunostaining, or in Carnoy 
fixative (60% methanol, 30% chloroform, 10% glacial acetic acid) for Alcian Blue/Periodic Acid 
(AB/PAS) staining. Samples were dehydrated, embedded in paraffin, sectioned at 4 µm and examined 
by light microscopy.  Bright-field microscopy was done using an Axio Scan.Z1 (Zeiss). For joint 
pathology, formalin-fixed, EDTA-decalcified, paraffin-embedded mouse tissue specimens were 
sectioned and stained with hematoxylin and eosin, Toluidine Blue and TRAP [Leukocyte Acid 
Phosphatase Kit; Sigma-Aldrich]. H&E-, Toluidine Blue- and TRAP-stained joint sections were semi-
quantitatively and blindly evaluated for the following parameters: synovial inflammation/ 
hyperplasia (scale of 0–5), cartilage erosion (scale of 0–5), and bone loss (scale of 0–5) as described29. 
Isolation and immortalization of mouse embryonic fibroblasts. 12.5 dpc embryos from A20ZnF7/+ or 
A20ZnF4ZnF7/+ matings were isolated and mouse embryonic fibroblasts (MEFs) were prepared. MEFs 
were immortalized through serial passaging and frozen in liquid nitrogen. Confluent cells were 
stimulated with 20 ng/ml recombinant mouse TNF, after which cells were lysed for immunoblotting 
or quantitative real-time PCR.  
Isolation of bone marrow-derived macrophages. BMDMs were obtained from bone marrow cells 
flushed from mouse femurs and tibia with ice-cold sterile RPMI medium, and cultured in RPMI 1640 
supplemented with 40 ng/ml recombinant mouse M-CSF, 10% FCS, 1% penicillin/streptavidin and 
glutamine. Fresh M-CSF was added on day 3 and medium was refreshed on day 5. On day 7 cells 
were seeded and stimulated with 20 ng/ml ultrapure LPS (Escherichia coli 0111:B4 strain, InvivoGen) 
or 20 ng/ml ultrapure LPS (E. coli 0111:B4 strain, Invivogen) for 3 h followed by 5 mM ATP (Sigma-
Aldrich) for 20 min for NLRP3 activation. 
Cytokine detection. Cytokine concentrations in culture medium were determined by magnetic bead-
based multiplex assay using Luminex technology (Bio-Rad), IL-1β ELISA (Affymetrix eBioscience), IL-18 
ELISA (Biotechne - R & D Syst. Eur.), according to the manufacturers’ instructions. 
Immunoprecipitation studies. BMDMs were stimulated with human Flag–TNF (1 µg/ml) (VIB Protein 
Service Facility) as indicated. Cells were lysed in NP40 buffer (150 mM NaCl, 1% NP40, 10% glycerol 
and 10 mM Tris–HCl pH 8) and FLAG pulldown was performed using M2 beads (Sigma). The TNF-R1 
signaling complex was eluted from beads using 3×FLAG peptide (Sigma) as described in the 
manufacturer’s instructions. For USP2 and PPase treatment, the beads were incubated with 
24 µg ml−1 USP2 (Enzo Life Sciences) and 8 U µl−1 λPPase (NEB) for 30 min at 37 °C before FLAG 
peptide elution. 
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Cell death assay.  For cell death analysis in MEFs, cells were seeded the day before at 1 × 10 4 per 
well in triplicates in a 96-well plate. The next day, cells were stimulated with the indicated 
concentration of mTNF in the presence of 2.5 µM SytoxGreen (Invitrogen). SytoxGreen intensity was 
measured at intervals of one hour using a Fluostar Omega fluorescence plate reader, with an 
excitation filter of 485 nm and an emission filter of 520 nm, gains set at 1, 100, 20 flashes per well 
and orbital averaging with a diameter of 3 mm. For pyroptosis assay in BMDMs, cells were seeded 
the day before at 2.5 x 104 per well in triplicates in a 96-well plate. The next day, cells were 
stimulated with the indicated concentration of LPS and ATP in the presence of 0.25 µM SytoxGreen 
(Molecular probes). SytoxGreen intensity was measured at intervals of 5 min, for a total of 1 h, using 
a Incucyte device (EssenbioScience). Percentage of cell death was calculated as (induced 
fluorescence − background fluorescence)/(maximum fluorescence − background fluorescence) × 100. 
The maximal fluorescence is obtained by full permeabilization of the cells by using Triton X-100 at a 
final concentration of 0.1 %. All cell death data are presented as mean ± SEM of n (indicated in the 
figure) independent experiments, unless stated otherwise. 
Immunoblot analysis. Cells and tissue extracts were prepared in E1A lysis buffer (250 mM NaCl, 50 
mM Tris pH 7.4, 0.1% NP-40) containing a complete protease inhibitor cocktail (1:25) (Roche) and 
centrifuged for 10 min at 14,000 rpm in a microcentrifuge at 4°C or were directly lysed in 2× Laemlli 
buffer. For cleaved Caspase 1 immunoblotting, cell lysates and culture supernatants were incubated 
with cell lysis buffer (20 mM Tris HCl pH 7.4, 200 mM NaCl, 1% NP-40) and denatured in Laemmli 
buffer. Supernatants were separated by SDS-polyacrylamide gel electrophoresis (PAGE), transferred 
to nitrocellulose and immunodetected with anti-IκBα (Santa Cruz Biotechnology, Inc., sc-371), anti-
phospho-IκBα (Cell Signaling, CST9246), anti-A20 (Santa Cruz Biotechnology, Inc., sc-166692), anti-
p38 (Cell Signaling, CST9212), anti-phospho-p38 (Cell Signaling, CST9215), anti-Caspase3 (Cell 
Signaling, CST9662), anti-SAPK/JNK (Cell Signaling, CST9252), anti-phospho-SAPK/JNK (Cell Signaling, 
CST4668), anti-caspase-1 (Adipogen, AG-20B-0042), anti-β-tubulin (Sigma-Aldrich, T4026) and anti-β-
actin (Santa Cruz Biotechnology, Inc., sc-47778) antibodies. 
In vivo TNF toxicity. Mice were injected i.p. with a sublethal dose of mouse TNF (5 µg mouse TNF/20 
g mouse). E. coli-expressed recombinant mTNF was produced and purified to homogeneity in our 
laboratory, and endotoxin levels did not exceed 1 ng/mg protein. Body temperature and survival 
were monitored every hour. In a separate experiment, mice were euthanized after 2 h (A20ZnF7) or 5 
h (Tnfaip3ZnF4ZnF7/ZnF4ZnF7Vil1-Cre) for histological analysis.  
Induction of DSS-induced colitis and clinical score. Acute colitis was induced by addition of 1.5 % 
dextran sodium sulphate (DSS, 36–50 kDa; MP Biomedicals) to the drinking water for 5 days. Body 
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weight, stool consistency and fecal blood were determined daily. Fecal blood was determined using 
Hemoccult SENSA (Beckman Coulter) analysis. The baseline clinical score was determined on day 0. In 
brief, no weight loss was scored as 0, weight loss of 1–5 % from baseline as 1, 5–10 % as 2, 10–20 % 
as 3, and >20 % as 4. For bleeding, a score of 0 was assigned for no blood, 2 for positive hemoccult, 
and 4 for gross bleeding. For stool consistency, a score of 0 was assigned for well-formed pellets, 
pasty and semi-formed stools were scored as 2, and liquid stools as 4. The average of these 3 scores 
was used as total clinical score, ranging from 0 (healthy) to 4 (maximal colitis). 
FITC–dextran intestinal permeability assay. Intestinal permeability was assessed by oral gavage of 
FITC–dextran (MW: 3000-5000, Sigma). Mice were administered 12 mg of FITC-dextran per 20 g body 
weight in sterile PBS by oral gavage. After 4 h, blood was collected from the facial vein, and FITC–
dextran concentrations were measured in 50 µl of serum by fluorometry (485 nm). Mice were 
anesthetized during blood collection. Serial dilutions of FITC–dextran in PBS were used each time to 
generate a standard curve and serum from PBS-gavaged mice was used as blanks. 
Clinical scoring for arthritis development. The severity of arthritis was assessed using a visual scoring 
system. Mice were scored every two weeks for development of peripheral arthritis. A score ranging 
from 0 to 3 was assigned to each paw, with 0 being normal, 0.5 being swelling of one or more toes, 1 
being mild swelling of the wrist and/or ankle or carpus and/or tarsus, 2 being moderate swelling of 
the wrist and/or ankle or carpus and/or tarsus or mild swelling of both, and 3 being severe swelling 
of the entire paw. 
Quantitative real-time PCR. Total RNA was isolated using TRIzol reagent (Invitrogen) and Aurum 
Total RNA Isolation Mini Kit (Biorad), according to manufacturer’s instructions. Synthesis of cDNA 
was performed using iScript cDNA synthesis kit (BioRad) according to the manufacturer’s 
instructions. cDNA was amplified on quantitative PCR in a total volume of 5 µl with SensiFAST SYBR® 
No-ROX Kit (Bioline) and specific primers on a LightCycler 480 (Roche). The reactions were performed 
in triplicates. The following mouse-specific primers were used: Rpl13a forward, 5’-
CCTGCTGCTCTCAAGGTT-3’; Rpl13a reverse, 5‘-TGGTTGTCACTGCCTGGTACTT-3’; Rpl13a forward, 5’-
AGTGTTGGATACAGGCCAGAC-3’; Rpl13a reverse, 5’-CGTGATTCAAATCCCTGAAGT-3’; Tnf forward, 5’-
ACCCTGGTATGAGCCCATATAC-3’; Tnf reverse, 5’-ACACCCATTCCCTTCACAGAG-3’; Il1b forward, 5’-
CACCTCACAAGCAGAGCACAAG-3’; Il1b reverse, 5’-GCATTAGAAACAGTCCAGCCCATAC-3’; Il6 forward, 
5’-GAGGATACCACTCCCAACAGACC-3’; Il6 reverse, 5’-AAGTGCATCATCGTTGTTCATACA-3’; Il18 
forward, 5’-CAGGCCTGACATCTTCTGCAA-3’; Il18 reverse, 5’-TCTGACATGGCAGCCATTGT-3’. 
Flow cytometry. Spleens were isolated and processed to a single-cell suspension. 5 × 106 splenocytes 
were stained with a combination of the following fluorochrome- or biotin-labeled monoclonal 
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antibodies: CD3 (Thermo Fisher Scientific, 145-2c11 or 17A2), CD4 (BD Biosciences, GK1.5), CD8 
(Thermo Fisher Scientific, 53-6.7), CD11b (BD Biosciences, M1/70), CD11c (Thermo Fisher Scientific, 
N418), CD16/32 (Bioceros, 2.4G2), CD19 (Thermo Fisher Scientific, 1D3), CD62L (BD Biosciences, MEL-
14), CD64 (BioLegend, X54-5/7.1), F4/80 (BioLegend, BM8), Ly6C (Thermo Fisher Scientific, HK1.4), 
Ly6G (BD Biosciences, 1A8), NK1.1 (BD Biosciences, PK136), SiglecF (BD Biosciences, E50-2440), and 
TNF (BD Biosciences, MP6-XT22). Intracellular staining for TNF was performed with the Foxp3 kit 
(eBioscience, 00-5523-00). Cell viability was measured using an eFluor 506 (eBioscience, 65-0866-18) 
or eFluor780 (eBioscience, 65-0865-14) fixable viability dye. Absolute cell counts were determined by 
use of 123 count ebeads (eBioscience, 01-1234-42).  Samples were measured on a FACS Fortessa 5 
laser or BD FACSymphony (BD Biosciences) and data were analyzed using FlowJo. 
Ex vivo cytokine production. To assess intracellular TNF production, 5 × 106 splenocytes were 
cultured in DMEM (Gibco) supplemented with 10% FCS (Bodinco) in the presence of monensin 
(420701, BioLegend) and brefeldinA (420601, Biolegend) and incubated 3.5 h at 37°C. 
Statistics. Results are expressed as the mean ± SEM or mean ± SD, as indicated in figure legend. 
Statistical significance between experimental groups was assessed using a nonparametric Mann–
Whitney U-statistical test. Statistical significance between multiple groups was assessed using either 
one- or two-way ANOVA with Tukey correction for multiple comparison. Comparison of 2 or more 
groups over time was analysed as longitudinal data (repeated measurements over time) using the 
residual maximum likelihood (REML) as implemented in Genstat v1930. Briefly, a linear mixed model 
(random terms underlined) of the form response = µ + genotype + time + genotype.time + 
subject.time was fitted to the longitudinal data. The term subject.time represents the residual error 
term with dependent errors because the repeated measurements are taken repeatedly from the 
same subjects, causing correlations among observations. Times of measurement were set as equally 
spaced, and the best correlation model was selected based on the Aikake Information Coefficient 
(AIC). Significance of genotype effects over time (i.e. genotype.time) and changes in differences 
between genotype effects over time were assessed by an approximate F-test, of which the 
denominator degrees of freedom were calculated using algebraic derivatives as implemented in 
Genstat v1930. 
Data availability statement. All data supporting the findings of this study are available from the 
corresponding author on reasonable request. 
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Tables 
Table 1 : Birth and survival rates of control A20+/+, A20ZnF4ZnF7/+ and A20ZnF4ZnF7/ZnF4ZnF7 offspring from 
A20ZnF4ZnF7/+ x A20ZnF4ZnF7/+ breeding couples. 
Genotype Expected Observed (at birth) Observed (at weaning) 
A20+/+ 25 % (20) 18 18 
A20ZnF4ZnF7/+ 50 % (40) 46 46 
A20ZnF4ZnF7/ZnF4ZnF7 25 % (20) 16 0 
Total (observed) 100 % (52) 52 64 
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Supplementary Figures 
 
Extended Data Figure 1. A20ZnF7 knock-in mice. (a) Schematic depiction of the A20/Tnfaip3 locus 
indicating the sequence of the single stranded oligonucleotide used for mutating the ZnF7 domain 
that was introduced by pronuclear injection into mouse zygotes, and sequencing result of the wild-
type (WT) and of the targeted ZnF7 knock-in allele. Boxes indicate exons 3 to 9 (E3–E9). (b) Birth and 
survival rates of control (A20+/+), A20ZnF7/+ and A20ZnF7/ZnF7 offspring from A20ZnF7/+ x A20ZnF7/+ breeding 
couples. (c) Gross appearance of A20ZnF7/+ and A20ZnF7/ZnF7 mice. (d) Representative pictures of spleen 
and inguinal lymph nodes from 28-week-old control (A20+/+) and A20ZnF7/ZnF7 littermate mice. (e) 
Representative pictures of hindpaws of 15-week-old control (A20+/+) and A20ZnF7/ZnF7 littermates, 
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showing extensive swelling of the toes of the A20ZnF7/ZnF7 mice. (f) Representative micro-CT pictures 
of hindpaws (left) and knees (right) of 28-week-old control (A20+/+) and A20ZnF7/ZnF7 littermates. (g) 
Representative hematoxylin-eosin-stained histological images of ankle joints (left) and toes (right) 
from 28-week-old control (A20+/+) and A20ZnF7/ZnF7 littermates. Scale bar, 500 µm.   
Extended Data Figure 2. FACS immunophenotyping of spleen of control and A20ZnF7 mice. (a-c) 
General gating strategy as applied for immune cell populations described in Figure 1g. (a) 
Lymphocytes, singlets, live, CD3-CD19+ (B cells), CD3+CD19- (T cells) and CD3-CD19- NK1.1+ (NK cells); 
(b) non-debris, singlets, live, lineage- (CD3-CD19-NK1.1-), F4/80+, CD64+ and autofluorescent; (c) non-
debris, singlets, live, lineage-, Ly6G+CD11b+ (neutrophils) and Ly6G-SiglecF-Ly6ChiCD11b+ (monocytes).
FSC: forward scatter, SSC: side scatter, A: Area, H: height, W: width, L/D: live/dead. (d-f) Bar graphs
representing absolute numbers of total (left) and naive (right) CD4 T cells (d), total (left) and naive
(right) CD8 T cells (e) and yd T cells (f) as measured by flow cytometry in the spleens of A20+/+,
A20ZnF/+ and A20ZnF7/ZnF7 animals. Data are expressed as mean ± SEM. *, ** represent p < 0.05 and p <
0.01 (Two-sided non-parametric Mann-Whitney test between indicated genotypes).
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Extended Data Figure 3. MyD88-dependent mechanisms contribute to the local inflammatory 
pathology in A20ZnF7 mice (a-b) Gross appearance (a) and bodyweight (b) of of 10 week-old  
A20ZnF7/+MyD88+/-, A20ZnF7/ZnF7MyD88+/- and A20ZnF7/ZnF7 MyD88-/-  mice. Each dot represents a 
biologically independent mouse (A20ZnF7/+MyD88+/-, n=9; A20ZnF7/ZnF7MyD88+/+, n=13 and A20ZnF7/ZnF7 
MyD88-/-, n=6). Data are expressed as mean ± SEM. * and **** represent p<0.05 and p<0.0001, 
respectively (parametric two-way ANOVA between indicated genotypes). (c) Representative 
hematoxylin-eosin-stained sections of liver from 18-week-old A20ZnF7/ZnF7MyD88+/+ and 
A20ZnF7/ZnF7MyD88-/- littermates. Scale bar, 50 μm. Picture representative for 3 biologically 
independent mice. (d) Representative pictures of hindpaws of 10-week-old A20ZnF7/ZnF7MyD88+/+ and 
A20ZnF7/ZnF7MyD88-/- littermates. Pictures representative for 3 biologically independent mice (e) Levels 
of IL-6 and TNF in serum of A20+/+MyD88+/+, A20+/+MyD88-/-, A20ZnF7/ZnF7MyD88+/+  and  
A20ZnF7/ZnF7MyD88-/- mice. Each dot represents a biologically independent mouse (A20+/+MyD88+/+, 
n=9; A20+/+MyD88-/-, n=3; A20ZnF7/ZnF7MyD88+/+, n=13  and  A20ZnF7/ZnF7MyD88-/-, n=6). Data are 
expressed as mean ± SEM. *, ** represent p<0.05 and p=0.0033 respectively (parametric one-way 
ANOVA between indicated genotypes). 
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Extended Data Figure 4. ZnF7 is critical for A20-mediated suppression of inflammatory signaling. 
Western blot analysis of whole cell lysates from A20+/+, A20ZnF7/ZnF7 and A20myel-KO BMDMs stimulated 
with TNF as indicated. β-tubulin is shown as a loading control. Figure representative for 3 
independent experiments. 
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Extended Data Figure 5. A20ZnF4ZnF7 knock-in mice. (a) Schematic depiction of the A20/Tnfaip3 locus 
indicating the position of ZnF4 and ZnF7 mutations. Boxes indicate exons 3 to 9 (E3–E9). Sequences 
of the donor vector, containing ~1kb 5' and 3' homologous arms around the Cys-to-Ala mutations 
used for mutating the ZnF4 and ZnF7 domains, that were introduced by pronuclear injection into 
mouse zygotes. Sequencing result of the wild-type (WT) allele and of the targeted ZnF4 and ZnF7 
knock-in alleles. (b) Gross appearance of 2-week old control (A20+/+), A20ZnF4ZnF7/+ and 
A20ZnF4ZnF7/ZnF4ZnF7 mice. (c) Gross appearance of 2-week old A20ZnF4ZnF7/ZnF4ZnF7MyD88-/- mice compared 
to A20ZnF4ZnF7/ZnF4ZnF7MyD88+/-mice. 
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Extended Data Figure 6. Conditional ‘floxed’ A20ZnF4/ZnF7 knock-in mice. (a) Targeting scheme 
showing the LoxP-flanked (Floxed) and knock-in A20 alleles. Boxes indicate exons 3 to 9 (E3-E9). LoxP 
sites are indicated by arrowheads. (b) Gross appearance of 2 week-old control 
(Tnfaip3ZnF4ZnF7/ZnF4ZnF7CreDel+/+) and Tnfaip3ZnF4ZnF7/ZnF4ZnF7CreDelTg/+ littermate mice. (c) Representative 
histological images of ankle joints from 30-week-old littermate mice with the indicated genotypes. 
Bone erosion was detected by tartrate-resistant acid phosphatase (TRAP) staining of osteoclast 
activity, and cartilage destruction was assessed by proteoglycan staining with toluidine blue. H/E, 
haematoxylin and eosin. Scale bar: 500 μm. Pictures representative for 5 biologically independent 
mice. (d) Clinical score, based on loss in body weight, stool consistency, and presence of fecal blood, 
of 30 week-old Tnfaip3ZnF4ZnF7/ZnF4ZnF7vilCreTg/+ (n=4) and control (Tnfaip3ZnF4ZnF7/ZnF4ZnF7vilCre+/+, n=4) 
littermate mice treated with 1.5 % DSS. The experiment was stopped at day 5 since 
Tnfaip3ZnF4ZnF7/ZnF4ZnF7vilCreTg/+ started dying. Data are expressed as mean ± SEM. * represents 
p=0.0204 (2-way ANOVA with Sidak’s multiple comparison) (e) Intestinal permeability assay using 
FITC-labelled dextran in 30-week-old Tnfaip3ZnF4ZnF7/ZnF4ZnF7vilCreTg/+ (n=4) and control 
(Tnfaip3ZnF4ZnF7/ZnF4ZnF7vilCre+/+, n=4) mice before and after 5 days of DSS treatment. Data are 
expressed as mean ± SEM. * represents p=0.0143 (2-way ANOVA with Sidak’s multiple comparison.
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Deficiency in the deubiquitinating enzyme A20 causes severe inflammation in mice, and impaired A20 function is associated 
with human inflammatory diseases. A20 has been implicated in negatively regulating NF·KB signalling, cell death and inflam­
masome activation; however, the mechanisms by which A20 inhibits inflammation in vivo remain poorly understood. Genetic 
studies in mice revealed that its deubiquitinase activity is not essential for A20 anti-inflammatory function. Here we show 
that A20 prevents inflammasome-dependent arthritis by inhibiting macrophage necroptosis and that this function depends 
on its zine finger 7 (ZnF7). We provide genetic evidence that RIPK1 kinase-dependent, RIPK3-MLKL-mediated necroptosis 
drives inflammasome activation in A20-deficient macrophages and causes inflammatory arthritis in mice. Single-cell imag­
ing revealed that RIPK3-dependent death caused inflammasome-dependent IL-1fJ release from lipopolysaccharide-stimulated 
A20-deficient macrophages. lmportantly, mutation of the A20 ZnF7 ubiquitin binding domain caused arthritis in mice, arguing 
that ZnF7-dependent inhibition of necroptosis is critica! for A20 anti-inflammatory function in vivo. 
A 2O (also known as TNF inducible protein 3, TNFAIP3) is a deubiquitinating enzyme with critica! anti-intlammatory func­tions. Genome wide association studies have identified A20 as a susceptibility gene in several human intlammatory and autoimmune diseases, including psoriasis, systemic lupus erythematosus, Crohn's disease and rheumatoid arthritis (reviewed in refs. 1-4). Moreover,mutations in the A20 gene have been identified in B cell lymphoma patients5-8. More recently, A20 haploinsufficiency was identified asthe cause of early-onset autointlammatory and autoimmune condi­tions9-13. Studies in genetic mouse models support a key role for A2O asan inhibitor of intlammation. Depending on the genetic background, A2O-deficient mice die perinatally or in the first weeks of life due to severe lethal multi-organ intlammation14-16. In addition, tissue-spe­cific A2O deficiency sensitizes mice to intlammatory and autoimmune pathologies17-26. Although its important anti-intlammatory role inboth humans and mice is indisputable, the mechanisms by which A2O suppresses intlammation in vivo remain poorly understood. Inhibition of NF-KB activation is considered the primary anti­intlammatory function of A2O (refs. 1 ·2·27·28). In addition, A2O wasalso suggested to inhibit necroptosis by deubiquitinating receptor interacting protein kinase 3 (RIPK3)15. Although RIPK3 deficiencyprolonged the survival of A20-knockout mice, mixed lineage kinase­like (MLKL) deficiency did not have any protective effects, arguing against a role for necroptosis in the pathology caused by A2O defi­ciency15·16. Degradation of lysine 63 (K63)-linked ubiquitin chains byA2O is considered important for the inhibition of intlammation by preventing the ubiquitin-dependent recruitment of the inhibitor of NF-KB kinase (IKK) and transforming growth factor beta-activating kinase 1 (TAKl) signalling complexes to upstream receptors1·2·27-29.In addition, the ZnF4 domain of A2O was proposed to limit tumour necrosis factor receptor 1 (TNFRl) signalling by mediating K48-linked ubiquitination of RIPKl 29. However, knock-in mice express­ing A2O with mutated catalytic ovarian tumour or ZnF4 domains did not develop spontaneous intlammatory pathology, arguing that ubiquitin-chain degradation and ZnF4-dependent functions are not essential for the A2O-mediated suppression of intlammation in vivo28·30·31. The capacity to bind to ubiquitin chains through itsZnF domains 4 and 7 has also been implicated in A2O function32-36.In particular, the ZnF7 of A2O was implicated in regulating TNFRl signalling by binding specifically to linear ubiquitin chains28·37 andinhibiting TNFRl-mediated apoptosis and necroptosis35·37. However,the in vivo function of the A2O ZnF7 remains unknown. We showed previously that mice with myeloid-cell-specific A2O deficiency (A2QMYc-Ko) spontaneously develop intlammatory jointpathology resembling rheumatoid arthritis23. Arthritis developmentin A2QMYc-Ko mice requires NLR family pyrin domain containing
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Supplementary Figure 1 
Leucocyte and cytokine analysis in the blood of wild type, A20MYC-KO, A20MYC-KO ASCMYC-KO, A20MYC-KO MyD88MYC-KO, and A20MYC-KO 
MyD88MYC mice. 
(a) Graphs indicating the number of white blood cells (WBC), lymphocytes (LY), monocytes (MO), and neutrophils (NE) in peripheral 
blood from mice with the indicated genotypes (wt, n=54; A20 MYC-KO, n=33; A20MYC-KO AscMYC-KO, n=23 mice). (b) Levels of the indicated 
cytokines and chemokines in the serum of mice with the indicated genotypes (n=10 mice per genotype). (c) Graphs indicating the 
number of white blood cells (WBC), lymphocytes (LY), monocytes (MO), and neutrophils (NE) in peripheral blood from mice with the 
indicated genotypes. Wild type and A20MYC-KO mice are the same shown in Supplementary Fig. 1 and are included for comparison (wt, 
n=54; A20MYC-KO, n=33; A20MYC-KO MyD88MYC-KO, n=22; A20MYC-KO MyD88MYC, n=12 mice). (d) Levels of the indicated cytokines and 
chemokines in the serum of mice with the indicated genotypes (n=10 mice per genotype). Dots in the graphs indicate individual mice. In
y (one-
way ANOVA post-Bonferonni test between indicated genotypes). All statistical tests are two-tailed. Raw data are provided in 
Supplementary Table 3. 
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Supplementary Figure 2 
MyD88 regulates LPS- and IL- -induced inflammatory signalling in synovial fibroblasts.
-
and analysis of NF- B and MAPK signalling was performed by immunoblotting with the indicated antibodies. Results of one 
representative out of two independent experiments are shown. (b-c) Synovial fibroblasts with the indicated genotypes were incubated 
- nd mRNA expression of the indicated genes was evaluated at the indicated time points 
after stimulation. Graphs depict pooled results from two independent experiments in which five independent isolations of syno vial 
fibroblasts for each genotype (n=5 independent isolations of synovial fibroblasts ) were used. (d) Graphs depicting spleen weight as well 
as the numbers of white blood cells (WBC), lymphocytes (LY), monocytes (MO), and neutrophils (NE) in peripheral blood from mi ce 
with the indicated genotypes. Dots indicate individual mice (wt to wt, n=7; wt to MyD88 SF-KO n=8; A20MYC-KO to wt, n=11, A20MYC-KO to 
MyD88SF-KO, n=10 mice
p<0.001 respectively (non-parametric Mann-Whitney test between indicated genotypes for d; two way ANOVA post Bonferroni for b, c). 
All statistical tests are two-tailed. Raw data are provided in Supplementary Table 3 and unprocessed immunoblots are provided in 
Supplementary Figure 9. 
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Supplementary Figure 3 
Synovial fibroblast-specific TLR4 knockout does not inhibit arthritis caused by myeloid cell specific A20 deficiency 
a) Representative macroscopic and histological images of the ankle joints of mice with the indicated genotypes analysed 32 weeks after 
adoptive transfer of bone marrow from wt or A20MYC-KO animals (scale bar: 500 m). (b) Graphs depicting clinical scores, average 
thickness of rear paws at the ankle area, as well as histological scores for inflammation, bone erosion, and cartilage destru ction in mice 
with the indicated genotypes transferred with bone marrow from wt or A20MYC-KO animals. Dots in the graphs indicate individual mice (wt 
to wt, n=9; wt to TLR4SF-KO n=12; A20MYC-KO to wt, n=24, A20MYC-KO to TLR4SF-KO, n=27 mice for a-b). (c) Graphs depicting spleen 
weight, the number of white blood cells (WBC), lymphocytes (LY), monocytes (MO), and neutrophils (NE) in peripheral blood from mice 
with the indicated genotypes. (wt to wt, n=9; wt to TLR4 SF-KO n=10; A20MYC-KO to wt, n=18, A20MYC-KO to TLR4SF-KO, n=22 mice). In all
 mice (non-parametric Mann-Whitney test between indicated genotypes). All 
statistical tests are two-tailed. Raw data are provided in Supplementary Table 3. 
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Supplementary Figure 4 
RIPK3 or MLKL deficiency or lack of RIPK1 kinase activity, does not affect TNF- and LPS-induced NF- B and MAPK activation as well 
as inflammatory gene expression in A20-/- macrophages. 
(a-b) BMDMs with the indicated genotypes were stimulated with 20 ng/ml of TNF for the indicated time points. (a) Analysis of NF- B 
and MAPK signalling was performed by immunoblotting with the indicated antibodies. Results of one representative out of two 
independent experiments are shown. (b) mRNA expression of the indicated genes was analysed by qRT-PCR Results shown were 
obtained from one experiment in which three independent isolations of BMDMs for each genotype (n=3  independent BMDM isolations) 
were included. (c-d) BMDMs with the indicated genotypes were stimulated with 20 ng/ml of LPS for the indicated time p oints. (c) 
Analysis of NF- B and MAPK signalling was performed by immunoblotting with the indicated antibodies. Results of one representative 
out of two independent experiments are shown. (d) mRNA expression of the indicated genes was analysed by qRT-PCR. Results 
shown were obtained from one experiment in which three independent isolations of BMDMs for each genotype (n=3  independent 
BMDM isolations <0.01 
and p<0.001 respectively (two way ANOVA post Bonferroni). All statistical tests are two-tailed. Raw data are provided in Supplementary 
Table 3 and unprocessed immunoblots are provided in Supplementary Figure 9. 
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Supplementary Figure 5 
A20mZnF7/mZnF7 knock-in mice generated using CRISPR/Cas9-mediated gene targeting develop dactylitis. 
(a) Schematic representation of the A20 gene indicating the location of the point mutations introduced in exon 9 to change cys teine (C) 
residues at positions 764 and 767 to alanines (A). Two silent mutations were also introduced to avoid re -editing of the DNA by Cas9 
after homology-directed repair. Sanger sequencing of wt and A20mZnF 7/mZnF7 mouse tail DNA to confirm correct introduction of the
designed mutations into the genome. (b) mCT analysis of forepaws of mice with the indicated genotypes depicts the extensive bone 
erosions in the digits of A20mZnF7/mZnF 7 and the milder erosions in carpal bones compared to A20MYC-KO mice (c) Representative
histological images from forepaws (right panel; transversal sections) and hindpaws (left panel; sagittal sections) of mice with the 
indicated genotypes. Note the development of dactylitis in A20mZnF7/mZnF 7 mice with a characteristic severe tenosynovitis leading to 
disruption of muscle/tendon fibres and the pannus orchestrating destruction of bones (arrow), all being more evident in the d istal and 
intermediate (arrowhead) than in proximal phalanxes (scale bar: 1mm) (A20wt/mZnF7, n=8 and A20mZnF7/mZnF7, n=10 mice).
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Supplementary Figure 6 
Comparison of immune cell infiltration and inflammatory cytokine and chemokine expression in joints from A20MYC-KO  and 
A20mZnF7/mZnF7  mice. 
(a) Representative images of histological serial sections from the ankle joints of mice with the indicated genotypes, which were 
immunostained with the indicated antibodies  (A20MYC-KO ,n=6 and A20ZnF7 n=5 mice). Immune cell numbers were evaluated within the 
affected areas (dotted line). Data (non-parametric Mann-Whitney test between indicated genotypes).   (b) The
mRNA expression of the indicated cytokines and chemokines was analyzed by qRT-PCR in RNA from hind paws of mice with the 
indicated genotypes. Each dot represents an individual mouse (A20wt/wt, n=9-10; A20wt/mZnF7, n=11-12 and A20MYC-KO, n=9 mice). 
-Wallis 
one-way ANOVA test between indicated genotypes). All statistical tests are two-tailed. Raw data are provided in Supplementary Table 
3.
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Supplementary Figure 7 
MyD88 deficiency prevents the development of arthritis and dactylitis in A20mZnF7/mZnF7  mice. 
a) Graphs depicting the body weight (BW) of mice with the indicated genotypes at the age of 20 -30 weeks. (b) Graph depicting spleen / 
BW ratio of mice with the indicated genotypes. (c) Representative pictures of forepaws and hindpaws of mice with the ind icated 
genotypes at the age of 20 weeks. (d) Representative histological images of ankle joints from 20 -30-week-old littermate mice with the 
lage destruction in 
mice with the indicated genotypes. Dots in the graphs indicate individual mice  (A20mZnF7/+ MyD88-/+ n=4; A20mZnF7/mZ nF7 MyD88-/+  n=5; 
A20mZnF7/mZnF7 MyD88-/- n=3 mice for a,b; A20mZnF 7/mZnF7 MyD88-/+  n=5; A20mZnF7/mZ nF7 MyD88-/- n=5 mice 
SEM is also shown for each group of mice. *, **, and *** represent p<0.05, p<0.01, and p<0.001 respectively (One -way ANOVA post- 
Bonferroni test for a; two-way ANOVA post-Bonferroni test for b). All statistical tests are two-tailed. Raw data are provided in 
Supplementary Table 3. 
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Supplementary Figure 8 
Schematic model depicting the mechanisms regulating the pathogenesis of inflammatory arthritis in A20MYC-KO mice. 
A20 prevents inflammasome activation and the release of mature IL-1  and IL-18 but also IL-1   in macrophages by inhibiting RIPK1-
RIPK3-MLKL-dependent necroptosis. In A20-deficient macrophages, RIPK1-RIPK3-MLKL-dependent signalling causes necroptosis 
that results in the release of IL-1  and other DAMPs. In addition, MLKL-dependent plasma membrane permeabilization triggers K+ 
efflux, which activates the NLRP3 inflammasome and the caspase-1-dependent processing and subsequent release of IL-1  and IL-18. 
IL-1  and IL-1 , likely together with IL-18 and other DAMPs released by necroptotic A20-deficient macrophages activate MyD88 -
dependent proinflammatory signalling in synovial fibroblasts causing joint tissue inflammation, as well as cartilage and bone  destruction 
resulting in the development of arthritis. 
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Addendum: A20 prevents inflammasome-
dependent arthritis by inhibiting macrophage 
necroptosis through its ZnF7 ubiquitin-binding 
domain 
We hypothesize that in myeloid specific A20 deficient mice, IL-1α and IL-1β likely together with IL-18 
and other DAMPs released by necroptotic macrophages activate MyD88-dependent proinflammatory 
signalling in synovial fibroblasts causing the development of arthritis1. Blocking inflammasome 
activation or necroptosis in A20MYC-KO mice, by crossing these mice in an ASC deficient or RIPK1 kinase 
dead (RIPK1D138N) background, rescues from arthritis development1. To test whether necroptosis and 
NLRP3 inflammasome activation are also involved in the RA pathology seen in A20ZnF7/ZnF7 mice, these 
mice were crossed in a NLRP3-/- or RIPK1D138N genetic background. Surprisingly, A20ZnF7/ZnF7NLRP3-/- 
and A20ZnF7/ZnF7RIPK1D138N mice still have reduced bodyweight and develop splenomegaly. 
Furthermore, these mice develop arthritis to the same extend as A20ZnF7/ZnF7 mice, as seen 
macroscopically by symmetric swelling of ankles, wrists and toes, and by histological analysis (Fig. 
1,2). Since these mice are full body A20ZnF7/ZnF7 mice, most likely the pathology is caused by the 
mutated ZnF7 in non-myeloid cells. Together, the ZnF7 domain prevents macrophage necroptosis 
and IL-1α/β release, however the phenotype seen in A20ZnF7 mice is partly caused by mechanisms 
relying on non-myeloid cells, independent of necroptosis and NLRP3-inflammasome activation. 
In addition, the inflammatory toe pathology seen in A20ZnF7/ZnF7 mice is never observed in myeloid-
specific A20 deficient mice. Removing a downstream sub-TAD domain, containing 4 enhancers, at the 
A20 locus significantly reduces the basal and induced levels of A202. Also, these mice develop 
spontaneous inflammatory arthritis and dactylitis with synovitis involving the digits of all paws2, 
comparable to what was seen in A20ZnF7/ZnF7 mice1,2. This observation suggests that the phenotype 
observed in the toes of A20ZnF7/ZnF7 mice  is probably also caused by the mutation in non-myeloid 
cells. 
Finally, previous research using conditional A20 knockout mice suggests that also apoptosis of A20-
deficient cells could contribute to the systemic inflammation seen in A20 deficient mice3,4. To assess 
the specific role of cell death, both apoptosis and necroptosis, in the inflammatory phenotype of 
A20ZnF7/ZnF7 mice or more general in the systemic and lethal inflammation of A20-deficient mice, it 
would be interesting to cross these lines into a FADD/Caspase-8 and RIPK3/MLKL deficient 
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background to inhibit both apoptosis and necroptosis, in order to  see if the inflammatory phenotype 
seen in these mice can be rescued.  
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Fig. 1 (a) Gross appearance of A20ZnF7/+ NLRP3+/- , A20ZnF7/ZnF7 NLRP3+/- and A20ZnF7/ZnF7 NLRP3-/- mice. 
(b) Representative pictures of hindpaws of mice with the indicated genotypes at the age of 20 weeks. 
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(c) Body weight of 20-week-old male and female mice with indicated genotypes (male:
A20ZnF7/+ NLRP3+/- n=10, A20ZnF7/+ NLRP3-/-  n=4, A20ZnF7/ZnF7 NLRP3+/- n=5, A20ZnF7/ZnF7 NLRP3-/- n=3;
female: A20ZnF7/+ NLRP3+/- n=7, A20ZnF7/+ NLRP3-/-  n=5, A20ZnF7/ZnF7 NLRP3+/- n=2, A20ZnF7/ZnF7 NLRP3-/-
n=7) (d) Spleen:body weight ratio in 20-week-old mice with indicated genotypes (A20ZnF7/+ NLRP3+/-
n=17, A20ZnF7/+ NLRP3-/-  n=9, A20ZnF7/ZnF7 NLRP3+/- n=7, A20ZnF7/ZnF7 NLRP3-/- n=10). Symbols used are
identical as in panel c. (e) Representative histological images and histological scores for
inflammation, bone erosion and cartilage destruction of the ankle joints of 20-week-old littermate
mice with the indicated genotypes (A20ZnF7/ZnF7 NLRP3+/- n=4, A20ZnF7/ZnF7 NLRP3-/- n=6). The dots in all
the graphs indicate individual mice In all graphs average ± SEM is also shown for each group of mice.
*, **, and *** represent p<0.05, p<0.01, and p<0.001 respectively (One-way ANOVA with Bonferroni
correction for c,d; Non-parametric Mann–Whitney test for e)
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Fig. 2 (a) Gross appearance of A20ZnF7/+ RIPK1-D138NKI/KI , A20ZnF7/ZnF7 RIPK1-
D138N+/+ and A20ZnF7/ZnF7 RIPK1-D138NKI/KI . (b) Representative pictures of hindpaws of mice with the 
indicated genotypes at the age of 20 weeks. (c) Body weight of 20-week-old male and female mice 
with indicated genotypes (male: A20ZnF7/+ RIPK1-D138NKI/KI n=4, A20mZnF7/mZnF7 RIPK1-D138NKI/KI  n=4; 
128 
female: A20ZnF7/+ RIPK1-D138NKI/KI n=4, A20ZnF7/ZnF7 RIPK1-D138NKI/KI  n=3 (d) Spleen:body weight ratio 
in 20-week-old mice with indicated genotypes (A20ZnF7/+ RIPK1-D138NKI/KI n=8, A20ZnF7/ZnF7 RIPK1-
D138NKI/KI  n=7). Symbols used are identical as in panel c. (e) Representative histological images and 
histological scores for inflammation, bone erosion and cartilage destruction of the ankle joints of 20-
week-old littermate mice with the indicated genotypes (A20ZnF7/ZnF7 RIPK1-D138N+/+ n=6, 
A20ZnF7/ZnF7 RIPK1-D138NKI/KI  n=7). The dots in all the graphs indicate individual mice In all graphs 
average ± SEM is also shown for each group of mice. *, **, and *** represent p<0.05, p<0.01, and 
p<0.001 respectively (One-way ANOVA with Bonferroni correction for c,d; Non-parametric Mann–
Whitney test for e) 
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A20 critically controls RANK-dependent 
osteoclastogenesis and bone physiology 
 
Abstract 
A20 (TNFAIP3) serves as a critical brake on NF-κB signaling and NF-κB-dependent inflammation. In 
humans, polymorphisms in or near the A20 gene have been associated with several inflammatory 
disorders, including rheumatoid arthritis (RA). In agreement, previous studies have demonstrated 
that mice with myeloid-specific A20 deficiency spontaneously develop a severe polyarthritis 
resembling human RA. Myeloid A20 deficiency, however, was also shown to promote 
osteoclastogenesis in mice, suggesting a role for A20 in the regulation of osteoclast differentiation 
and bone remodeling. We show here that osteoclast-specific A20 knockout mice develop severe 
osteoporosis, but no signs of inflammatory arthritis. In vitro, we demonstrate that A20 inhibits RANK-
induced NF-κB signaling independent from its deubiquitinating activity but dependent on its zinc 
finger (ZnF) 4 and 7 ubiquitin-binding function. In addition, A20 expression is shown to be induced by 
the activation of RANK signaling in osteoclast cultures. Together, these data demonstrate that A20 
acts as a negative regulator of RANK-induced NF-κB signaling to control osteoclastogenesis assuring 
proper bone development and turnover. 
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Introduction 
Bone is continuously being remodeled in a process of bone matrix synthesis by osteoblasts and bone 
resorption by osteoclasts1. This is a highly regulated process requiring “coupling” of bone resorption 
and reformation, and  perturbations in this balance lead to a loss in bone mineral density, a disease 
called osteoporosis, or in to dense bones, known as osteopetrosis2. Osteoclasts are large, 
multinucleated cells formed by the cytoplasmatic but not nuclear fusion of cells that differentiate 
from the macrophage/monocyte lineage3. Activated mature osteoclasts adhere to the bone surface 
and form tightly sealed compartments with the bone surface, called resorption pits, in which 
osteoclasts release lytic enzymes such as tartrate-resistant acid phosphatase (TRAP) and pro-
cathepsinK (CATK) next to hydrogen ions to acidify the environment4.  
Osteoclastogenesis critically relies on two factors, viz. macrophage colony-stimulating factor (M-CSF) 
and receptor activator of nuclear factor kappa-B ligand (RANKL), which are sufficient to induce 
osteoclast differentiation in vitro5. Binding of RANKL to its receptor RANK, a member of the TNF 
superfamily expressed on the surface of osteoclast precursors, recruits TRAF6 which will induce the 
activation of several downstream signaling pathways leading to the activation of the transcription 
factors nuclear factor-ĸB (NF-ĸB) and activator protein-1 (AP-1)6. RANK signaling also induces the 
activation of nuclear factor-activated T cells c1 (NFATc1), the so called “master regulator of 
osteoclast differentiation” responsible for the expression of critical osteoclast genes coding for TRAP, 
cathepsin K and the calcitonin receptor (CalcR)7. 
The NF-κB family of transcription factors play critical roles in a wide variety of cellular processes of 
which inflammation is the best described. Several mechanisms are known to control NF-κB activation 
assuring a tight control of the inflammatory response. The anti-inflammatory protein A20 (also 
known as tumor necrosis factor alpha-induced protein 3, TNFAIP3) is one of the key molecules 
involved in the regulation of NF-κB signaling and inflammatory gene expression, and genetic deletion 
of A20 in mice leads to a lethal multi-organ inflammation, confirming the importance of A20 in the 
control of inflammatory responses8. Myeloid A20 deficiency in mice was shown to result in the 
spontaneous development of a severe destructive polyarthritis with many features of rheumatoid 
arthritis (RA) in humans9, and single nucleotide polymorphisms in the human TNFAIP3 locus were 
shown to be associated with increased susceptibility to RA10,11.  Besides its role in inflammation, A20 
may also regulate NF-κB signaling pathways controlling developmental processes. In this context, we 
previously identified A20 as a negative regulator of NF-κB signaling downstream of the Ectodysplasin 
A receptor (EDAR), a pathway important for the development of epidermal appendages such as skin, 
hair, nails, teeth, and sweat glands12. Since NF-κB is important for osteoclast differentiation, and NF-
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κB inhibition blocks osteoclastogenesis13, A20 may also play a regulatory role in the control of RANKL-
induced NF-κB signaling and osteoclastogenesis. Cylindromatosis (CYLD), a deubiquitinating protein 
with functions similar to A20, was shown to negatively regulate RANK signaling and 
osteoclastogenesis14, and CYLD deficient mice develop severe osteoporosis due to aberrant 
osteoclast formation and activation. CYLD was shown to negatively regulate RANK signaling by 
inhibiting TRAF6 ubiquitination and activation of downstream signaling events14. A20 may perform 
similar activities, since leukocyte cultures from myeloid-specific A20 deficient mice were shown to 
form many more TRAP-positive osteoclasts in presence of RANKL and M-CSF compared to wild-type 
leukocyte cultures, suggesting a role for A20 in the process of osteoclastogenesis9. However, the 
enhanced osteoclastogenesis in myeloid A20 knockout mice may also be the result of the more 
general inflammatory phenotype of these mice, since inflammatory cytokines such as TNF, IL-1β and 
IL-6 promote osteoclastogenesis 15,16.  
For this study we generated transgenic mice with osteoclast-specific A20 deficiency, and show that 
these mice spontaneously develop severe osteoporosis with increased numbers of TRAP-positive 
osteoclasts. In vitro, bone marrow cells from osteoclast-specific A20 deficient mice produce more 
osteoclasts with increased expression of osteoclast specific markers upon incubation with M-CSF and 
RANKL, compared to control cells. Moreover, we show that A20 is upregulated under conditions of 
RANKL-induced osteoclastogenesis Together, these data identify A20 as a critical negative regulator 
of RANK-induced osteoclastogenesis and bone formation.   
 
Results 
Myeloid-specific A20 deficiency promotes osteoclastogenesis 
Myeloid-specific A20 deficient (A20myel-KO) mice spontaneously develop a severe destructive 
polyarthritis with many features of human RA9. This inflammatory phenotype was shown to be 
caused by the necroptosis of A20 deficient macrophages triggering inflammasome activation and IL-
1β release, which induces MyD88-dependent signaling in synovial fibroblasts causing joint 
destruction and inflammation17,18.  Myeloid A20 deficient mice also show an expansion of peripheral 
CD115+CD117+ osteoclast precursors, and blood leukocytes from these mice produce more and larger 
osteoclasts in vitro upon stimulation with RANKL and M-CSF than cells derived from wild type mice9. 
These findings suggest that A20 deficiency promotes osteoclastogenesis, a condition which may 
contribute to the severe bone degradation seen in these mice. We here confirmed these findings and 
demonstrate that stimulation of bone marrow-derived osteoclast precursor cells with RANKL and M-
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CSF results in a significant increase in the number of tartrate-resistant acid phosphatase (TRAP) 
positive osteoclasts in A20 deficient conditions. These osteoclasts are also significantly larger and 
contain substantially more nuclei than osteoclasts derived from wild type progenitor cells (Fig. 1a). 
Next, we assessed the expression analysis of osteoclast specific markers in ankle joints isolated from 
A20myel-KO mice and control littermates, and demonstrate that their expression is significantly higher 
in A20myel-KO tissue compared to that of control wild-type mice (Fig. 1b). These data indeed suggest 
that increased osteoclast differentiation in the absence of A20 might contribute to the severe 
osteoporosis in myeloid A20 deficient mice. This phenotype may, however, also result from the more 
general inflammatory phenotype of A20myel-KO mice9,  since inflammatory cytokines such as TNF, IL-1β 
and IL-6 are known to promote osteoclastogenesis15,16. Indeed, incubation of bone marrow cultures 
with M-CSF and RANKL to induce osteoclastogenesis results in an increased expression of the 
inflammatory cytokines IL-1β and IL-6 in A20 deficient conditions at the later stages of 
osteoclastogenesis (Fig. 1c). Also, increased IL-6 levels can be detected in the supernatant of A20 
deficient cultures after treatment with M-CSF and RANKL (Fig. 1d). 
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Fig. 1 Myeloid specific A20 deficiency  results in increased osteoclastogenesis in vivo and 
upregulated inflammatory cytokine expression in vitro. (a) TRAP staining on osteoclast cultures 
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derived from bone marrow cells isolated from hind paws of wild-type (WT) and A20myel-KO mice and 
incubated for 7 days with M-CSF only or with M-CSF + RANKL. (b) qRT-PCR mRNA expression analysis 
of the indicated genes on RNA isolated from ankles of mice with the indicated genotypes (A20WT, 
n=9; A20myel-KO, n=10). Data are expressed as mean ± SEM. * and **represent p<0.05, p<0.01, 
respectively (parametric one-way ANOVA test between indicated genotypes). (c) qRT-PCR mRNA 
expression analysis of inflammatory cytokines on bone marrow cultures from A20WT and A20myel-KO 
mice, incubated with M-CSF (25 ng/ml) and RANKL (100 ng/ml) for 7 days to induce 
osteoclastogenesis. (A20WT, n=3; A20myel-KO, n=3). Data are expressed as mean ± SEM. 
****represents p<0.0001 respectively (Kruskal-Wallis one-way ANOVA test between indicated 
genotypes). (d) IL-6 levels in supernatant of bone marrow cultures from A20WT and A20myel-KO mice, 
incubated with M-CSF (25 ng/ml) and RANKL (100 ng/ml) for 7 days to induce osteoclastogenesis. 
Data are expressed as mean ± SEM. ** represents p<0.01 (Two-way ANOVA test with Sidak’s 
multiple comparisons between indicated genotypes for each timepoint). 
Osteoclast-specific A20 deficient mice develop severe osteoporosis 
To assess if A20 plays a direct regulatory role in RANK-induced NF-κB signaling and 
osteoclastogenesis, we generated transgenic mice with osteoclast-specific A20 deficiency by crossing 
the floxed A20 line with mice expressing Cre recombinase under control of the Cathepsin K 
promoter, which is selectively active in differentiated osteoclasts19. Osteoclast-specific A20 deficient 
(A20OC-KO) mice develop normally and do not show signs of arthritis development as seen in  A20myel-
KO mice (data not show). Also, A20OC-KO mice do not have elevated levels of the inflammatory cytokine 
IL-6 in their serum in contrast to A20myel-KO mice (Fig. 2a). To investigate the consequence of 
osteoclast-specific A20 deletion for bone physiology, we next analyzed the structure, bone mass and 
bone density of both the femur and tibia of A20OC-KO and control littermate mice by microcomputed 
tomography (microCT) analysis. As shown in Fig. 2b and suppl. Fig. 1, A20OC-KO mice at the age of 27 
weeks display severe loss of trabecular bone compared to wild-type mice. In agreement, the volume 
and density of trabecular bone is significantly reduced in A20OC-KO mice (Fig. 2c). However and in line 
with what is visually seen on microCT images, no significant differences between A20OC-KO and control 
mice could be observed for cortical bone parameters (Suppl. Fig. 2). Next we tested the strength of 
the femoral diaphysis by measuring ultimate load until failure (N) via a three-point bending test, 
representing the highest force the bone can withstand. A20OC-KO mice require significant less force (N) 
before they break, as could be expected based on the severe bone loss observed by microCT analysis 
(Fig. 2d). Finally, histological analysis of tibia of 20 week-old mice shows significantly more TRAP-
positive osteoclasts in A20OC-KO mice compared to control littermates (Fig. 2e, f). Although old A20OC-
KO mice (50 weeks of age) have reduced numbers of osteoclasts present in their tibia, they still have 
significantly more osteoclasts than wild-type controls of that age (Suppl. Fig. 3). Together, these data 
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indicate that A20 plays a direct role in regulating osteoclastogenesis in vivo, independent of its anti-
inflammatory functions.  
 
Fig. 2 Osteoclast-specific deletion of A20 in mice induces severe osteoporosis due to hyperactive 
osteoclastogenesis. (a) Levels of IL-6 in serum of A20WT, A20OC-KO and  A20myel-KO mice. Each dot 
represents an individual mouse (A20WT, n=9; A20OC-KO, n=6 and  A20myel-KO, n=4). Data are expressed as 
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mean ± SEM. * represents p<0.05 (parametric one-way ANOVA between indicated genotypes). (b) 
Representative micro-CT pictures of hind legs of 27 week-old control (A20WT) and A20OC-KO 
littermates. Note the severe osteoporosis in A20OC-KO mice. (c) Trabecular parameters, calculated on 
micro-CT scans of hind legs of 27 week-old control (A20WT) and A20OC-KO littermates. Each dot 
represents an individual mouse (A20WT, n=6; A20OC-KO, n=6). Data are expressed as mean ± SEM. *, ** 
represent p<0.05 and p<0.01, respectively (Non-parametric Mann Whitney test between indicated 
genotypes). (d) Functional femur strength was determined by the three-point bending test and is 
expressed as the maximum force (Fmax, Newton) bones can resist before breaking corrected for 
femur weight, with higher values mirroring stronger bones. Each dot represents an individual mouse 
(A20WT, n=9; A20OC-KO, n=6). Data are expressed as mean ± SEM. * represents p<0.05 (Non-parametric 
Mann Whitney test between indicated genotypes). (e) Representative pictures of TRAP-stained 
sections from tibia of 20 week-old A20WT and A20OC-KO mice. (f) Quantification of the number of TRAP-
positive cells on sections from tibia of 20 week-old A20WT and A20OC-KO mice. . Each dot represents an 
individual mouse (A20WT, n=6; A20OC-KO, n=6). Data are expressed as mean ± SEM. * represents 
p<0.05 (Non-parametric Mann Whitney test between indicated genotypes). 
A20 regulates RANK-induced NF-κB activation and osteoclastogenesis 
Next we assessed the consequence of osteoclast-specific A20 deletion for RANK-induced 
osteoclastogenesis in vitro. Upon culturing of bone marrow-derived osteoclast precursor cells in the 
presence of M-CSF and RANKL, equal numbers of TRAP-positive multinucleated osteoclasts are 
observed in A20OC-KO and control cultures after 7 days of incubation (Fig. 3a). Also, at this timepoint, 
similar expression levels of osteoclast-specific markers are seen in both cultures. However, at day 4-
5, a stronger expression of TRAP, Ctsk and NFATc1 is observed in A20OC-KO cultures compared to 
control cultures (Fig. 3b). Given that osteoclasts rapidly undergo apoptosis in the absence of 
sufficient amounts of growth factors and/or substrates in vitro, A20 deficiency possibly results in 
enhanced and earlier osteoclast formation (around day 5), which can no longer be detected at later 
time-points. Follow-up experiments should be performed at early stages of osteoclast differentiation 
to confirm the importance of A20 in the regulation of osteoclastogenesis.  
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Fig. 3 Increased osteoclastogenesis in bone marrow cells from A20OC-KO mice. (a) Bone marrow from 
A20WT and A20OC-KO mice was cultured on glass coverslips for 7 days in α-MEM medium 
supplemented with M-CSF (25 ng/ml) alone or with M-CSF and RANKL (100 ng/ml). On day 7, TRAP 
staining was performed. (b) qRT-PCR mRNA expression analysis on RNA isolated from bone marrow 
cultures incubated for the indicated time-points with M-CSF (25 ng/ml) and RANKL (100 ng/ml) (D0 
represents a 7 day culture with M-CSF alone). Data are expressed as mean ± SEM. * and *** 
represent p<0.05, p<0.001 respectively (Two-way ANOVA test with Sidak’s multiple comparisons 
between indicated genotypes for each time-point).  
 
In most cell types, A20 expression levels are low at steady state, but are rapidly upregulated in 
inflammatory conditions as a result of NF-κB activation20. A20 expression is also low in unstimulated 
BMDMs, however becomes rapidly upregulated upon incubation with RANKL, indicating that A20 is 
an NF-kB response gene in the RANK pathway acting as a negative feedback regulator of RANK-
induced NF-kB signaling (Fig. 4a, b). As the loss of A20 in osteoclasts results in enhanced 
osteoclastogenesis in vitro, we hypothesized that A20 might be a negative regulator of the RANK-
induced NF-kB pathway.  Indeed, by using an NF-κB-dependent luciferase reporter assay we 
demonstrated that A20 blocks RANK-induced activation of NF-kB in HEK293T cells (Fig. 4c). We next 
tested an A20 point mutant (A20 C103A), which is critically mutated in its N-terminal de-
140 
ubiquitinating (DUB) activity, and could show that this A20 variant is as effective as wild-type A20 in 
inhibiting RANK-induced NF-kB activation, indicating that the A20 DUB activity is not required for this 
effect 21 (Fig. 4d). However, an A20 mutant affected in its zinc finger 7 (ZnF7) domain (C775A/C779A), 
which was previously shown to have high binding affinity for linear ubiquitin22,23, showed slightly 
reduced NF-κB-inhibiting activity, while an A20 variant mutated in both its ZnF4 (C624A/C627A) and 
ZnF7 ubiquitin-binding domains completely lost its ability to suppress RANK-induced NF-κB signaling 
(Fig. 4d). These results indicate that A20 negatively regulates RANK-induced NF-κB activation via its 
ubiquitin-binding activity, at least in in vitro overexpression studies in HEK293T cells.  
We next examined the effect of A20 deficiency on RANKL-stimulated NF-κB and MAP kinase 
signaling. A20 deficient BMDMs  show slightly increased NF-κB signaling in response to RANKL, as 
shown by stronger and prolonged IĸBα phosphorylation and degradation, than wild-type cells. Also 
increased phosphorylation of the MAP kinase p38 is observed in A20 deficient BMDMs, while no 
difference could be observed for phosphorylated JNK in response to RANKL (Fig. 4e). Next to 
canonical NF-ĸB signaling, RANK signaling is also known to induce the non-canonical NF-ĸB pathway 
which involves processing of the NF-κB2 precursor protein p100 to generate p5224. Interestingly, A20 
deficient BMDMs have higher levels of p100, a non-canonical NF-ĸB response protein25, in agreement 
with increased NF-ĸB activation in these cells. Moreover, increased processing of p100 to p52 could 
be observed in A20 deficient cells compared to wild-type cells upon treatment with RANKL, 
confirming increased activation of the non-canonical NF-ĸB pathway. Together these results indicate 
that A20 is directly involved in controlling signaling downstream of  the RANK receptor driving the 
process of osteoclastogenesis.  
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Fig. 4 A20 regulates RANK-induced NF-ĸB signalling. (a) Immunoblot analysis for A20 on wild-type 
BMDMs stimulated for the indicated time-points with RANKL (100 ng/ml). Actin was used as a 
loading control.  (b) qRT-PCR mRNA expression analysis on RNA isolated from BMDM cultures 
isolated from control (A20WT) mice incubated for the indicated time-points with RANKL (100 ng/ml). 
Data are representative of 2 independent experiments (c) Measurement of NF-kB luciferase activity 
in lysates of HEK293T cells transfected with combinations of an NF-κB luciferase reporter plasmid and 
plasmids encoding A20 and RANK.  Data are expressed as the mean of technical triplicates ± SD. 
Results are representative of two independent experiments.  (d) Inhibition of RANK-induced NF-kB 
luciferase activity by different A20 mutant variants. A20DUB (D100A - C103A), A20ZF4 (C624A - C627A), 
A20ZF7 (C775A - C779A), and A20ZF4/ZF7 (C624A - C627A/C775A - C779A). Data are expressed as the 
mean of technical triplicates ± SD. Results are representative of two independent experiments. (e,f) 
Western blot analysis of whole cell lysates from BMDMs differentiated from A20WT and A20myel-KO 
mice, stimulated with RANKL (100 ng/ml) for the indicated time periods. Actin is shown as a loading 
control. 
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Discussion 
Bone formation is a highly dynamic process involving bone-forming osteoblasts and bone-resorbing 
osteoclasts. Perturbations in the balance between both cell types will lead to either low bone 
density, a disease called osteoporosis, or to abnormally dense bones or osteopetrosis2. In this study 
we identified the NF-κB-inducible protein A20 as a negative feedback regulator of RANKL-induced 
osteoclastogenesis, independent of its anti-inflammatory functions. Osteoclast-specific A20 deletion 
in mice induces the development of severe osteoporosis, and increased numbers of TRAP+ 
osteoclasts can be detected in bone tissue of A20 deficient mice, indicating that A20 acts as a critical 
regulator of osteoclastogenesis and bone homeostasis. Increased osteoclastogenesis is also observed 
in vitro at early stages of osteoclast differentiation, while these differences are no longer clear at 
later stages possibly due to osteoclast apoptosis in culture conditions. RANK stimulation of BMDMs 
induces the expression of A20, and absence of A20 in BMDMs enhances NF-ĸB signaling, 
demonstrating that A20 acts as a negative regulator of RANK-induced NF-ĸB signaling. The 
mechanism by which A20 regulates RANK-induced signaling is however not clear. Previous studies 
have shown that the deubiquitinating enzyme CYLD directly regulates RANK-induced NF-ĸB signaling 
by restricting TRAF6 ubiquitination14. Although A20 has also been described to act as a 
deubiquitinating enzyme which may affect the ubiquitination status of TRAF6 and possibly other 
targets26, we have no evidence of such role in RANK-induced osteoclastogenesis in vitro. Although we 
could not demonstrate a role for the DUB activity of A20 in the inhibition of RANK signaling, we could 
demonstrate that expression of A20 variants mutated in their ability to bind ubiquitin chains via its 
ZnF4 and ZnF7 domains no longer suppress RANK-induced  NF-ĸB signaling. This in agreement with 
recent reports that demonstrate that A20 function critically relies on its ubiquitin binding property to 
control inflammation in vivo17. However, these observations need to be validated in more 
physiological models, including mice with disruptive mutations in the A20 ZnF4 and ZnF7 domains, to 
clarify the mechanism by which A20 controls osteoclastogenesis in vivo.    
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Materials and Methods 
Myeloid and Osteoclast-specific A20 knockout mice. Conditional A20/tnfaip3 knockout mice, in 
which exons IV and V of the tnfaip3 gene are flanked by two LoxP sites, were generated as described 
before27. A20 floxed mice were crossed with LysM-Cre28 or CathepsinK-Cre transgenic mice19 to 
generate a myeloid-specific (A20myel-KO) or osteoclast-specific A20 knockout mouse (A20OC-KO). All 
experiments were performed on mice of C57BL/6 genetic background. Mice were housed in 
individually ventilated cages at the VIB Center for Inflammation Research in a conventional animal 
facility. All experiments on mice were performed according to institutional, national and European 
animal regulations. 
Isolation of bone marrow-derived macrophages. BMDMs were obtained from bone marrow cells 
flushed from mouse femurs and tibia with sterile RPMI medium, and cultured in RPMI 1640 
supplemented with 40 ng/ml recombinant mouse M-CSF, 10% FCS, 1% penicillin/streptavidin and 
glutamine. Fresh M-CSF was added on day 3 and medium was refreshed on day 5. On day 7 cells 
were seeded and stimulated with 100 ng/ml RANKL (Peprotech) for the indicated timepoints.  
Isolation of bone marrow-derived osteoclasts. Osteoclasts were obtained from bone marrow cells 
flushed from mouse femurs and tibia with sterile RPMI medium, and cultured overnight in αMEM 
medium (Gibco) containing 20% FCS in a petridish. The next day, the cells were seeded on glass 
coverslips in αMEM medium containing 20% FCS, 25 ng/ml M-CSF and 100 ng/ml RANKL (Peprotech). 
Medium was refreshed on day 5 ,and on day 7 cells were stained or processed for further analysis.  
In vitro TRAP staining. Osteoclasts were obtained as described above. TRAP staining was performed 
according to the manufacturers instruction (Sigma-Aldrich). Staining solutions were freshly prepared 
before use. Bright-field microscopy was done using an Axio Scan.Z1 (Zeiss, Germany). TRAP+ 
multinucleated cells with three or more nuclei were defined as osteoclasts. 
TRAP Histology. Formalin-fixed, EDTA-decalcified, paraffin-embedded mouse tissue specimens were 
sectioned and stained with haematoxylin and eosin and TRAP [Leukocyte Acid Phosphatase Kit; 
Sigma-Aldrich], and TRAP-positive cells were quantified. 
Bone microCT analysis. All samples were scanned at the Centre for X-Ray tomography of the Ghent 
University (UGCT, www.ugct.ugent.be). Optimal scanner settings were selected based on the sample 
size and composition. The samples were scanned on HECTOR29 using a directional X-ray source set at 
130kV and 10 Watt beam power with a 1 mm Aluminum filtration, with a detector (Perkin-Elmer) 
measuring 40 x 40 cm and a pixel pitch of 200 µm. A total of 2000 projections of 1 sec exposure time 
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each was recorded. Resulting scan images had a voxel size of 4 µm. Projection images were 
reconstructed using Octopus Software for quantification of X-ray microtomography30, and 3D 
visualisations were made using the commercial rendering software VGStudioMAX (Volume Graphics). 
Analysis of bone morphology was performed using a custom script in ImageJ.  A tibial region of 
interest (ROI) with a length of 1200 µm was manually defined, starting 200 µm below the growth 
plate.  The bone structures within this ROI were then automatically classified using an algorithm 
similar to that of Buie et al31.  For quantification purposes, we measured both the average thickness 
of these structures (using the Thickness plugin from BoneJ and their entire volume (determined by 
the number of voxels).  The trabecular spacing measure is the average thickness of the non-bone 
volume between the trabeculae.   
Mechanical testing. On the day of sacrifice, mouse femurs were collected, cleaned from soft tissue, 
wrapped in saline moistened gauze, and frozen at −20°C for later ex vivo biomechanical 
measurements. The strength of the femoral diaphysis was determined by a three-point bending test 
on a Lloyd Instruments universal testing machine (LRXplus, Lloyd Instruments, Fareham, UK), after 
rehydration in a saline solution at room temperature. For this, a loading point is applied on the mid-
diaphysis of the femur and is moved downwards with increasing force and displacement. The 
maximum force (Newton) reflects the load applied right before the femur fractures.  
Quantitative real-time PCR. Total RNA was isolated using TRIzol reagent (Invitrogen) and Aurum 
Total RNA Isolation Mini Kit (Biorad), according to manufacturer’s instructions. Synthesis of cDNA 
was performed using SensiFAST™ cDNA Synthesis Kiy according to the manufacturer’s instructions. 
cDNA was amplified for quantitative PCR in a total volume of 5 µl with SensiFAST SYBR® No-ROX Kit 
(Bioline) and specific primers on a LightCycler 480 (Roche). The reactions were performed in 
triplicates. The following mouse-specific primers were used: A20 fwd AAACCAATGGTGATGGAAACTG; 
A20 rev GTTGTCCCATTCGTCATTCC; OC-Stamp fwd TGGGCCTCCATATGACCTCGAGTAG; OC-Stamp rev 
TCAAAGGCTTGTAAATTGGAGGAGT; TRAP fwd TGGTCCAGGAGCTTAACTGC; TRAP rev 
GTCAGGAGTGGGAGCCATATG; Ctsk fwd AGGCATTGACTCTGAAGATGCT; Ctsk rev 
TCCCCACAGGAATCTCTCTG; RANK fwd ATGAGTACACGGACCGGCC; RANK rev 
GCTGGATTAGGAGCAGTGAACC; NFATc1 fwd AGGCTGGTCTTCCGAGTTCA; NFATc1 rev 
ACCGCTGGGAACACTCGAT; HPRT fwd AGTGTTGGATACAGGCCAGAC; HPRT rev 
CGTGATTCAAATCCCTGAAGT; cFms fwd TGGCATCTGGCTTAAGGTGAA; cFms rev 
GAATCCGCACCAGCTTGCTA;  IL-6 fwd GAGGATACCACTCCCAACAGACC; IL-6 rev 
AAGTGCATCATCGTTGTTCATACA; IL-1β fwd TGGGCCTCAAAGGAAAGA IL-1β rev 
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GGTGCTGATGTACCAGTT TNF fwd ACCCTGGTATGAGCCCATATAC; TNF rev 
ACACCCATTCCCTTCACAGAG 
Cytokine detection. Cytokine levels in culture medium were determined by magnetic bead-based 
multiplex assay using Luminex technology (Bio-Rad), according to the manufacturers’ instructions. 
Western blotting. Cells were lysed directly in 2 x Laemlli and boiled for 5 min. Lysates were separated 
by SDS polyacrylamide gel electrophoresis, transferred to nitrocellulose membranes with a semi-dry 
blot system (Invitrogen), and immunoblotted with anti-IκBα (Santa Cruz Biotechnology, Inc., sc-371), 
anti-phospho-IκBα (Cell Signaling, CST9246), anti-A20 (Santa Cruz Biotechnology, Inc., sc-166692), 
anti-p38 (cell signaling, CST9212), anti-phospho-p38 (cell signaling, CST9215), anti-SAPK/JNK (cell 
signaling, CST9252), anti-phospho-SAPK/JNK (cell signaling, CST4668), anti-NF-kB2 p100/p52 (cell 
signaling, CST4882),  and anti-β-actin (Santa Cruz Biotechnology, Inc., sc-47778) antibodies.  
NF‐κB‐dependent reporter assays. HEK293T cells were seeded at 2×105 cells/well in 6-well plates. 
Cells were transiently transfected the next day by DNA calcium phosphate coprecipitation. Each 
transfection contained 100 ng of pNFconluc, 100 ng pactβgal and 100 ng of a specific A20 expression 
plasmid. The total amount of DNA per well was kept constant at 1 µg by adding empty pCAGGS 
vector. After 24 h, cells were lysed in luciferase lysis buffer (25mM Tris phosphate pH 7,8; 2 mM DTT; 
2 mM CDTA(1,2 diaminocyclohexane-N.N.N.N-tetraacetic acid); 10 % glycerol; 1 % Triton X-100). 
Substrate buffer was added (658 mM luciferin, 378 mM coenzyme A and 742 mM ATP) and 
Luciferase activity (Luc) was assayed in a GloMax 96 Microplate Luminometer (Promega). Β-
Galactosidase (Gal) activity in cell extracts was assayed with chlorophenol-red β-D-galactopyranoside 
substrate (Roche Applied Science, Basel, Switzerland) and the optical density was read at 595 nm in a 
Benchmark microplate Reader (Bio-Rad Laboratories, Nazareth, Belgium). Luc values were 
normalized for Gal values to correct for differences in transfection efficiency (plotted as Luc/Gal). The 
data represent the average ± S.D. of technical triplicates. 
Statistics. GraphPad Prism V8 software was used for statistical analysis. Results are expressed as the 
mean ± SEM or mean ± SD, as indicated in figure legend. Statistical significance between 
experimental groups was assessed using a nonparametric Mann–Whitney U-statistical test. Statistical 
significance between multiple groups was assessed using either one- or two-way ANOVA with Tukey 
correction for multiple comparison. 
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Supplementary figures 
 
Suppl. Fig. 1 Osteoclast specific A20 deficient mice develop severe osteoporosis. Representative 
micro-CT pictures of hind legs of control (A20WT) and A20OC-KO littermates at the age between 16 and 
27 weeks old. Note the severe osteoporosis in A20OC-KO mice. 
 
Suppl. 
Fig. 2 Osteoclast specific A20 deficiency does not affect cortical bone. Cortical bone parameters, 
calculated on micro-CT scans of hind legs of 27 week-old control (A20WT) and A20OC-KO littermates. 
Each dot represents an individual mouse (A20WT, n=6; A20OC-KO, n=6). Data are expressed as mean ± 
SEM (Non-parametric Mann Whitney test between indicated genotypes). 
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Suppl. Fig. 3 50-week old A20OC-KO mice still show increased numbers of osteoclasts. (a) 
Representative pictures of TRAP-stained sections from tibia of 50 week-old A20WT and A20OC-KO mice. 
(b) Quantification of the number of TRAP-positive cells on sections from tibia of 50 week-old A20WT
and A20OC-KO mice. Each dot represents an individual mouse (A20WT, n=5; A20OC-KO, n=4). Data are
expressed as mean ± SEM. * represents p<0.05 (Non-parametric Mann Whitney test between
indicated genotypes).
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General conclusions, discussion and future 
perspectives 
 
The protein A20 is best known for its role as a negative regulator of pro-inflammatory NF-κB signaling 
and cell death, and several genome wide association studies (GWAS) have identified A20/TNFAIP3 as 
a disease susceptibility gene for numerous inflammatory and autoimmune diseases1. Next to its role 
in the control of NF-κB-dependent inflammation, A20 might also be involved in regulating NF-κB 
signaling pathways controlling developmental processes. Initially, A20 was characterized as a 
ubiquitin-editing enzyme modifying the ubiquitination status of specific signaling proteins via its 
deubiquitinating (DUB) activity (OTU domain) and E3 ligase activity (ZnF4 domain)2. However, mice 
with a disruptive point mutation abolishing either the DUB or the E3 ligase activity do not develop 
spontaneous inflammatory disease as seen in A20 knockout mice, questioning the importance of 
these catalytic functions of A20 in vivo3-5. A20 has also been identified as a ubiquitin-binding protein 
which has strong binding affinity for both K63-specific ubiquitin chains via its ZnF4 domain and for 
linear (M1) ubiquitin chains via its ZnF7 domain. In vitro studies have also shown that A20’s ZnF7 
domain is critical for limiting NF-κB signaling and preventing cell death6-9.  To further investigate the 
mechanisms by which A20 regulates inflammation and cell death in vivo and to examine the role of 
A20’s ubiquitin binding functions, we have generated mice with disruptive mutations in the ZnF7 
domain as well as in both the ZnF4 and ZnF7 domains. These mice were analyzed for spontaneous 
pathologies as well as in established models of inflammatory stress. In a second study, and based on 
earlier observations regarding the phenotype of myeloid A20 knockout mice10, we investigated the 
role of A20 in bone development. For this we generated osteoclast-specific A20 deficient mice 
(A20OC-KO) to investigate A20’s role in RANK signaling and osteoclastogenesis. 
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Fig. 1 Summary of the findings. Domain structure of the A20 protein. The N-terminus of A20 contains 
an ovarian tumor (OTU) domain, which has deubiquitinating (DUB) activity. The C-terminal part of 
A20 contains 7 zinc finger (ZnF) domains. The 4th ZnF domain has K63-linked polyubiquitin binding 
affinity and possesses E3 ubiquitin ligase activity, while the 7th ZnF domain has strong binding affinity 
for linear (M1) ubiquitin chains. Mice were generated with disruptive mutations in the ZnF7 domain 
abolishing M1 binding, or in both the ZnF4 and ZnF7 domains abolishing K63- and M1-Ub binding, 
and mice were analyzed for the presence of inflammatory pathology. 
Two distinct ubiquitin-binding motifs in A20 mediate its anti-inflammatory 
and cell- protective activities 
We have shown that the 7th ZnF domain of A20 is critical for controlling inflammatory responses in 
vivo. Mice with a disruptive mutation in the ZnF7 domain (A20ZnF7 mice) spontaneously develop mild 
systemic inflammation characterized by splenomegaly and lymphadenopathy, high levels of 
circulating inflammatory cytokines, increased inflammatory cell infiltration in liver, and increased 
levels of monocytes, macrophages and neutrophils in blood and spleen. Consistent with the essential 
role of A20 as a negative feedback regulator of inducible NF-κB–dependent gene expression, MEF 
cells and BMDMs stimulated with TNF or LPS, respectively, show increased inflammatory signaling 
and release of inflammatory cytokines in A20ZnF7 cells. Since binding of NEMO to linear ubiquitin 
chains is critical for NF-κB activation, A20 might compete with NEMO for binding to M1 chains, 
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thereby preventing downstream NF-κB activation11. However, if increased inflammatory signaling is a 
direct effect of A20 deficiency on NF-κB signaling or a secondary response to aberrant cell death 
induction still remains elusive. A20 deficiency enhances pro-inflammatory and pro-survival signaling, 
however also sensitizes cells to TNF induced cell death12-15. Myeloid-specific A20 deficient (A20myel-KO) 
mice develop systemic inflammation, splenomegaly and polyarthritis, which is not rescued by 
myeloid-specific IKK2/IKKβ deficiency16. This argues against a direct effect of A20 deficiency on NF-κB 
activation and suggests that an NF-κB-independent function of A20 in myeloid cells is critical for 
preventing inflammation in vivo. Furthermore, the 7th ZnF domain of A20 was shown to suppress TNF 
induced apoptosis17.  
Previous research using conditional A20-knockout mice has demonstrated that apoptosis of A20-
deficient cells, as shown for intestinal epithelial cells and liver parenchymal cells, could contribute to 
the systemic inflammation seen in A20 deficient mice14,18. Significant numbers of cleaved caspase 3-
positive cells could be detected in livers of A20ZnF7 mice. Moreover, we showed that A20ZnF7 mice are 
hypersensitive to TNF-induced lethality due to the TNF-induced apoptosis of the intestinal 
epithelium. Mechanistically, in BMDMs we could show that the ZnF7 mutation in A20 prevents the 
recruitment of A20 to the TNFR1 complex, confirming earlier findings in cell lines7,9. Previous studies 
had suggested that A20 binds M1 chains via its ZnF7 domain, thereby  protecting these chains from 
CYLD-mediated degradation9. Indeed, reduced recruitment of A20ZnF7 to TNFR1 leads to a strong 
reduction in linear ubiquitin chains present at the complex, while increased ubiquitination on RIPK1 
(most likely K63 chains) could be observed. Since linear ubiquitin chains are known to stabilize 
complex 1 and prevent cell death induction19-21, reduced levels of M1 chains results in the formation 
of complex 2 and cell death as seen in TNF-stimulated MEF cell cultures isolated from A20ZnF7 mice, 
which we showed to be sensitized to TNF-induced apoptosis, similar to what was described for A20-/- 
MEFs12. M1 ubiquitin pulldown assays should be performed to identify the targets in the TNFR1 
complex that show a reduction in linear ubiquitination in absence of a functional ZnF7 domain, 
compared to the WT situation. In cell lines, CYLD deficiency was shown to result in increased levels of 
M1 and K63 on RIPK1, TNFR1 and TRADD, while A20 deficiency was shown to result in reduced M1 
ubiquitination of TNFR19. Since TNF is a potent inducer of cell death in A20 deficient conditions22, and 
A20ZnF7 mice have high levels of TNF in their serum, TNF might be an important mediator of the 
inflammatory phenotype of A20ZnF7 mice. In this context, recent studies have identified inflammation 
as a consequence of aberrant TNF-induced cell death in models of inflammatory pathology23. To 
clarify if TNF drives the inflammatory phenotype of A20ZnF7 mice, A20ZnF7 mice are being crossed with 
TNFR1 and TNF knockout mice. However, A20 is also critically involved in regulating TNF-independent 
signaling, such as in signaling downstream of TLRs and NLRs, and the backcross of A20 deficient mice 
156 
(A20-/-) in a TNFR1 or TNF knockout background could not rescue these mice from the severe 
inflammatory pathology and perinatal lethality24,25.  
MyD88 deficiency or treatment with broad spectrum antibiotics was shown to rescue the perinatal 
lethal phenotype of A20-/- mice, indicating that A20 restricts TLR signaling induced by the commensal 
intestinal flora 26. In agreement, deletion of MyD88 in A20ZnF7 mice partly restored body weight and 
A20ZnF7MyD88-/- mice developed less severe splenomegaly and were protected from developing 
spontaneous tissue inflammation, demonstrating that MyD88-dependent mechanisms contributed to 
the local inflammatory pathology in A20ZnF7 mice. However, A20ZnF7MyD88-/- still demonstrate 
systemic inflammation, as evidenced by detection of inflammatory cytokines in serum of these mice. 
To undeniably assess if the intestinal flora crucially contributes to the pathology of A20ZnF7 mice, 
these mice will need to be rederived in germ free conditions. 
Cell death has long been considered a consequence of sustained inflammation in many diseases, 
however recent studies identified cell death as a driver of inflammation. Particularly lytic forms of 
cell death, including necroptosis and pyroptosis, were shown to induce inflammation by the release 
of Danger Associated Molecular Patterns (DAMPS)27,28. To test if necroptosis is involved in the 
inflammatory pathology seen in A20ZnF7 mice, A20ZnF7 mice were crossed into a RIP1 kinase death (KD, 
RIPK1D138N) background. These mice were, however, not rescued from systemic inflammation. 
Previously, it was shown that RIPK3 deficiency significantly restored the survival of A20-deficient 
mice, though these A20-RIPK3-/- mice still succumb to severe inflammation29. It was suggested that 
A20 prevents RIPK1-RIPK3 complex formation by interfering with RIPK3 ubiquitination via its 
deubiquitinating OTU domain15. However, A20 mutant mice that have a catalytically inactive OTU 
domain do not develop spontaneous disease, questioning the importance of RIPK3 ubiquitination by 
A20. Another study confirmed the partial rescue of A20-/- mice in a RIPK3 deficient background and 
further showed that a RIPK1 KD background also extended the survival time of A20-/-  mice. However, 
MLKL deficiency could not  rescue or delay the perinatal death of A20-/- mice29, questioning the 
involvement of necroptosis in the inflammatory lethality of A20-/- mice and indicating that 
necroptosis-independent functions of RIPK1 and RIPK3 are involved in the pathology. Indeed, RIPK1 
and RIPK3 have been shown to have necroptosis-independent pro-inflammatory functions and to 
induce apoptosis30. Furthermore, RIPK3 was shown to promote NLRP3 inflammasome activation, 
independent of its role in MLKL activation and necroptosis31. Based on this, A20ZnF7 mice should be 
crossed with MLKL deficient mice rather than with RIPK1 KD or RIPK3 deficient mice to assess the 
involvement of necroptosis.  
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In myeloid cells, A20 was shown to regulate the activation of the NLRP3 inflammasome and the 
execution of pyroptotic cell death. Studies on BMDMs demonstrated that A20 deficiency enhanced 
NLRP3 inflammasome activation, IL1β and IL18 release and pyroptosis upon stimulation with LPS and 
ATP32. Also in primary microglia cultures, A20 deficiency was shown to induce NLRP3 inflammasome 
hyperactivation and pyroptosis33. BMDMs isolated from A20ZnF7 mice also show NLRP3 
inflammasome hyperactivation  upon stimulation with LPS and ATP, to the same extend as seen in 
A20 deficient BMDMs. LPS/ATP treatment also induced massive pyroptosis of A20ZnF7 BMDMs, 
comparable to what is seen in A20-/- BMDMs. This indicates that A20 critically relies on its ZnF7 
ubiquitin binding domain to prevent inflammasome activation.  
In vivo, A20myel-KO mice were shown to develop spontaneous polyarthritis resembling rheumatoid 
arthritis. Treatment with neutralizing IL-6 antibodies offered significant protection from arthritis 
development, identifying IL-6 as an important mediator of disease progression10. Furthermore, 
arthritis development in A20myel-KO mice was prevented by crossing these mice with IL-1R-/-, NLRP3-/- 
or Caspase 1/11-/- mice, indicating that excessive NLRP3 inflammasome activation and IL1β release 
are driving arthritis pathology32. NLRP3 or Caspase 1/11 deficiency also prevented excessive IL-6 
production, showing that elevated IL-6 levels are a consequence of NLRP3 inflammasome 
hyperactivation. Since A20 critically relies on its ZnF7 domain to control the activation of the NLRP3 
inflammasome, and excessive NLRP3 inflammasome activation leads to the development of arthritis , 
we hypothesized A20ZnF7 mice might develop arthritis pathology. Indeed, we could demonstrate that 
A20ZnF7 mice progressively develop an inflammatory joint pathology, although the overall disease 
severity in these mice was generally milder compared with age-matched A20myel-KO mice. However, 
increased numbers of infiltrating neutrophils could be detected in the joints of A20myel-KO mice 
compared to A20ZnF7 animals. Since neutrophils are considered a key pathogenic component in joint 
inflammation both in humans and in animal models34, this could account for the more severe arthritis 
development in A20myel-KO mice. In agreement with the phenotype of A20myel-KO mice, A20ZnF7 MyD88-/- 
mice no longer developed arthritis pathology, indicating that the arthritis phenotype seen in A20ZnF7 
mice is caused by aberrant MyD88-dependent signaling locally at the site of arthritic pathology, and 
not by the systemic increase in inflammatory cytokines.  
The mechanisms by which A20, via its ZnF7 domain, limits NLRP3 inflammasome activation remain 
poorly understood. In collaboration with the research group of Prof. Manolis Pasparakis (University 
of Cologne), we have demonstrated that A20 prevents NLRP3 inflammasome-mediated arthritis by 
preventing macrophage necroptosis. Myeloid-specific  deletion of ASC, an adaptor protein crucial for 
inflammasome assembly, ameliorates the arthritis phenotype of A20myel-KO mice, confirming the 
importance of inflammasome hyperactivation in myeloid cells in the absence of A20. However, 
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crossing of A20myel-KO mice into a RIPK3-/-, RIPK1 KD or MLKL-/- genetic background completely 
prevented arthritis development, identifying myeloid cell necroptosis as a crucial driver of arthritis 
pathology in A20myel-KO mice. Dynamic real-time imaging of cell death and IL-1β release 
simultaneously at the single cell level in BMDMs could demonstrate that IL-1β release from A20-
deficient macrophages requires RIPK3-dependent cell death, consistent with the in vivo genetic data 
showing that necroptosis drives IL-1β production and the development of arthritis in A20myel-KO mice. 
The upstream ligands triggering macrophage necroptosis are, however, currently not known. TLR4-
MyD88 signaling might function in a redundant and cooperative fashion with TRIF-dependent 
TLR3/TLR4 and/or type I and type II interferon (IFN) signaling. TLR3/4 signaling can induce 
necroptosis in BMDMs via TRIF, but independently of TNF35,36, and TRIF can induce IFNβ via activation 
of TBK1 and IFN regulatory factor-3 (IRF-3)37. Interestingly, IFNs signal via the JAK-STAT pathway, and 
our previous research has shown that A20 negatively regulates JAK-STAT1 signaling in BMDMs and 
demonstrated that pharmacological inhibition of JAK reduced enthesitis development in A20myel-KO 
mice 38. 
BMDMs isolated from A20ZnF7 mice release IL-1β as well as IL-1α upon treatment with LPS, although 
at lower levels compared with A20-knockout cells. This shows that A20 is, at least partly, relying on 
its M1-binding ZnF7 domain to prevent macrophage necroptosis and arthritis development. Our 
mechanistic studies further showed that A20 is recruited to the TNFR1 via its ZnF7 domain. However, 
ZnF7 might also be essential to recruit A20 to the TLR4 complex. Although A20 was previously shown 
to limit IKK activation and NF-κB signaling downstream of TLR4 by removing K63 chains from TRAF6 
5,24, the role of LUBAC and linear ubiquitination in TLR4/IL-1R signaling is not clear. K63-M1-hybrid 
chains can be detected on IRAK-1, IRAK-4 and MyD88 upon activation of the IL-1R39, which might be 
applicable to other signaling complexes including TLR4. Further experiments should be performed to 
investigate if the ZnF7 mutation in A20 prevents A20 recruitment to the TLR4 signaling complex 
preventing downstream signaling. Indeed, A20 binding to M1-chains via its ZnF7 might prevent 
downstream NF-κB activation by competing with NEMO/IKK for M1-ubiquitin binding. We showed 
that A20ZnF7 BMDMs treated with LPS have sustained NF-κB activation and increased IL-6 and TNF 
production compared to control BMDMs. Furthermore, since CYLD was shown to promote LPS-
induced necroptosis in BMDMs40, A20 might also protect ubiquitin chains in the TLR4 complex from 
being degraded by CYLD, preserving signaling complex stability, similar to what is seen in the TNFR1 
signaling complex. Since mutating the ZnF4 domain of A20 does not render mice susceptible to LPS 
induced lethality, nor interferes with A20’s ability to limit NF-κB activation in LPS treated BMDMs, 
A20 does not rely on its K63 binding activity to control TLR4 signaling5.  
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Although A20myel-KORIPK3-/-, A20myel-KORIPK1 D138N or A20myel-KOMLKL-/- mice are completely protected 
from arthritis development, A20ZnF7RIPK1D138N are not and develop pathology to the same extent as 
A20ZnF7 mice. Also, NLRP3 deficiency could also not prevent arthritis development in A20ZnF7 mice. 
However and in contrast to our previous studies using A20myel-KO mice16,32, A20ZnF7 mice are full body 
knockin mice, and the mutant ZnF7 domain is expressed in all cells, also in cells other than the 
myeloid cells, which may also contribute to the arthritis phenotype, independent of NLRP3 
inflammasome activation and necroptosis. In contrast to A20myel-KO mice, A20ZnF7 mice also show 
severe inflammatory pathology and bone erosion in fingers and toes, hence, A20 deficiency in non-
myeloid cells is likely responsible for this. Mice expressing low levels of A20, due to the genetic 
removal of a sub-TAD domain containing 4 enhancers at the A20 locus, develop an inflammatory 
arthritis involving inflammation in the digits of the paws, similar to what is observed in A20ZnF7 mice41. 
Furthermore, mice lacking A20 specifically in the keratinocytes develop ectodermal organ 
abnormalities, due to aberrant EDAR-signaling in the absence of A2042. These mice also develop mild 
skin inflammation and increased sensitivity to experimental psoriasis43, but also display pronounced 
swelling of their digits which may represent a form of psoriatic arthritis. These observations suggest 
that part of the phenotype of A20ZnF7 mice may result from the expression of the mutant A20 in 
keratinocytes. Keratinocytes, together with T-cells and dendritic cells are central players in psoriasis 
and psoriatic arthritis44. Although we observed a small reduction in CD3+ T-cells in A20ZnF7 mice, more 
in-depth immunophenotyping through flow cytometry should be performed to investigate if there 
are differences in immune mediators critical for psoriasis and arthritis. Overall, we conclude that 
both myeloid and non-myeloid cells contribute to the arthritis phenotype of A20ZnF7 mice, and that 
blocking macrophage necroptosis or inflammasome activation is not sufficient to prevent arthritis 
development in these mice. 
Although A20ZnF7 mice develop a spontaneous inflammatory phenotype, they do not fully 
recapitulate the phenotype of A20-/- mice that develop severe multi-organ inflammation and 
cachexia and die in the first weeks after birth12. Furthermore, a small portion of A20ZnF7 proteins is 
still detected at the TNFR1 complex upon stimulation of BMDMs with TNF. Also in HOIP-/- cells, which 
are defective in linear ubquitination, A20 is still recruited to the TNFR1 complex, although to a much 
lesser extent than in wild-type cells45. This suggests that A20 exerts additional protective functions 
independent of its ZnF7 linear ubiquitin binding activity. In this respect, the ZnF4 domain of A20 has 
been demonstrated to bind K63-linked polyubiquitin, and mutations in the A20 ZnF4 ubiquitin-
binding interface were shown to result in slightly impaired regulation of NF-κB signaling. However,  
mice with a disruptive mutation in their ZnF4 domain do not develop spontaneous disease3,5,6. In a 
M1 sufficient situation, A20 solely relies on its ZnF7 domain for the recruitment to TNFR1, while in a 
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M1 deficient context (e.g. HOIP deficiency) A20 recruitment becomes dependent on its ZnF4 
domain45. To clarify the physiological role of A20’s ZnF4 domain in suppressing inflammation, we 
introduced point mutations in the ZnF4 motif of A20ZnF7 mice, generating mice which express A20 
that is no longer able to bind both K63 ubiquitin as well as M1 ubiquitin (A20ZnF4ZnF7 mice). A20ZnF4ZnF7 
mice are born in normal numbers but die before weaning age due to severe inflammation in multiple 
organs, including intestine, liver, and skin, comparable to what is seen in A20 deficient mice12. 
A20ZnF4ZnF7MyD88-/- survive past weaning age and do not longer develop the severe multi-organ 
pathology, however, they still have significantly reduced bodyweight with presence of inflammatory 
cytokines in serum, and do not get older than 20 weeks. This indicates that MyD88 dependent 
signaling is involved in the initial, post-natal, inflammatory response in these mice, while at later age 
MyD88-independent contribute to pathology. Crossing A20ZnF4ZnF7 mice in a RIPK1 KD background 
unexpectedly did not prevent nor delay postnatal lethality, contrasting to what has been described 
for A20-/- mice before29. Most likely there is a difference in genetic background and/or microbiome 
between both mouse lines, since in our hands A20-/- all die within 2 weeks after birth, in contrast to 
the A20-/- mice described by Newton et al.  that have a median survival of 5 weeks 29. To address the 
role of cell death in the lethal inflammatory pathology of A20ZnF4ZnF7 mice, these mice should be 
crossed  into a FADD or Caspase-8 and MLKL deficient background to inhibit both apoptosis and 
necroptosis. These crosses are currently ongoing. Given that A20ZnF4ZnF7 mice largely phenocopy A20 
deficient mice, we conclude that A20 primarily acts in a non-enzymatic way to suppress inflammation 
by allowing its recruitment and the stabilization of ubiquitin chains in the receptor complex. 
However, also the E3-ligase activity of the ZnF4 domain is disrupted in our model, which might also 
contribute to the observed phenotype. Furthermore A20’s DUB activity may still have important 
functions in the downstream regulation of signaling. Indeed, since the mutation in the ZnF4 and ZnF7 
domains prevents A20 recruitment to the TNFR1 complex and likely also to other signaling receptor 
complexes, the A20 OTU domain is no longer brought in close proximity with its possible substrates.  
A20ZnF4ZnF7 mice are not viable, preventing further research to determine the in vivo physiological 
functions of A20’s ZnF4 and ZnF7 activity. Therefore we generated a conditional A20ZnF4ZnF7 knockin 
mouse line, allowing us to assess the tissue-specific role of these ubiquitin binding ZnF domains. We 
previously demonstrated that A20 deficiency in intestinal epithelial cells (IECs, A20IEC-KO), sensitizes 
IECs to TNF-induced apoptosis, leading to intestinal barrier disruption and lethality in mice14. 
Similarly, mutating the ZnF4 and ZnF7 domains of A20 in IECs renders mice susceptible to TNF-
induced lethality due to severe IEC apoptosis. However, these mice show a delay in lethality 
compared to A20IEC-KO mice. Myeloid-specific A20ZnF4ZnF7 mice develop splenomegaly and show high 
serum levels of TNF and IL-6, as seen in A20myel-KO cells. These mice also develop a progressive 
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polyarthritis, although to a lesser extend as seen in A20myel-KO mice. However, no swelling of digits, as 
seen in A20ZnF7 mice, was observed, further proving that part of the A20ZnF7 phenotype is caused by 
non-myeloid cells. In vitro, BMDMs isolated from myeloid-specific A20ZnF4ZnF7 mice show increased 
release of inflammatory cytokines TNF and IL-6, although still not to the same level as seen in A20 
deficient BMDMs. Together, these results identified the ZnF4 and ZnF7 domains as critical for A20’s 
anti-inflammatory and cytoprotective activities.  
Although A20ZnF4ZnF7 mice phenocopy A20 deficient mice, tissue-specific A20ZnF4ZnF7 mice develop 
milder pathology compared to tissue-specific A20-/- mice. We hypothesize that the mutation of the 
ZnF4 and the ZnF7 domain in the whole organism is sufficient to trigger a cascade of responses 
leading to severe inflammation and perinatal death, while tissue-specific mutation results in milder 
phenotypes revealing subtle differences between the A20-/- and A20ZnF4ZnF7 condition. However, next 
to its function as a ubiquitin-binding protein, A20 is also recruited to signaling complexes via 
interaction with other proteins. In this context, ABIN-1 recruits A20 to the IKK complex where it 
removes ubiquitin chains from NEMO46,47. Also tax1-binding protein 1 (TAX1BP1) was shown to 
recruit A20 to TRAF6 and RIPK148,49. These and possibly other A20 binding proteins might still recruit 
A20 to signaling complexes in absence of A20’s ubiquitin binding functions. Furthermore, as already 
mentioned, also the OTU-DUB domain may still control regulatory functions once A20 is recruited 
upon activation of the inflammatory pathway. In that respect, A20 was recently shown to rely on its 
DUB function to prevent TNF induced cell death in M1 deficient conditions in vitro45. 
 
A20 critically controls RANK-dependent osteoclastogenesis and bone 
physiology 
Next to its role in the control of NF-κB-dependent inflammation, A20 also regulates NF-κB signaling 
pathways controlling developmental processes. In this context, A20 was previously shown to regulate 
Ectodysplasin A receptor (EDAR)-induced NF-κB signaling, important for the development of 
epidermal appendages such as skin, hair, nails, teeth, and sweat glands42. We have now also 
demonstrated a role for A20 as a direct negative feedback regulator of RANKL-induced 
osteoclastogenesis. Bone is a dynamic organ which is constantly renewed in a process called ‘bone 
remodeling’. This is a highly regulated process and uncontrolled remodeling can result in a disease 
called osteoporosis, characterized by low bone density, or in osteopetrosis caused by too dense 
bones50. We have developed mice which lack A20 only in mature osteoclasts (A20OC-KO). These mice 
develop severe osteoporosis, and increased numbers of TRAP-positive osteoclasts can be 
demonstrated in the bones of these mice. A20OC-KO mice do not show increased levels of 
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inflammatory cytokines in their serum, indicating that A20 regulates osteoclastogenesis independent 
of its anti-inflammatory functions. In vitro, increased expression of osteoclast specific markers were 
detected in osteoclast cultures derived from A20OC-KO bone marrow progenitor cells in the early 
stages of osteoclast differentiation but not at the final stages of osteoclastogenesis. Osteoclasts are 
short-lived cells, that undergo apoptotic cell death to prevent excessive bone degradation and 
sustain homeostasis. Differentiating osteoclasts upregulate Fas expression, and mice lacking 
functional Fas develop osteroporosis due to increased numbers of osteoclasts51. In culture, 
osteoclasts survive significantly longer when grown on bone matrix compared to plastic52. Therefore, 
A20OC-KO bone marrow might show enhanced osteoclastogenesis resulting in more osteoclasts at 
early stages of osteoclast differentiation, while this is no longer visible at later stage due to rapid 
osteoclast apoptosis in absence of bone matrix. In-depth analysis at the initial stages of osteoclast 
differentiation in vitro should be performed to further characterize the importance of A20 for 
osteoclastogenesis.  
Mechanistically we showed that A20 is upregulated in BMDMs by RANKL stimulation, and 
demonstrated that A20 deficiency results in increased RANK-induced NF-κB signaling. This 
demonstrates that A20 can directly control signaling downstream of RANK. However, the 
mechanisms by which A20 regulates RANK signaling still remains elusive. Upon binding of RANKL to 
its receptor RANK, different TRAF molecules are recruited to the receptor of which TRAF6 was shown 
to be critical for osteoclast differentiation and maturation53. TRAF6 was shown to auto-
ubiquitinate in response to RANKL54, and K63 polyubiquitin chains on TRAF6 were shown to be crucial 
for the recruitment of the IKK complex and the induction of downstream signaling55. Expression of a 
RING mutant of TRAF6 preventing TRAF6 auto-ubiquitination fails to rescue NF-κB signaling and 
osteoclastogenesis in RANKL-stimulated TRAF6 deficient monocytes54. A20 was previously shown to 
regulate TRAF6 ubiquitination downstream of TLRs via its DUB domain24, however there is currently 
no evidence that A20 is also involved in the deubiquitinating of TRAF6 downstream of RANK, in 
contrast to the deubiquitinating enzyme CYLD which was previously shown to directly regulate RANK-
induced NF-ĸB signaling by restricting TRAF6 ubiquitination56. Overexpression of an A20-DUB mutant 
could not affect A20’s ability to suppress RANK induced NF-κB signaling, questioning the role of A20’s 
DUB function in regulating RANK signaling. Pulldown experiments of TRAF6 should be performed to 
see if A20 deficiency alters the TRAF6 ubiquitination status upon RANKL stimulation. In contrast to 
the DUB mutant, overexpression of a ZnF7 mutant slightly impaired inhibition, but expression of a 
double ZnF4/ZnF7 mutant completely prevented A20 mediated inhibition of RANK-induced NF-κB 
signaling in overexpression experiments. This is in agreement with our previous study showing that 
A20 primarily functions as a ubiquitin binding protein to prevent cell death and inflammation16. 
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Additional studies using bone marrow from A20ZnF7 and A20ZnF4ZnF7 mice will be needed to unravel the 
specific role of these domains in RANK signaling and osteoclast maturation. Also, osteoclast-specific 
A20ZnF4ZnF7 mice will need to be generated in order to find out if these mice would develop 
osteoporosis similar to what is observed in A20OC-KO mice. 
The role of linear ubiquitination in RANK signaling is currently not known. Mice deficient for Sharpin, 
a component of the LUBAC complex, develop TNF-dependent multi-organ inflammation and show 
significantly reduced levels of linear ubiquitinylation at the TNFR1 signaling complex57. However, 
these mice also show reduced trabecular and cortical bone volume, and cells from Sharpin deficient 
mice show significantly reduced osteoclast formation and function in vitro58. This indicates that linear 
ubiquitination may be important for RANK signaling, however further research is needed to identify 
the targets that are ubiquitinated by the LUBAC complex.  
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buffers te maken voor mij, zonder u was ik waarschijnlijk nog niet kunnen beginnen schrijven aan 
mijn doctoraat. Ik blijf nog wat langer in het labo en ik zal proberen in de toekomst mijn eigen 
materiaal (tipjes, whatman papier,epjes,…) te gebruiken in plaats van alles van u te stelen, al lijkt dit 
weinig geloofwaardig. Ik zal u binnenkort eens een duveltje trakteren, maar we zullen het bij eentje 
houden voor uw eigen welzijn . 
Hanna you also helped me a lot with all the mouse experiments and my histology work. Now you are 
leaving, maybe it’s time to learn and do these things on my own (otherwise Mozes might get a 
burnout). Congratulations with your Master’s degree and good luck with your next adventure in 
Germany. Esther, you always make time for discussions about experiments and scientific problems in 
between all your experiments and funding applications. I hope you manage to become independent 
and start your own group soon, you would do great. Lisette, when you arrived in the lab you were 
quiet, but now we really notice the silence when you’re not in the lab. Under bad influence of Sofie, 
you turned into a partygirl (hence the nickname “Lizatje”), but your wild times seem to be over since 
she left. You don’t have to stress too much about your papers and PhD, you still have 2 years and in 
the end everything will be fine. See you on the train �. Sahana, thanks to you our lab knows how to 
dance on Indian music, including the “sweeping with an imaginary broom”-move. Too bad your 
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wedding was so far away, otherwise I would probably have done something memorable again that 
you could use for my movie. I wish you all the best with your PhD.  (Otu)Lien, the youngster of the 
lab. In the beginning you were quiet, but you slowly started to open up. You already have a paper in 
your first year, so no stress for your PhD. Since you don’t like wine or beer, maybe we should go on a 
cocktail night once with the lab (although I don’t think Mozes would survive that). 
I would also like to thank Leen, Sofie and Karolina who more recently left the lab. You were there 
already since I started my master thesis, and probably saw me evolving from a very quiet person to 
“a less quiet” person that likes to make fun of other people. We had a lot of fun and I even got pretty 
good at gossiping. Leen, you were the mommy of the group with excellent conflict handling skills, 
trying to make and keep everyone happy in the lab. Good luck at your new job! I’m pretty sure you 
will easily be integrated in the new team, since it’s almost impossible not to like you. Voetje, your 
bench in the lab is still a big mess, but that’s just because I crossed the imaginary border between our 
benches and I’m now using both of them. We had a lot of fun at work, but also outside work at 
parties and weddings where you, after a couple of “wijntjes”, demonstrated some typical Sofie dance 
moves and shouted along with some dance hits like “Give me a hand after midnight”. I wish you all 
the best in Argenx and I’ll keep you updated with the latest gossips �. Karolina, thank you for 
helping me with all the gut stuff! As far as I remember I had a lot of fun at your wedding in Poland, 
and I learned that I’m not very good at drinking wodka, although after a couple of wodka’s I could 
suddenly sing songs in Polish. You were always very ambitious and I wish you good luck with your job 
and career.  
Next to the people from the lab, I would also like to thank some other people from the building. 
Special thanks to the people from the Bertrand group for adopting me at social events, saving me 
from all the girl talk. Although I always aim to take the last train home after a party, I often end up 
taking the first train in the morning or wake up in a couch due the 
persuasiveness of some persons (or my lack of character). In this context, Dario and Yves, thanks for 
all the fun nights out and for letting me crash on your couch when parties took longer than originally 
planned. Gillian, thank you for dropping me off at home in the first years, when you were still by car 
from Oostrozebeke. I told you a lot I would drive the next party, but at least I was BOB once. Also 
thank to the Berx unit for the nice weekend in the Ardennes.  
Daarnaast wil ik ook nog mijn ouders bedanken. Danku om me altijd de vrijheid te geven in mijn 
studiekeuzes. Ik ben nooit echt een voorbeeldstudent geweest, maar jullie vertrouwden mij (of 
dachten we laten hem maar even doen) toen ik zei dat jullie zich geen zorgen hoefden te maken en 
dat alles wel goedkwam. Floor, ook bedankt om mijn scan en knieoperatie zo snel te regelen, anders 
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zou ik hier nu misschien nog niet kunnen staan. Daarnaast wil ik nog mijn schoonouders Piet en 
Conny bedanken voor het schilderen en klaar maken van de kinderkamers, terwijl ik mijn doctoraat 
en paper moest schrijven en daarna niet kon rondlopen door mijn knieblessure. 
Finaal wil ik ook nog Tine bedanken voor alle moral support en de leuke dingen die we samen 
beleven. Ook bedankt om me te helpen met het opmaken van mijn thesis, vooraleer mijn laptop 
door de lucht vloog omdat alles maar blijft verspringen. Nu staan we voor een dubbel groot 
avontuur, maar ik ben er zeker van dat we dat samen supergoed gaan doen .  
